

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/57, 9/52, 15/76, 1/21, 1/15, C07K 5/06, C12N 15/62, C07K 14/47, C12P 21/06, G01N 33/535 // C12N 1/21, C12R 1:465, C07K 14/54, 14/475, 14/535, 14 /505	A2	(11) International Publication Number: WO 95/17512 (43) International Publication Date: 29 June 1995 (29.06.95)
(21) International Application Number: PCT/US94/14772 (22) International Filing Date: 22 December 1994 (22.12.94) (30) Priority Data: 08/173,508 23 December 1993 (23.12.93) US (60) Parent Application or Grant (63) Related by Continuation US 08/173,508 (CIP) Filed on 23 December 1993 (23.12.93) (71) Applicant (for all designated States except US): CANGENE CORPORATION [CA/CA]; 6280 Northwest Drive, Mississauga, Ontario L4V 1J7 (CA). (72) Inventors; and (75) Inventors/Applicants (for US only): BARTFELD, Daniel [IL/CA]; 89 Overlook Place, North York, Ontario M3H 4P5 (CA). BUTLER, Michael, J. [GB/GB]; Worts Causeway, Cambridge CB1 4RN (GB). HADARY, Dany [IL/CA]; 40 Maryvale Crescent, Richmond Hill, Ontario L4C 6P8	(CA). JENISH, David, L. [CA/CA]; 4104 Fieldgate Drive, Mississauga, Ontario L4W 2C4 (CA). KRIEGER, Timothy, J. [US/CA]; 24 Jameson Crescent, Brampton, Ontario L6S 3W3 (CA). MALEK, Lawrence, T. [US/CA]; 3 Viewmount Crescent, Brampton, Ontario L6Z 4P4 (CA). WALCYZK, Eva [CA/CA]; 6037 Childham Crescent, Mississauga, Ontario L5N 2R8 (CA). SOOSTMEYER, Gisela [CA/CA]; 166 Hedgerow Lane, Kleinburg, Ontario LOG 1C0 (CA). (74) Agents: BENT, Stephen, A. et al.; Foley & Lardner, Suite 500, 3000 K Street, N.W., Washington, DC 20007-5109 (US). (81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ). Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(54) Title: PROTEASES FROM STREPTOMYCES AND USE THEREOF IN PROTEIN EXPRESSION SYSTEMS		
(57) Abstract A family of proteases endogenous to <i>Streptomyces</i> cells degrades exogenous proteins secreted from <i>Streptomyces</i> host cells. The previously unidentified proteases include (1) tripeptidyl aminopeptidase designated "Tap", (2) tripeptidyl aminopeptidase designated "Ssp", (3) X-Pro-Metalloendoproteinase designated "XP-Mep", and (4) other proteases derived from <i>Streptomyces</i> which degrade certain substrates under certain conditions. Degradation was alleviated by selective inhibition of secreted proteases or by using improved strains which lack or have impaired degradation proteases. An irreversible inhibitor was designed based upon the mechanism and substrate specificity of the target protease. Hosts expressing proteases were also produced. Uses of the proteases include immunoassays and proteolytic removal of peptides and polypeptides to improve secretion of exogenous proteins.		

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

PROTEASES FROM STREPTOMYCES AND USE THEREOF IN PROTEIN EXPRESSION SYSTEMS

BACKGROUND OF THE INVENTION

This invention relates to improved *Streptomyces* strains which lack degradative proteases. The strains are used for expression of peptides and polypeptides. The invention also relates to inhibitors of such proteases and uses of such proteases. New *Streptomyces* proteases and their genetic coding sequences are presented. Uses of the proteases and impaired proteases are described.

Genetic expression systems generally consist of host cells encompassing a gene to be expressed, and vectors which introduce the gene into the host cells. Under conditions allowing expression, the host cells make a product, generally a protein.

A problem is that host cells have a variety of endogenous proteases which degrade proteins expressed by the systems. These proteases, of which aminopeptidases, dipeptidyl aminopeptidases, tripeptidyl aminopeptidases and endoproteases are examples, interfere with the commercial use of genetic expression systems by degrading proteins expressed by the systems in different ways.

Aminopeptidases remove N-terminal amino acids from proteins. Examples of aminopeptidases include leucine aminopeptidase (Hanson and Frohne, 1976) and aminopeptidase P (Yoshimoto, et al., 1988).

Dipeptidyl aminopeptidases remove N-terminal dipeptides including X-Pro dipeptides from proteins (Lloyd, et al., 1991; Fukusawa and Harada, 1981). Tripeptidyl aminopeptidases remove N-terminal tripeptides from proteins. Tripeptidyl aminopeptidases have not previously been reported in prokaryotes; however, they have been reported in eukaryotes (McDonald, et al., 1985; Balow, et al., 1986; Tomkinson and Jonsson, 1991).

Endoproteases degrade secreted proteins by cleaving amino acid bonds within proteins. Examples of

endoproteases include serine proteases and metalloproteases. They exist in various microbial species and have a wide variety of cleavage site specificities, including specificities adjacent to positively charged, negatively charged, and aromatic amino acids.

Proteases may be neutralized by various methods. One method is to use inhibitors to prevent the degradation of proteins during their purification. This method has been used for proteins derived from yeast and higher eukaryotes and from inclusion bodies derived from *E. coli*. Inhibitors employed in this manner include leupeptin, EDTA, phenylmethanesulfonylfluoride and pepstatin.

But protease inhibitors can harm a living organism. EDTA increases the fragility of many microorganisms and can cause cell lysis. Some inhibitors may be taken up by the organism possibly causing cell death or disrupting cellular functions. Ideally, a protease inhibitor should (1) be soluble in the fermentation media, (2) inhibit the target protease as selectively as possible, (3) not inhibit cell growth, and (4) be cost-effective.

Chloromethylketones are known to provide selective inhibition of some proteases. The earliest studied chloromethylketones, tosyl-L-lysine chloromethylketone (TLCK) and tosylphenylalanine chloromethylketone (TPCK), selectively inhibit trypsin and chymotrypsin, respectively (Schoellman, et al., 1963; Shaw, et al., 1965).

Another method to impair proteases is to use improved strains with impaired proteases to prevent degradation of proteins during production. Improved strains carrying deletional mutations in multiple protease-encoding genes have been made in *Bacillus* strains (Sloma, et al., 1992; PCT/US92/01598 of Omnigene, Inc.).

International Application Number PCT/US92/05532 of Amgen Inc. entitled "Isolation and Characterization of a Novel Protease from *Streptomyces lividans*" describes a protease called "Protease X" of *S.lividans*, and a strain of *S.lividans* deficient in such protease. However, the strain deficient in Protease X does not significantly improve the commercial production of exogenous proteins secreted from *Streptomyces*.

Endogenous proteases have deleteriously affected the quality, quantity or stability of proteins expressed in a *Streptomyces* recombinant genetic expression system designated CANGENUS™. This expression system has been used to ferment and produce a variety of proteins including therapeutic proteins such as granulocyte macrophage-colony stimulating factor (GM-CSF), interleukin-3 (IL-3), interleukin-6 (IL-6), and erythropoietin (EPO) (see Canadian Patent No. 1,295,563, No. 1,295,566 and No. 1,295,567, and U.S. Patent No. 5,200,327) and may be used to produce other proteins including tumor necrosis factor (TNF), stem cell factor (SCF), interleukin -7 (IL-7) and interleukin-2 (IL-2).

To improve commercial production of proteins, a need exists to impair the action of endogenous *Streptomyces* proteases in *Streptomyces* expression systems. Furthermore, a need exists for additional commercial uses of these proteases. It would be helpful if these proteases could be used: (1) in processing recombinant proteins by removing propeptides or fused polypeptides incorporated into a genetic construct to facilitate expression and secretion to prevent degradation by other proteases, to facilitate purification of polypeptides, and other suitable products; (2) in removing blocked N-terminals from proteins; (3) in digesting connective tissue proteins; (4) in an immunoassay to enable the removal of one or more amino acids from a protein; (5) in a coupled assay for aminopeptidases to remove peptide

blocking groups. The specificity of proteases of the present incitation as described in this patent application enables those skilled in the art to carry out such uses.

5 Exogenous protein secretion in bacterial cells has been facilitated by the inclusion of propeptides between the signal peptide and the amino acid sequence of the actual exogenous protein. A signal peptide is a peptide that directs or facilitates secretion of a protein from
10 a cell. These propeptides have been useful for stabilizing the secreted protein against proteolytic activities and enhancing secretion of the protein by providing an endogenous signal peptidase processing site.

The use of propeptides for the secretion of exogenous
15 proteins in *Streptomyces* has been described using signals and propeptides from β -galactosidase for interleukin-1 β (Lichenstein, et al., 1988) and thaumatin (Illingworth, et al., 1989); from tendamistat for proinsulin (Koller, et al., 1989), interleukin-2 (Bender, et al., 1990a) and
20 hirudin (Bender, et al., 1990b); and from serine protease inhibitor for domains of immunoglobulin G (Yoshikata, et al., 1993; Ueda, et al., 1993), and CD4 (Fornwald, et al., 1993). In most of the above-cited cases, the removal of the propeptide results in a decrease in the
25 level of secreted exogenous protein.

The processing of the signal peptide leaves the propeptide fused to the amino terminus of the exogenous protein. This situation is undesirable for a therapeutic protein as the presence of the propeptide may alter its
30 biological or immunological activities. To overcome these problems, the propeptide is generally removed by treatment with an exogenous protease(s) following recovery of the secreted protein. Proteases with relatively narrow substrate specificities, e.g., factor
35 Xa, thrombin, collagenase and enterokinase, have been used for the removal of propeptides. Thus a need

exists for the use of proteases with additional substrate specificities to process proteins as desired.

SUMMARY OF THE INVENTION

This invention meets needs in the art by
5 (A) providing new *Streptomyces* strains which lack or have impaired degradative proteases, (B) providing a method for improving the expression and secretion of correctly processed exogenous proteins, (C) providing a method to
10 correctly process proteins with additional sequences incorporated into a genetic construct to prevent degradation by other proteases, (D) inhibiting certain *Streptomyces* proteases, and (E) providing new uses of *Streptomyces* proteases.

A protease isolated and characterized in this
15 invention is a tripeptidyl aminopeptidase designated Tap. Another protease with similar proteolytic activity is a tripeptidyl aminopeptidase, whose nucleotide sequence has a strong homology to the nucleotide sequence of a subtilisin protease and, for that reason, was designated
20 Ssp. Another protease is an X-Pro metalloendoprotease designated XP-Mep. By this invention, other degradative proteases, each with a characteristic action, were isolated and characterized. This invention includes the nucleic and amino acid sequences, the promoter and signal
25 sequences of such proteases. Protease X of PCT/US92/05532 has different DNA and amino acid sequences than the proteases of this invention and cleaves different substrates than those of this invention.

This invention further includes introducing a DNA
30 sequence encoding a protease into a recombinant vector which, when transformed into suitable host strain, produces an exogenous protease having the biological activity of a wild type protease. Both prokaryotic and eukaryotic hosts may serve as hosts, for producing such
35 proteases.

DNA sequences for a protease of the present invention with a suitable, promotor and/or signal may be used in vectors to direct the expression and secretion of exogenous proteins from *Streptomyces*, or to express
5 increased levels of protein by using multicopy vectors.

The improved strains of this invention have impaired protease production systems, resulting in an increase in quality, quantity or stability of expressed proteins. Such a strain is impaired by deleting, mutating or
10 substituting one or more nucleotides in the sequence encoding for at least one protease. The strains of this invention are produced from the *Streptomyces* genera including species consisting of *S.lividans*, *S.ambofaciens*, *S.coelicolor*, *S.alboniger*, *S.parvulus* and
15 *S. rimosus*.

A method of fermentation using genetically engineered *Streptomyces* host cells with impaired protease activity is part of this invention. The method includes the steps of: (a) constructing *Streptomyces* host cells with
20 impaired protease activity and which express a desired exogenous protein under suitable conditions; and (b) placing the cells in suitable conditions for expression of the desired protein. The method of fermentation is used to express GM-CSF, IL-3, IL-6, EPO, TNF, SCF, IL-7,
25 IL-2 or any other desired protein.

A method for improving the secretion of proteins from a genetic expression system is part of this invention. The primary amino acid sequence of certain secreted proteins may impose certain physicochemical
30 properties and/or conformational properties which may interfere with the processing of the signal peptide. Secretion of such proteins by a genetic expression system is improved by adding tripeptides (propeptides) to the amino terminal end of the protein which is a precursor to
35 the desired product of the system. The addition is made immediately adjacent to the signal peptidase cleavage

site. The propeptide is removed from the protein by use of a protease such as Tap, Ssp or another protease of this invention.

The inhibitors of this invention are capable of protecting expressed proteins. An inhibitor of this invention is L-alanyl-L-prolyl-L-alanine chloromethylketone, its salts and analogs. This invention includes the use of this inhibitor to inhibit one or more tripeptidyl aminopeptidases derived from *Streptomyces*.

Kits of this invention contain one or more isolated and purified proteases derived from *Streptomyces* to remove one or more amino acids from a protein. An example is a kit for ELISA which consists of a protease and a substrate cleaved by the protease.

DEFINITIONS

In this application, the following terms have the following meanings, unless the context requires otherwise:

"Endogenous protease" means a protease which occurs naturally in a particular host cell and which cleaves one or more of the substrates referred to in this application.

"Exogenous" refers to DNA sequences and proteins which do not occur naturally in a host cell.

"Host cell" means a prokaryotic or eukaryotic cell, strain, species or genera, that may be suitable for introduction and for expression of exogenous DNA sequences.

"Impaired" means reduction or elimination of an activity of a protease produced by a nucleotide sequence compared to the activity of the wild type protease.

"Proteins" includes amino acids, peptides and polypeptides.

"Wild type" means the activity characteristic of a naturally occurring nucleic acid and protein.

"Selective inhibitor" means a molecule that inhibits proteins, such as proteases, on a selective basis.

ABBREVIATIONS

5	-3	=	protein from which three amino acid residues have been removed from the N-terminus of the protein
10	-4	=	protein from which four amino acid residues have been removed from the N-terminus of the protein
15	-6	=	protein from which six amino acid residues have been removed from the N-terminus of the protein
	aa	=	amino acid
	pNA	=	L-alanine p-nitroanilide
	AA-pNA	=	L-alanyl-L-alanine p-nitroanilide
20	AAPA-pNA	=	L-alanyl-L-alanyl-L-prolyl-L-alanine p-nitroanilide
	AMC	=	7-amino-4-methylcoumarin
25	APACMK	=	L-alanyl-L-prolyl-L-alanine chloromethylketone
	APA-AMC	=	L-alanyl-L-prolyl-L-alanine 7-amino-4-methylcoumarin
30	APF-bNA	=	L-alanyl-L-prolyl-L-phenylalanine beta-naphthylamide
	APA-pNA	=	L-alanyl-L-prolyl-L-alanine p-nitroanilide
35	APM-pNA	=	L-alanyl-L-prolyl-L-methionine p-nitroanilide

	APPS-bNA	=	L-alanyl-L-prolyl-L-prolyl-L-serine beta-naphthylamide
5	APS-bNA	=	L-alanyl-L-prolyl-L-serine beta-naphthylamide
	bNA	=	beta-naphthylamide
	Boc	=	N-t-butoxycarbonyl
10	Boc-AAPA-pNA	=	N-t-butoxycarbonyl-L-alanyl-L-alanyl-L-prolyl-L-alanine p-nitroanilide
	Boc-APARSPA-bNA	=	N-t-butoxycarbonyl-L-alanyl-L-prolyl-L-analyl-L-arginyl-L-seryl-L-prolyl-L-alanine beta-naphthylamide
15	Boc-APS-bNA	=	N-t-butoxycarbonyl-L-alanyl-L-prolyl-L-serine beta-naphthylamide
20	Boc-FSR-AMC	=	N-t-butoxycarbonyl-L-phenylalanyl-L-seryl-L-arginine 7-amino-4-methylcoumarin
	Boc-LSTR-pNA	=	N-t-butoxycarbonyl-L-leucyl-L-seryl-L-threonyl-L-arginine p-nitroanilide
25	D-FPR-bNA	=	D-phenylalanyl-L-prolyl-L-arginine beta-naphthylamide
30	D-PFR-pNA	=	D-prolyl-L-phenylalanyl-L-arginine p-nitroanilide
	DMSO	=	dimethyl sulphoxide
	EDTA	=	ethylenediaminetetraacetic acid
35	ELISA	=	enzyme-linked immunosorbent-assay

	FPLC	=	fast protein liquid chromatography
	GPL-bNA	=	Glycyl-L-prolyl-L-leucine beta-napthylamide
5	GP-pNA	=	Glycyl-L-proline p-nitroanilide
	GPM	=	Glycyl-L-prolyl-L-methionine
10	GR-pNA	=	Glycyl-L-arginine p-nitroanilide
	HEPES	=	N-2-hydroxyethylpiperazine-N'-2-ethanesulphonic acid
15	HOHH	=	2-hydroxy-6-oxohepta-2,4-dienoate hydrolase
	iPrOH	=	isopropanol
	L-pNA	=	L-leucine p-nitroanilide
	MNNG	=	N-methyl-N'-nitro-N-nitrosoguanidine
20	N-(3-carboxypropionyl)-APS-bNA	=	N-(3-carboxypropionyl)-L-alanyl-L-prolyl-L-serine beta-napthylamide
	N-Ac	=	N-acetyl
25	N-Ac-APA-pNA	=	N-acetyl-L-alanyl-L-prolyl-L-alanine p-nitroanilide
	N-Ac-APPT-bNA	=	N-acetyl-L-alanyl-L-prolyl-L-prolyl-L-threonine beta-napthylamide
30	N-Bz	=	N-benzoyl
	N-Bz-GSHLV-4MbNA	=	N-benzoyl-L-glycyl-L-seryl-L-histidiny-L-leucyl-L-valine 4-methoxy-beta-napthylamide
35			

	N-Bz-R-pNA	=	N-benzoyl-L-arginine p-nitroanilide
	N-Bz-VGR-pNA	=	N-benzoyl-L-valyl-glycyl-L-arginine p-nitroanilide
5	N-Bz-VLK-pNA	=	N-benzoyl-L-valyl-L-leucyl-L-lysine p-nitroanilide
	nt	=	nucleotide
	ORF	=	open reading frame
10	PAGE	=	polyacrylamide gel electrophoresis
	pEGR-pNA	=	L-pyroglutamyl-glycyl-L-arginine p-nitroanilide
	Pd	=	Palladium
15	PMSF	=	phenylmethanesulfonyl fluoride
	pNA	=	p-nitroaniline
	P-pNA	=	L-proline p-nitroanilide
	R-pNA	=	L-arginine p-nitroanilide
20	SDS	=	sodium dodecyl sulphate
	S-bNA	=	L-serine beta-napthylamide
	SPA-bNA	=	L-seryl-L-prolyl-L-alanine beta-napthylamide
25	Ssp	=	<i>Streptomyces</i> Subtilisin-like protein
	ssp	=	gene encoding Ssp
	Tap	=	tripeptidyl aminopeptidase-S
30	tap	=	gene encoding Tap
	TSB	=	Trypticase Soya Broth
	XP-Mep	=	X-Pro Metalloendoproteinase

DESCRIPTION OF DRAWINGS

- FIG. 1. Degradation of GM-CSF and IL-3 by *S.lividans* fermentation broth (gel electrophoresis).
- 5 FIG. 2. Purified Tap analyzed by SDS-PAGE.
- FIG. 3. Inhibition of Tap by PMSF: IL-3 assay.
- FIG. 4. Cleavage of synthetic substrates by *S.lividans* fermentation broth.
- 10 FIG. 5. Nucleic acid and encoded amino acid sequences of tap.
- FIG. 6. (A) Common restriction map for tap-containing plasmid DNA isolated from clone P3-13 and P3-5.
(B) The tap deletion clones.
15 (C) The tap integration clones.
- FIG. 7. Conversion of GM-CSF to GM-CSF(-3) upon incubation with fermentation culture supernatants from cells carrying the tap clones.
- 20 FIG. 8. SDS-PAGE stained with Coomassie Brilliant Blue staining of fermentation supernatants from cultures of *S.lividans* 66 and *S.lividans* MS7 mutant protoplasts transformed with the GM-CSF expression vector pAPO.GM-CSF.
- 25 FIG. 9. Conversion of GM-CSF to GM-CSF(-3) upon incubation with fermentation culture supernatants from cells carrying P5-4, P5-6 and P5-10.
- 30 FIG. 10. Restriction map for P5-4 and P5-15 and their deletion clones.
- FIG. 11. Nucleic acid and encoded amino acid sequences of P5-4.
- 35 FIG. 12. Comparison of the predicted amino acid sequence encoded by P5-4 DNA and that of subtilisin BPN'.

- FIG. 13. Restriction map for P5-6 and P5- 17n and their deletion clones.
- FIG. 14. Nucleic acid and predicted amino acid sequences of P5-6.
- 5 FIG. 15. Comparison of the amino acid sequences of Tap and P5-6.
- FIG. 16. Restriction map for P5-10 and its deletion clones.
- FIG. 17. Nucleic acid and predicted amino acid sequences of P5-10.
- 10 FIG. 18. Restriction map for P8-1 and P8-2 and their deletion clones.
- FIG. 19. Nucleic acid and predicted amino acid sequence of P8-2.
- 15 FIG. 20. Synthetic DNA sequence encoding SCF.
- FIG. 21. Synthetic DNA sequence encoding IL-7.
- FIG. 22. Synthetic DNA sequence encoding EPO.
- FIG. 23. Demonstration of the use of Tap in ELISA technology by standard calibration curve in hIL-3
- 20 FIG. 24. SDS PAGE silver stained showing recombinant stem cell factor (SCP) secreted by AP3, AP6, APO and APz vectors.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

Tap A previously unknown protease, a tripeptidyl aminopeptidase designated Tap, derived from *Streptomyces*, has been identified, isolated, and characterized. The enzyme was purified by pH precipitation and chromatography. The pure protease had an apparent molecular weight of 55 kd as determined by SDS-PAGE.

Ssp Another previously unknown protease, a tripeptidyl aminopeptidase designated Ssp, derived from *Streptomyces*, has been identified, isolated, and characterized. The enzyme was purified by pH precipitation and chromatography. Ssp showed a significant amino acid sequence homology to that of *Bacillus subtilis* protease BPN' and was therefore designated Ssp (Subtilisin-like protein).

XP-Mep Another previously unknown protease, an X-Pro metalloendoproteinase derived from *Streptomyces*, has been identified, enriched and characterized. The enzyme was purified by a combination of chromatography and electrophoresis. The protease has an apparent molecular weight of 57-60 kd as determined by SDS-PAGE.

Other Proteases Other previously unknown proteases derived from *Streptomyces* have been identified, and partially characterized.

Degradation Products The major degradation products of Tap were isolated and analyzed by amino acid sequencing. This analysis indicated that the major degradation products were produced by the removal of the N-terminal tripeptides, APA and APM, from GM-CSF and IL-3 (FIG. 1A, Lanes 2, 3 and FIG. 3, lanes 5-8 respectively).

Based upon this information, the molecule APA-pNA and other analogues were synthesized as a potential substrate for Tap. This and several commercial substrates were employed in a survey of proteolytic activities in *S.lividans* fermentation broths (FIG. 4).

APA-pNA cleaving activity was greater than any other activity measured in the broth. This data suggested that one or more tripeptidyl proteases were responsible for the activity. Additionally, the lack of this activity towards the amino-blocked analog, N-Ac-APA-pNA, indicated that the proteases responsible were one or more aminopeptidases.

The presence of a two step cleavage via removal of AP followed by hydrolysis of A-pNA was eliminated by the low activities towards AP-pNA and A-pNA. This presence of an elastase-like endoproteinase was discounted by the lack of measurable cleavage of Boc-AAPA-pNA or N-Ac-APA-pNA in the filtrates (Ashe, et al., 1977; Hunkapiller, et al., 1976; Fink, et al., 1976).

Pure Tap cleaved the N-terminal tripeptide from GM-CSF and cleaved the N-terminal tripeptide from IL-3. When GM-CSF or IL-3 were used as a substrate, the cleaved products produced by pure Tap were identical to the major degradation products found in *Streptomyces* fermentations.

Pure Ssp cleaved the N-terminal tripeptide from M-CSF GM-CSF and sequentially removed tripeptide units from the N-terminus of IL-3. Unlike Tap, Ssp showed no preference for APA-pNA relative to APM-pNA.

The proteolytic activity of XP-Mep was followed by assaying the conversion of recombinant M-CSF GM-CSF to the N-terminally degraded forms, M-CSF GM-CSF(-4) and M-CSF GM-CSF(-6) (Fig. 1A, Lane 4). When M-CSF GM-CSF was secreted by *S.lividans*, these degradation products were found in the fermentation broth.

Studies with IL-3 and IL-6, indicated that XP-Mep was also capable of cleaving these proteins. SDS-PAGE analysis revealed that the pattern of IL-3 degradation generated by XP-Mep was very similar to that obtained during fermentation. The endoproteolytic cleavages generated by XP-Mep significantly reduced the

yield of protein biopharmaceuticals obtained from fermentation with *S.lividans*. The losses were particularly severe when the enzyme produced synergistic degradation with Tap and Ssp by removing N-terminal segments resistant to these enzymes.

Inhibitor A selective inhibitor of the proteases Tap and Ssp, L-alanyl-L-prolyl-L-alanine chloromethylketone (APACMK), was designed, synthesized, and applied to inhibit these proteases. APACMK stopped the release of p-nitroaniline from APApNA by Tap and Ssp. APACMK stopped the cleavage of M-CSF GM-CSF by Tap and Ssp. In fermentations of M-CSF GM-CSF, APACMK prevented cleavage of GM-CSF by Tap and Ssp during fermentation but did not significantly retard the rate of cell growth.

Impaired Strain DNA sequences adjacent to the tap and ssp genes were used to construct a subclone in which the tap and ssp genes were precisely deleted. This deletion clone was then substituted into the chromosomes of *S.lividans* 66 strains by homologous recombination to replace the wild type tap and ssp loci with mutant tap and ssp genes.

Disruption of the chromosomal tap gene in *S.lividans* resulted in a reduction in the generation of -3 forms of at least tenfold, indicating that this enzyme was responsible for the majority of the activity observed in *S.lividans* strains. Deletional inactivation of the ssp gene resulted in a further reduction in the ability of cell-free broth to hydrolyse the chromogenic substrate APA-bNA. Strains carrying chromosomal DNA deletions such as those described herein generally exhibited significantly lower protease activity, reducing the degradation of proteins expressed by genetically engineered host cells, and enabling higher recovery of secreted proteins from the culture supernatant produced by fermentation of the host strain in liquid medium.

Methods of preparing nucleic acid sequences capable of coding for the impaired proteases include: site specific mutagenesis to alter the sequence coding for an essential component for the activity or the expression of the protease; and deletion or mutation of the wild type gene by exposure to mutagens. Generally, the insertion of an impaired gene together with the deletion of a wild type gene is preferred.

Recombinant vectors are useful both as a means for preparing quantities of the protease-encoding DNA itself, or as a means of producing defective proteases to transform recombinant host cells for use in fermentation processes to produce various proteins.

Uses of the Proteases The proteases of this invention are used: (1) in processing recombinant proteins by removing propeptides or fused polypeptides incorporated into a genetic construct, thereby to facilitate expression and secretion to prevent degradation by other proteases, to facilitate purification of polypeptides, etc.; (2) in removing blocked N-terminals from proteins; (3) in digesting connective tissue proteins; (4) in effecting an immunoassay to enable the removal of one or more amino acids from a protein; (5) in carrying out a coupled assay for aminopeptidases to remove peptide blocking groups.

Protease XP-Mep of this invention may be used in a coupled assay for aminopeptidases, such as Tap or dipeptidyl peptidase IV, by removing a peptide blocking group thereby revealing a free amino terminal with an X-Pro sequence for reaction with the targeted enzyme.

Because XP-Mep is capable of digesting gelatin and collagen-like sequences, it is useful in processes involving digestion of connective tissue proteins. Such processes may include a) reduction of scar tissue in muscles, ligaments and tendons, b) wound debridement, c) meat tenderization, and d) cosmetic skin treatment. The

protease XP-Mep is useful as a scientific tool for the removal of blocked N-terminals from proteins to facilitate protein sequencing or for the digestion of proteins for peptide mapping and sequencing studies. The
5 protease XP-Mep is also useful for the processing of recombinant proteins by removing propeptides or fusion proteins incorporated into a genetic construct to prevent degradation by other proteases, to enhance the level of expression of the desired protein, or to
10 facilitate purification of a desired protein.

In addition, to uses previously described, the protease Tap of the present invention is used in coupled assays for proteases, especially those which require an extended P' peptide sequence for substrate
15 recognition, in which the target enzyme cleaves the substrate generating a free amino terminal 3 (or multiples of 3) residues from a reporter group, such as p-nitroaniline, which is then released by Tap yielding a readily measurable and quantifiable colorimetric or
20 fluorometric change.

The protease Tap of this invention is useful in protein sequencing for the removal of proline-containing tripeptides from proteins and peptides thereby giving cleaner sequence data by eliminating residual signals
25 caused by the incomplete cyclization of proline during sequence cycles.

Kit Kits of this invention contain isolated and purified proteases derived from *Streptomyces* to remove one or more amino acids from a protein. The uses of
30 high performance immunoassay have increased greatly in the last decade, extending to almost every discipline in the life sciences. In the majority of applications, antibodies are labelled with enzymes, biotin or fluorochromes, and serve as components of a signal
35 generating/amplifying system. This technology has a broad applicability and can be used in a wide variety of

laboratory techniques including enzyme-linked immunosorbent-assay (ELISA), immunoblotting, immunohisto/cytochemistry and immuno-electrophoresis. Example 31 shows how one can use Tap in the most widely used technique - microwell ELISA. Ssp or another protease of this invention is also suitable for this use.

A kit for ELISA would consist of:

(1) A protease covalently linked to biotin or other carrier capable of participating in the formation of an antigen-antibody complex (example: Tap or Ssp covalently linked to a goat antirabbit IgG);

(2) A substrate, APA-pNA or APA-AMC, which is cleaved by the protease bound in the antigen-antibody complex thereby generating an increase in light absorbance at 405nm with APA-pNA as substrate or an increase in fluorescence when an excitation/emission near 380/460nm is employed with APA-AMC as substrate.

There would be some advantages to using Tap in the ELISA system compared to the common enzymes. The substrates for Tap are more stable, less sensitive to interference due to presence of excipients, and more reliable. The reaction could be incubated much longer and could be measured at any time without stopping the reaction. If necessary, the reaction could be stopped specifically by APA-CMK. Tap activity would not be affected by peroxidases, catalases, phosphatases, chelators, or sodium azide which may interfere with common ELISA enzymes. Using Tap in ELISA would not compromise the sensitivity and may even increase sensitivity by using fluorescent substrates.

Example 1. Purification of Wild-Type Tripeptidyl Aminopeptidase

S.lividans 66 was grown in 11 liters of minimal media (minimal media = 12g Difco Soytone, 10.6g K_2HPO_4 , 5.3g KH_2PO_4 , 2.5g $(NH_4)_2SO_4$, and 1.0g $MgSO_4 \cdot 7H_2O$ per liter) for 24 hours at 32°C with stirring at 300 rpm in a Chemap

fermenter. Cells were removed from the media by ultrafiltration with a 0.45 μ m filter (Pellicon System, Millipore). Proteins in the filtrate were concentrated 20 fold by ultrafiltration employing a membrane with a 10 kd cutoff (Millipore). The protease activity was followed by assaying with APAPNA and M-CSF GM-CSF as described in Example 2. The protease was precipitated at 4°C by lowering the pH to 4.0 with 0.1M HCl. The precipitate was collected by centrifugation (Model J2-21, Beckman) at 10,000g at 4-10°C and was re-dissolved in 50 ml 10mM Tris-HCl, pH 8.0. After dialysis against 4 liters of the Tris buffer at 4°C, the protease was loaded at ambient temperature onto a 1.6 x 10cm anion exchange column (Q-Sepharose Fast Flow, Pharmacia) equilibrated with the Tris buffer. After washing with equilibration buffer, the bound protease was eluted with a 200ml gradient from 0 to 500mM NaCl at a flow rate of 2ml/minute. The active fractions were pooled to a concentration of 2M in ammonium sulfate. This material was loaded at ambient temperature onto a 1.6 x 10cm hydrophobic interaction column (Phenyl-Sepharose Fast Flow, Pharmacia) equilibrated in 10mM Tris-HCl, pH 8.0, 2M ammonium sulfate. After washing with equilibration buffer, the column was eluted with a 200ml gradient from 2 to 0M ammonium sulfate at a flow rate of 2ml/minute. The active fractions were assayed for purity by SDS-PAGE. The purification of Tap is summarized in FIG. 2 and shows about 20 μ g of protein were denatured under reducing conditions and analyzed by SDS-PAGE on 10% polyacrylamide gel. (A) represents purification of wild type. st=Molecular weight standards; Lane 1=Broth obtained after cell removal and concentration of broth by ultrafiltration through a 10kd membrane; Lane 2= Re-dissolved precipitate pH 4.0; Lane 3= Q-Sepharose chromatography pool; Lane 4=Phenyl-Sepharose chromatography pool. (B) represents purified Tap from

the universal search for expressor strain (see Example 12). st=Molecular weight standards; Lane 1=Tap purified from fermentation of the expressor (P3-5) strain.

Example 2. Assays of Tap Activity

5 Aliquots of Tap column fractions were diluted 100-fold with 20mM Tris-HCl, pH 8.0.

M-CSF GM-CSF as Substrate

To 10 μ l of rhM-CSF GM-CSF (1 μ g/ μ l, Cangene) and 20 μ l 20mM Tris-HCl, pH 8.0, 20 μ l of Tap were added. The
10 samples were incubated at 37°C for 2 hours. 20 μ l of 125mM Tris-HCl, pH 6.8, 0.1% bromophenol blue in 50% aqueous glycerol were added. Products were separated by native gel electrophoresis at constant current on a 17% polyacrylamide gel by a modification of the method of
15 Davies (Davies, 1964) in which the pH of all buffers was modified with H₂SO₄. Products were visualized by staining with Coomassie Blue G-250.

FIG. 1(A) demonstrates this technique by analyzing the M-CSF GM-CSF degradation, where Lane 1 shows intact, full
20 length M-CSF GM-CSF. Lane 2 shows M-CSF GM-CSF from *S.lividans* fermentation. Lane 3 shows degraded isolated M-CSF GM-CSF (-3). Lane 4 shows a mixture of degraded isolated M-CSF GM-CSF(-4) and M-CSF GM-CSF(-6.)

IL-3 as Substrate

25 To 50 μ l 20mM Tris-HCl, pH 8.0, 40 μ l rhIL-3 (2.5 μ g/ μ l, Cangene) were added followed by 10 μ l Tap. The samples were incubated at 37°C. 25 μ l aliquots were withdrawn at the desired time points and frozen on crushed dry ice. The products were separated by
30 isoelectric focusing from pH 3-10 using Pharmalyte 3-10 (Pharmacia) ampholytes (FIG. 3 - see Example 3). Products were visualized by staining with Coomassie Blue G-250. Intact IL-3 had a pI= 7.4. IL-3(-3) demonstrated a pI= 7.1.

35 APA-pNA as Substrate

The assay was conducted in a 96 well microtiter plate. To each well in the assay, 50 μ l 100mM Tris-HCl, pH 8.0, were added followed by 25 μ l 3.2mM APA-pNA. 25 μ l of Tap were added to the wells and the absorbance was read at 405nm. The assays were incubated at 37°C for 2 hours. The absorbance was read at 405nm. The activity (release of p-nitroaniline) was calculated from the change in absorbance.

A Survey of Proteolytic Activity in *S.lividans* Fermentation Broths

FIGURE 4 shows the quantification of proteolytic activities in the fermentation broth as measured with synthetic substrates. The assays were conducted in 50mM Tris-HCl, pH 8.0 with 0.8mM substrate incubated at 37°C. The change in absorbance at 405nm was measured after 1, 2, and 4 hours of incubation. The results were reported as micromoles of p-nitroaniline released in 1 hour by 1.0 ml of fermentation broth. 1= APA-pNA; 2= D-PFR-pNA; 3= L-pNA; 4= R-pNA; 5= P-pNA; 6= AP-pNA; 7= A-pNA; 8= AA-pNA; 9= N-Benzoyl-R-pNA; 10= Boc-AAPA-pNA; 11= N-Acetyl-APA-pNA; 12= N-Benzoyl-Y-pNA.

Other Assays and Characterizations

The cleavage specificity of the pure enzyme was examined with both proteins and synthetic substrates. The enzyme readily removed the first N-terminal tripeptide from M-CSF GM-CSF and IL-3 but failed to cleave IL-6 (possessing an additional N-terminal alanine residue). Attempts to force cleavage of IL-6 and further cleavage of M-CSF GM-CSF and IL-3 by increasing the enzyme: substrate ratio by a factor of 1,000 while simultaneously extending the digestion time by a factor of 10 yielded no new products. This resistance may be a function of the primary sequence or protection of the cleavage site by the folding of the target molecule. IL-3 underwent a significant shift in pI from 7.4 to 7.1 upon removal of the APM tripeptide

suggesting a structural rearrangement or the possible formation of a salt bridge by the new N-terminal.

Crystal structures showed the first 14 residues of M-CSF GM-CSF were solvent accessible and the M-CSF GM-CSF(-3) form could be further degraded by enzymes attacking the N-terminus while NMR studies indicated that the N-terminus of IL-6 was also accessible (Diedrichs, et al., 1991; Proudfoot, et al., 1993). It is also possible that the enzyme did not cleave tripeptides containing charged residues. EPO(-3) and (M-CSF GM-CSF(-3) have arginine as their N-terminal residues and appeared to resist further cleavage. The resistance of IL-6 may reside in the primary sequence, Ala-Pro-Val-Pro-Pro. The bulky valine side chain may prevent proper alignment in the active site. Alternatively, the secondary amide may be resistant to cleavage.

APA-pNA, APA-AMC, APM-pNA, and APS-bNA were synthesized by coupling Boc-AP (Bachem) with A-pNA (Sigma), A-AMC (Bachem), M-pNA (Bachem), and S-bNA (Bachem), respectively, by the mixed anhydride method followed by de-blocking with trifluoroacetic acid. AAPA-pNA was prepared by de-blocking Boc-AAPA-pNA (Bachem) with trifluoroacetic acid. N-Carbobenzoxymethyl-APARSPA-pNA was synthesized by manual solid phase methods employing a SASRIN resin (Bachem).

The protease was active against APA-pNA and the fluorogenic analog APA 7-amido-4-methylcoumarin (APA-AMC). The kinetic constants for cleavage of APA-pNA by TAP were $K_m = 37 \mu M$ and $V_{max} = 55 \mu moles \text{ min}^{-1} \text{ mg}^{-1}$ at pH 8.0. The enzyme cleaved APA-pNA 10 times as rapidly as the IL-3 analog, APM-pNA. This result agreed with those obtained when comparing the rates of M-CSF GM-CSF and IL-3 cleavage. The tripeptide beta-naphthylamide (bNA), APS-bNA, was also hydrolyzed.

The elastase substrate, N-Ac-APA-pNA, was completely resistant to cleavage by Tap. The N-blocked Boc-APS-bNA was not hydrolyzed by Tap. The extended N-blocked M-CSF GM-CSF analogs, Boc-APARSPA-bNA and N-carbobenzoxy-
5 APARSPA-pNA, were not affected by Tap, but in a coupled assay the reporter groups were rapidly released by simultaneously incubating the molecules with Tap and TPCK-treated trypsin (Sigma). This clearly demonstrated absolute requirement for an un-blocked N-terminal group
10 in the substrate. Additionally, Tap did not release the reporter group from Boc-AAPA-pNA (Bachem), N-Bz-R-pNA (Sigma), N-Bz-VGR-pNA (Sigma), A-pNA (Sigma), R-pNA (Sigma), L-pNA (Sigma), P-pNA (Sigma), S-bNA (Bachem), AA-pNA (Sigma), GP-pNA (Sigma), D-PFR-pNA (Kabivitrum),
15 or AAPA-pNA (Cangene Corporation). The enzyme has shown no ability to act on monoamino acid, dipeptide, or tetrapeptide substrates. The lack of activity towards D-PFR-pNA may result from the N-terminal D-isomer or the presence of the charged arginine as discussed herein.

20 The effect of pH on the activity of Tap has been examined. When APA-pNA was used as a substrate, the enzyme was active from between pH 5.0 and 9.5 with the maximal activity obtained from between 8.0 and 8.5.

The enzyme cleaved M-CSF GM-CSF from between pH 4.0
25 and 10.0 with greatest activity from between 5.0 and 9.0. The broad maximum for M-CSF GM-CSF reflected the high sensitivity of this substrate to Tap. The enzyme cleaved IL-3 from between pH 5.0 and 9.0 with maximal activity attained between 7.0 and 8.5. The enzyme was similar in
30 size to the lysosomal tripeptidyl aminopeptidases isolated from bovine anterior pituitary glands and porcine ovaries but does not exhibit the acidic pH optimum of those serine proteases (McDonald, et al., 1985; Doebber, et al., 1978). The pH optimum more closely
35 resembled that of the extracellular enzymes from human liver and erythrocytes but was considerably smaller than

these 135,000 dalton enzymes (Balow, et al., 1983). Examination of the tap DNA sequence may provide some insight into evolutionary relationships between the prokaryotic and eukaryotic enzymes.

5 Example 3. Inhibitors of Tap

Inhibitor Survey: Assay With APA-pNA

Tap was not inhibited or stimulated by chelating agents, divalent cations, or sulfhydryl reagents, thereby eliminating any relation to the subtilisins, 10 thiol proteinases, or metalloproteinases. Pepstatin was also ineffective. The failure of the peptide aldehydes, elastatinal and chymostatin, may reflect Tap's lack of endoproteolytic activity.

An inhibitor survey indicated that Tap was a serine 15 protease. Table I shows the inhibition of Tap activity by various protease inhibitors. The protease and inhibitor were preincubated for 15 minutes at 22°C. Substrate was added and the mixture was incubated at 37°C. Activity was measured by monitoring the change in absorbance at $\lambda =$ 20 405nm.

The enzyme was inhibited by the serine protease inhibitor, phenylmethanesulfonyl fluoride (PMSF). Treatment of Tap with PMSF inhibited cleavage of M-CSF 25 GM-CSF, IL-3, and APA-PNA.

Table I

Inhibition of TAP in the APA-pNA Assay

Sample	Concentration	Residual Activity
Enzyme only	-----	100
PMSF	1.6 mM	7
HgCl ₂	0.1 mM	99
	1.0 mM	93
CaCl ₂	1.0 mM	96
	10 mM	97
CoCl ₂	1.0 mM	98
	10 mM	97
EDTA	1.0 mM	95
	10 mM	95
IDA	1.0 mM	82

5

DTT	1 mM	86
DTT + EDTA	1 mM + 10 mM (respectively)	97
Elastatinal	0.1 mM	97
Chymostatin	0.1 mM	98
Pepstatin	0.1 mM	95
Benzamidine	10 mM	94

Inactivation of Tap with PMSF: Assayed with IL-3

Tap stock (Example 1) was diluted 100-fold with 20mM Tris-HCl, pH 8.0. A fresh solution of 80mM PMSF was prepared in isopropanol (iPrOH). A stock buffer of 20mM Tris-HCl, pH 8.0 was prepared. Four solutions were preincubated as follows.

	iPrOH	= 58 μ l Stock Buffer + 2 μ l iPrOH
	PMSF	= 58 μ l Stock Buffer + 2 μ l PMSF/iPrOH
10	Tap + iPrOH	= 18 μ l Stock Buffer + 40 μ l Tap 2 μ l iPrOH
	Tap + PMSF	= 18 μ l Stock Buffer + 40 μ l Tap + 2 μ l PMSF/iPrOH

These solutions were incubated at 22°C for 30 minutes. When the preincubation was complete, 40 μ l rhIL-3 (2.5 μ g/ μ l, Cangene) were added and incubation was initiated at 37°C. Aliquots of 25 μ l were removed at 0, 1, 2, and 4 hours. These aliquots were immediately frozen on dry ice. When the sampling process was complete, the products were analyzed by isoelectric focusing from pH 3-10 (Example 2).

FIGURE 3 shows the inactivation of Tap against IL-3. Lanes 1-4 show the incubation of IL-3 with Tap that was treated with PMSF. Lane 1= 4 hours; Lane 2= 2 hours; Lane 3= 1 hour.; Lane 4= 0 hours. Lanes 5-8 show the incubation of IL-3 with uninhibited Tap. Lane 5= 4 hours.; Lane 6= 2 hours.; Lane 7= 1 hour.; Lane 8= 0 hours. Lane 9 is a human carbonic anhydrase marker, pI= 7.4. Lane 10 contains pI markers. As can be seen in Lanes 5-8 of FIG. 3, the IL-3 (pI= 7.4) was completely converted to IL-3(-3) (pI= 7.1) by Tap within 2 hours. Lanes 1-4 show that with PMSF treatment, intact IL-3 is clearly detected after 4 hours. Tap was not affected by sulfhydryl reagents, chelators or aspartyl protease inhibitors (Table I).

Example 4. Amino Acid Sequencing of Tap

Tap was purified as described in Example 1 and was desalted by size exclusion chromatography. An Immobilon polyvinylidenedifluoride (PVDF) membrane (Millipore) was
5 solvated according to the manufacturer's instructions. Tap was adsorbed to the membrane by filtration employing a slot blot assembly. Protein bound to the membrane was visualized with Amido Black. The sample was excised and subjected to automated Edman degradation for 15 cycles.
10 The N-terminal sequence of the isolated wild-type Tap was NH₂-Asp-Gly-His-Gly-His⁵-Gly-Arg-Ser-Trp-Asp¹⁰-Arg-Glu-Ala-Arg-Gly¹⁵.

Table II

<u>Amino Acid</u>	<u>Mole percentage</u>	
	<u>Protein</u>	<u>DNA</u>
Asp + Asn	13.6	12.4
Glu + Gln	10.9	7.6
Ser	4.7	4.7
Gly	10.0	8.9
His	2.2	2.3
Arg	7.4	7.4
Thr	6.3	6.3
Ala	14.3	14.3
Pro	7.2	7.2
Tyr	3.9	3.8
Val	6.4	7.6
Met	1.2	1.3
Ile	2.3	3.0
Leu	5.6	6.3
Phe	1.7	2.5
Lys	2.5	4.4

20 The first 15 residues of the N-terminal of the
 isolated wild-type protease were determined and
 identically matched amino acids 40-54 derived from the
 DNA sequence (FIG. 5). Residues -39 to -4 appeared to
 be a signal peptide. An autolytic tripeptide cleavage
 removing APA after signal peptide removal would yield the
 25 N-terminal found for the secreted protease.

Table II shows the amino acid composition of the wild-
 type Tap. The amino acid composition derived from the
 corresponding portion of the tap gene DNA sequence (FIG.
 5) is shown for comparison. The small differences in
 30 composition may be attributable to low level impurities
 in the enzyme sample.

Example 5. Synthesis of APACMK

21.3g (70mmol) Boc-Ala-Pro (Bachem Biosciences) dissolved in 175ml anhydrous dimethylformamide (DMF) were activated by adding 7.8ml (70.7mmol) 4-methylmorpholine followed by 9.3ml (70.7mmol) isobutylchloroformate at -20°C with stirring. After 15 minutes, 15.1g A-OBz in 175ml anhydrous DMF were added. The solution was stirred for 1 hour at -20°C and then for 17 hours at ambient temperature. The DMF was removed by vacuum rotary evaporation. The residue was taken up in 175ml ethyl acetate and extracted each with 5% citric acid, saturated sodium bicarbonate, water, and brine. The organic layer was dried over anhydrous sodium sulfate for 1 hour. The sodium sulfate was removed by filtration.

2.5g 5% Pd on activated carbon were added and the suspension was agitated under a hydrogen atmosphere for 2 hours. At that time, the starting material had been completely converted to product. The hydrogenation catalyst was removed by filtration through Celite. The solvent was removed by vacuum rotary evaporation.

The resulting 23.7g (66.3mmol) of Boc-APA were dissolved in 140ml anhydrous ethyl acetate and reacted with 7.8ml (70mmol) of 4-methylmorpholine followed by 9.2ml (70 mmol) of isobutylchloroformate at -20°C with stirring. After 15 minutes, a solution of diazomethane in anhydrous ether prepared from 100mmol N-methyl-N-nitroso-p-toluenesulfonamide (Aldrich) was added. After 1 hour at ambient temperature, the solution was extracted twice with 140 ml portions of water. The organic layer was dried over 2 g anhydrous sodium sulfate powder for 1 hour. The solution was removed by decantation. Deblocking of the N-terminal and generation of the chloromethylketone group were achieved simultaneously by adding 100ml of HCl(g) saturated ethyl acetate. The resulting solution was allowed to stand at ambient

temperature for 30 minutes. The product was removed from the organic solvent by extraction into 400ml of water. The aqueous pool was frozen and lyophilized to yield the product, APACMK, as its hydrochloride salt.

5 **Example 6. Inactivation of Tap by APACMK: Assayed with APA-pNA**

10 A stock solution of 10nM Tap in 100mM Tris-HCl, pH 8.0 was prepared. Serial dilutions of 210 μ M, 21 μ M, 2.1 μ M, 210nM, 21nM, and 2.1nM APACMK (Example 5) were prepared. To the microtiter well, 25 μ l of Tap followed by 25 μ l of an APACMK dilution or distilled water, for an uninhibited control, were added. The assays were incubated for 20 minutes at 22°C. 50 μ l 1.6mM APA-pNA were added to each well. The absorbance was read at 15 405nm then incubated at 37°C. The change in absorbance at 405nm was read after 15 and 60 minutes of incubation.

Example 7. Inactivation of Tap by APACMK: Assayed with M-CSF GM-CSF

20 A stock solution of 10nM Tap in 20mM Tris-HCl, pH 8.0 was prepared. Serial dilutions of 210 μ M, 21 μ M, 2.1 μ M, 210nM, 21nM, and 2.1nM APACMK (Example 5) were prepared. To 20 μ l Tap, 20 μ l of an APACMK dilution (or water for an uninhibited enzyme control) were added and 25 incubated at 22°C for 30 minutes. 10 μ l of M-CSF GM-CSF (1 μ g/ μ l, Cangene) were added and incubated at 37°C for 2 hours. Products were analyzed by native gel electrophoresis as described in Example 2.

**Example 8. Inactivation of Tap by APACMK -
Determination of Kinetic Constants**

A stock solution of 1.1 μ M Tap in 50mM Tris-HCl, pH 8.0 was prepared. APACMK stock solutions of 11 μ M, 13.8 μ M, 17.3 μ M, 21.7 μ M, 27.0 μ M, 54.0 μ M, 108 μ M, and 1.08mM were prepared. The substrate solution was 50mM Tris-HCl, pH 8.0, 0.8mM APA-pNA. The inactivation was performed by placing 90 μ l of Tap (1 nanomole) in a 1.5 ml Eppendorf tube on ice and adding 10 μ l of water (uninhibited control) or 10 μ l of APACMK. A 10 μ l aliquot was removed immediately and was assayed by adding it to a cuvette containing 390 μ l substrate solution at 22°C. The initial velocity was obtained from the change in absorbance at 405nm during the first 10 seconds of the assay. Additional aliquots were removed at time points and assayed by the same method. At APACMK concentrations greater than 5.0 μ M in the incubation, it was not possible to remove an aliquot from the incubation before 90% inactivation occurred.

The inhibitor APACMK yielded $K_i = 3.3 \mu\text{M}$ and $k_{\text{inact}} = 0.14 \text{ min}^{-1}$ with >99% inactivation within 6 minutes at 0°C at an inhibitor concentration of 2.7 μ M and an inhibitor/enzyme molar ratio of 2.7.

Example 9. Application of APACMK in Fermentation

A 100ml volume of media was inoculated in 500ml baffle-bottom flasks with 100 μ l of *S.lividans* 66 working seed bank material. The cultures were grown in a New Brunswick gyratory incubator at 32°C and 240rpm. The cultures were sampled at 25, 27, 29, 31 and 48 hours post-inoculation and were analyzed by native gel electrophoresis. Following removal of the 25 hour sample, 100mM APACMK in sterile water were added to yield a final concentration of 10 μ M. A control flask without APACMK was retained. The addition of APACMK

significantly reduced formation of M-CSF GM-CSF(-3) but did not inhibit cell growth.

Example 10. Construction and Screening of a *S.lividans* Genomic Library

5 A *S.lividans* 66 (Hopwood, et al., 1983) genomic library was made using size fractionated (3-12 Kb) fragments of chromosomal DNA partially digested with *Sau3AI* and ligated into the *Bam*HI site of the bifunctional cloning vector, pSS12 (Butler, et al., 10 1992). The ligated DNA was used to transform competent cells of *E.coli* HB101 and pooled plasmid DNA was isolated from a mixture of approximately 30,000 transformed colonies grown in SOB medium (Maniatis, et al., 1982) containing ampicillin (Sigma). This DNA was 15 used for transformation of *S.lividans* 66 protoplasts yielding 15,000 transformant colonies resistant to thiostrepton (E.R. Squibb). Two days later the colonies were screened by overlaying with substrate mixture [containing 5 ml phosphate buffer (50 mM, pH 20 7.0), 25 μ l GPL-bNA (20 mg/ml in DMSO), 0.1 ml Fast Garnet GBC (10 mg/ml in water)]. The plates were incubated for three minutes at room temperature and washed three times with saline solution (Atlan, et al., 1989, Alvarez, et al., 1985). Positive colonies 25 stained intensely red against a background for pale red colonies.

Two colonies reproducibly showed strong color. Plasmid DNA was isolated from each of these two colonies and the phenotype was retained when the DNA 30 was used to transform protoplasts of *S.lividans* 66. The plasmid DNA from each of these clones (P3-5 and P3-13) was investigated by restriction enzyme analysis. The data indicated that P3-5 and P3-13 were identical (presumably siblings). The peptidase gene was 35 localized within the cloned DNA fragment by monitoring the GPL-bNA hydrolyzing activity of strains containing

various subclones and deletion clones derived from the original clones.

FIGURE 6 (A) shows a restriction enzyme site map of cloned P3-5 DNA. Phenotype in the GPL-bNA hydrolysis agar plate assay is shown qualitatively as the number of + signs judging red color developed on the colonies. The *EcoRI* site shown in parentheses was present in the pSS12 vector adjacent to the *BamHI* cloning site. None of the three deletion clones, shown in FIG. 6(B), produced any more red color in colonies than did the pSS12 control plasmid. Each were scored as "+" due to the background level of hydrolysis from the chromosomal *tap* gene in the *S.lividans* 66 host.

Example 11. Tap Activity of *S.lividans* 66 Strains Carrying the P3-5 and P3-13 Clones

The *S.lividans* 66 strains carrying the P3-5 and P3-13 clone or pSS12 were grown in TSB (containing 1% glucose, 0.1 M MOPS and 20 $\mu\text{g ml}^{-1}$ thiostrepton). Aliquots (40 ml) of each culture were removed at 23 and 29 hours, and the supernatant and mycelium fractions were separated by centrifugation. Aliquots of the supernatant fractions were added to reactions (100 μl) containing various tripeptide-bNA substrates (8nmol) in microtiter wells. After incubation at 37°C for 4 hours, a solution (50 μl) containing Fast Garnet GBC dye was added and the A_{540} was measured in a microtiter plate reader. The results are shown in Table III.

Table III
Tripeptidyl Aminopeptidase Activity
(A₅₄₀ above background)

Sample	GPL- bNA	GPM- bNA	APF- bNA	D-FPR- bNA
5 Supernatants				
P3-5/23 -	Max	Max	Max	0.02
Hours				
P3-5/29 -	Max	Max	Max	0.08
Hours				
10 SS12/23 -	0.19	0.28	0.63	0.02
Hours				
SS12/29 -	1.38	2.46	Max	0.17
Hours				

("Max" indicates a A₅₄₀ reading of >3.0)

15 At as early as 23 hours of culture, a 1 μ l aliquot of the supernatant from *S.lividans* carrying the P3-5 clone was showing strong activity against the GPL-, GPM- and APF-bNA substrates. At the same time point, a 25 μ l aliquot of the control culture had at least 15 to 20 fold

20 lower activity with the same substrates. However, against the D-FPR- and APF-bNA substrates, the Tap expressor had little increased activity over the control. An aliquot (1 μ l) of each supernatant (which was harvested after 23 hours of growth) was added to a

25 reaction containing 4 μ g of purified intact M-CSF GM-CSF. Following a 2.5-min. incubation at 37°C, the proteins were analyzed by native PAGE and stained with Coomassie Brilliant Blue.

30 FIGURE 7 shows the conversion of exogenously added, purified full length M-CSF GM-CSF (lane 1) degraded to GM-CSF(-3) upon incubation with fermentation culture supernatants from culture samples carrying the p3-5 and

P3-13 clones (lanes 2 and 3, respectively). By contrast, no significant degradation was observed when M-CSF GM-CSF was incubated with the control culture (lane 4) due to the small volumes of culture supernatant and short time of incubation used compared to those described in Example 2.

Example 12. Analysis of Extracellular Proteins From *S.lividans* 66 Strains Carrying the p3-5 and p3-13 Clones

The *S.lividans* 66 carrying the P3-5 and P3-13 clones were grown in liquid culture, and supernatant fractions were collected following the teaching of Example 11. As described by Laemmli (1970), samples were prepared from aliquots (200 μ l) of the supernatant fractions, and SDS-10% polyacrylamide gels were run at 100 v for 5 to 6 hours. The profile of separated proteins was then visualized by staining with Coomassie Brilliant Blue.

An abundant protein with an apparent molecular weight of 55,000 daltons was present among the extracellular proteins from *S.lividans* 66 carrying either P3-5 or P3-13. From 23 to 29 h of culture, the level of Tap increased to approximately 0.1 mg/ml, relative to the BSA standards that were included on the same gel.

Example 13. Amino-Terminal Sequence of the Tap Protein Purified from an *S.lividans* 66 Strain Carrying the P3-13 Clone

The *S.lividans* 66 strain carrying the P3-13 clone was grown in liquid culture and supernatant fractions were collected, following Example 11. The extracellular proteins were separated by SDS-PAGE, following the teaching of Example 12, and transferred onto Immobilon PVDF (Millipore) membranes as directed by the supplier. After briefly staining the filters with Coomassie Brilliant Blue, the bands containing the major protein were excised from the filter, and subjected to automated Edman degradation analysis. The amino-terminal amino

acid sequence determined was: Asp-Gly-His-Gly-His-Gly-Arg-Ser-Trp-Asp-Arg.

The amino-terminal sequence of the protease from the expressor (P3-5) matched the amino-terminal sequence of the Tap purified from the extracellular broth of untransformed *S.lividans* 66. In addition, the enzymes from both sources had similar substrate specificities and the same apparent molecular weight of 55,000 daltons as determined by SDS-PAGE (FIG. 2). These factors indicate that the protease isolated from wild type *S. lividans* 66 and the P3-5 transformant were the same enzyme.

Example 14. Nucleotide Sequence of the tap gene

The nucleotide sequence for the *S.lividans* tap gene is shown in Figure 5. Inspection of the sequence reveals a potential protein encoding region of 537 codons amino acids consistent with the molecular weight of the observed secreted protein of 55kd. The potential protein coding region is indicated by an arrow in FIG. 6(A) and the deduced amino acid sequence is shown in Figure 5 for each codon. The putative translation initiation codon is a TTG which is preceded by a strong potential ribosome binding site GGAGG. The deduced amino acid sequence shows a predicted signal peptide (von Heijne, 1986) which could be cleaved between residues 36 and 37 (ASA↓A). The experimentally determined amino acid sequence of the mature secreted protein was identical to that encoded by residues 41 to 51 of the predicted protein sequence. This suggests that the protein is secreted as a propeptide with a three amino acid propeptide (APA). Since the enzyme removes such tripeptides from polypeptides it is highly likely that the removal of this APA is autocatalytic (although this was not experimentally tested). When the deduced amino acid sequence was compared to sequences in the protein databases, the closest match was with that of the 2-

hydroxy-6-oxo-2,4-heptadienoate hydrolase (HOHH) from *Pseudomonas putida* F1 (Menn, et al., 1991) as follows.

Tap (199) K L N Y L G V S Y G T Y L G A V Y G T L F P D H V R R
M V V (288)
5 HOHH (98) R V D L V G N S F G G A L S L A F A I R F P H R V R R
L V L (127)

The weak homology includes the GVSYG sequence which includes the serine residue potentially involved in the catalytic action of this protease. The coding sequence
10 is closely followed by a substantial inverted repeat ($\Delta G = -62 \text{ kcal.mole}^{-1}$ calculated according to Tinoco, et al., (1973) suggesting that the tap gene is transcribed independently of other adjacent DNA sequences. A potential protein encoding region is present upstream of
15 the tap gene, however, since an inverted repeat sequence ($\Delta G = -39 \text{ kcal.mole}^{-1}$) follows this region it may be transcriptionally independent of the tap gene.

Example 15. Analysis of the Chromosomal tap Gene of Various *Streptomyces* Species

20 Genomic DNA was isolated from the following *Streptomyces* strains. *S.alboniger* 504 (P. Redshaw, Austin College, Texas, USA), *S.ambofaciens* ATCC 23877, *S.coelicolor* M130 (John Innes Institute), *S.fradiae* ATCC 14544, *S.griseus* IMRU 3499, *S.griseus* ATCC 10137,
25 *S.lividans* 66 (B. Pogell, Univ. of Maryland, MD, USA), *S.parvulus* 2283 (John Innes Institute) *S.rimosus* ATCC 10970. 10 μg of each DNA were digested in 100 μl of appropriate buffer for the restriction enzymes BamHI and
30 *Pst*I respectively. 30 units of each enzyme were added together with 1 μl of RNase A (10 mg/ml, Sigma). The reactions were incubated at 37°C for 3 hours. A further 15 units of enzyme were added and the samples incubated overnight at 37°C. Digestions were terminated by the

addition of 11 μ l of stop buffer (0.08% Orange G; 50% glycerol; 67 mM EDTA, pH8). Approximately 3 μ g of each digested DNA sample were loaded onto a 1% agarose horizontal gel and electrophoresed at 100V for 4 hours.

5 A molecular weight marker was included (Lambda DNA digested with *Hind*III, Bethesda Research Laboratories) to calibrate the gel. After electrophoresis the gel was soaked in 0.25 M HCl, followed by 0.5M NaOH, 1.5M NaCl and rinsed in water. The DNA was transferred to a Nylon

10 membrane (Boehringer Mannheim) using a Vacublot (Pharmacia) apparatus with 20 x SSC buffer for 1 hour at 50 mbars pressure. After transfer the membrane was washed in 2 x SSC and baked for 1.5 hours at 80°C.

The DNA insert fragment from the *Eco*RI site to the

15 right-most *Bam*HI site was isolated by partial *Bam*HI and complete *Eco*RI digestions of the P3-13 DNA. The fragment was subcloned into the *E.coli* plasmid vector pT7T3 (Pharmacia). From this clone it was possible to isolate larger quantities of the same DNA fragment by digestion

20 with *Eco*RI and *Hind*III. 0.5 μ g of this 3.3 Kb- fragment were labelled according to the manufacturer's recommendations (Boehringer Mannheim) to produce a digoxigenin - labelled probe. 25 ng of probe were used per ml of hybridization solution. Lambda DNA was

25 labelled in the same way to allow visualization of the molecular weight marker fragments. Hybridization was carried out at 68°C overnight using 2.5 ml of hybridization solution per 100 cm² of nylon membrane. The hybridization solution contained; 5 x SSC; blocking

30 reagent, 1% (w/v); N-lauroylsarcosine, 0.1% (w/v); sodium dodecyl sulphate, 0.02% (w/v). Filters were prehybridized for 1 hour at 68°C. Probes were boiled for 10 minutes, quick chilled on an ice/NaCl bath, diluted with 100 μ l hybridization solution and added to the prehybridized

35 membrane in a stoppered glass bottle. Hybridization and prehybrization were carried out using a Hybaid mini-

hybridization oven. Membranes were washed twice at 68°C for 30 minutes in 5 x SSC, 0.1% SDS (50 ml/100 cm² membrane). The membranes were then transferred to plastic containers and processed according to the manufacturer's instructions. Finally, the membranes were transferred to plastic bags, sealed and incubated at 37°C for 30 minutes, and then exposed to X-ray film for 10 minutes. The resulting autoradiogram showed hybridizing bands in all lanes except those containing *S.fradiae* DNA. Identical hybridizing bands were observed with *S.lividans* and *S.coelicolor* with a common band in both *S.griseus* strains as well as the *S.parvulus* DNA. *S.ambofaciens*, *S.rimosus* and *S.alboniger* produced hybridizing bands at different molecular weights, suggesting restriction fragment length differences in these species. This indicates the likely presence of a *tap* gene in other *Streptomyces* species which would be expected to be detrimental to product yield when expression of secreted proteins is desired in these strains. Taken overall the results suggest that the *Tap*-encoding DNA sequence occurs widely throughout the *Streptomyces* strains examined.

In a similar experiment Southern hybridization analysis of chromosomal DNA, using the plasmid P3-13 as a probe suggested that the DNA contained in P3-13 had not been rearranged during cloning.

Example 16. Construction of A Deletion Subclone From the *tap* Clone

Specific deletions were made in the *tap* clone to localize the gene and enable chromosomal disruption. A 1.2 -Kb DNA fragment was removed between *Bam*HI (1100) and *Bgl*III (2300) (see FIG. 6B) to construct the deletion clone Δ 1. P3-5 DNA was digested by means of *Eco*RI and *Bgl*III, and the vector fragment was isolated; and P3-5 was digested with *Eco*RI and *Bam*HI and the 1.1 -Kb insert fragment was isolated. The vector and insert fragments were ligated, using T4 DNA ligase, and used to transform

E.coli. The plasmids were screened by restriction analysis and the correct plasmid, $\Delta 1$, used to transform protoplasts of *S.lividans* 66. The *S.lividans* 66 carrying the $\Delta 1$ deletion clone was screened with a plate assay
5 using GPL-bNA. A transformant was grown in liquid culture, and the level of Tap activity was determined in a liquid assay using GPL-bNA and APA-bNA substrates. The *S.lividans* 66 carrying the $\Delta 1$ deletion subclone had a similar Tap activity to that of the untransformed host
10 strain.

Deletion clone $\Delta 2$ was constructed by subcloning the *EcoRI*-*BglIII* fragment into the vector pSS12 which had previously been digested with *EcoRI* and *BamHI*. $\Delta 3$ was made by digestion of P3-5 DNA with *BglIII*, followed by
15 religation, resulting in the loss of the 300 nt *BglIII* fragment around the centre of the *tap* gene. The high level of Tap activity associated with the P3-5 plasmid was not observed with $\Delta 2$ or $\Delta 3$, confirming that the deletions resulted in loss of enzyme activity.

20 **Example 17. Deletion Clones Used for Integrational Mutation of *tap* into the *S.lividans* 66 Chromosome**

This example describes the use of the deletion clones of the *tap* gene for integrational mutation into the
25 *S.lividans* 66 chromosome resulting in inactivation of the wild type *tap* gene. Loss of the wild type *tap* gene occurred by homologous recombination with the integrated mutant DNA sequence using the natural ability of the *S.lividans* host cell to resolve such regions of
30 chromosomal DNA containing directly repeated nucleotide sequences. Resolution occurred apparently at random to produce strains carrying either the wild type parental *tap* gene or the exchanged mutant *tap* gene. Mutant strains were identified by their inability to hydrolyse
35 the chromogenic substrate GPL-bNA.

Subcloning of the DNA insert sequences from the deletion clones was not straightforward due to the presence of multiple *Bam*HI sites. A partial *Bam*HI digestion of P3-5 DNA was followed by a complete *Eco*RI digestion. The 3.1 Kb *tap*-encoding fragment was isolated from an agarose gel and subcloned into the *E.coli* vector pT7T3 which had previously been digested with *Bam*HI and *Eco*RI. Appropriate transformants were identified and the DNA insert was used to create further subclones in the pINT vector as follows: Δ 1int was produced by a three way ligation of the *Eco*RI-*Bam*HI, *Bgl*II -*Hind*III (in the polylinker of the pT7T3 vector) fragments from the pT7T3 subclone and the *Eco*RI-*Hind*III fragment produced by digestion of pINT. Δ 2int was the result of a direct subcloning of the *Eco*RI-*Bgl*II fragment from the pT7T3 subclone into pINT digested with *Eco*RI and *Bam*HI. Δ 3int involved the *Bgl*II-*Hind*III fragment from the pT7T3 subclone and *Bam*HI plus *Hind*III digested pINT. Δ 4int was a direct subcloning of the whole inserted fragment in the pT7T3 subclone (*Eco*RI + *Hind*III) into the same sites in pINT. Δ 5int was made from Δ 4int by digestion with *Bgl*II and religation. The DNA contained within the various Δ int clones is shown in FIG. 6C.

Plasmid DNA of the various Δ int clones was isolated and used to transform protoplasts of *S.lividans* 66 (wild type) and MS5 (a strain derived from *S.lividans* 66 by deletion of DNA fragments at the *slpA* and *slpC* (Butler, et al., 1992) loci; in addition the *pepP* gene (Butler, et al., 1993) and a second *PepP*-encoding gene (Butler, et al., 1994) were also subjected to specific chromosomal DNA deletion events, each of which reduced the *PepP* activity of the *S.lividans* strains). Integrative transformants resistant to thiostrepton were purified and allowed to grow in the absence of thiostrepton to allow recombinational resolution to occur. Strains which had undergone excision events were

easily identified by screening for the loss of the ability to hydrolyse GPL-bNA.

The results obtained were somewhat unexpected. Δ lint did not produce any integrative thiostrepton-resistant transformants from *S.lividans* MS5 in three independent experiments. Δ 2int did lead to integrative transformants, indicating that there was no practical impediment to recombination events at this locus on the *S.lividans* chromosome. Subsequent experiments using Δ lint were successful using *S.lividans* 66 protoplasts (to make a strain designated MS9 which was defective only at the tap locus) suggesting that the earlier failure in the MS5 experiment was due to the lower transformation capability of that particular batch of MS5 protoplasts. Δ 3int failed to produce integrative transformants, possibly due to the relatively small length of DNA (900nt) available for homologous recombination to occur. However, Δ 4int yielded transformants as did Δ 5int.

Integrative transformants from *S.lividans* 66 and MS5 using Δ 5int were grown in the absence of the thiostrepton selection on agar medium. After sporulation had occurred the spores were harvested and replated onto fresh agar plates. Colonies were screened using the GPL-bNA substrate assay for Tap activity. The frequency of excision events which led to loss of the activity was very low (approximately 1 in 1000). Three colonies were obtained with reduced Tap activity.

Following the teaching of Example 15, chromosomal DNA was isolated from *Streptomyces lividans* 66 and deletion mutant strains and Southern hybridization analysis of the chromosomal tap locus was performed. The DNA was digested with *Bam*HI or *Stu*I and transferred to a nylon membrane (Hybond, Amersham). Using a 32 P-labelled probe for the *Bgl*III fragment internal to the tap gene resulted in a strong band of hybridization at approximately 1.8 Kb in the *Bam*HI digests and two bands in the *Stu*I digests

for both the *S.lividans* control and colony #3 indicating that this DNA fragment was present in both strains. However, no hybridizing bands were observed for colonies 1 and 2 confirming the loss of the 0.3 Kb *Bgl*III fragment. Similar experiments with a 3.3 Kb DNA probe revealed a complex hybridizing band pattern in colony 1 chromosomal DNA whereas colony 2 DNA showed only the expected bands with a reduction in size of one band consistent with the desired specific chromosomal deletion. Colony 2 was designated *Streptomyces lividans* MS7. Another strain was constructed using $\Delta 5int$ and *S.lividans* 66 protoplasts. This strain was designated MS8 and shown to have properties indistinguishable from those of MS9.

Example 18. The *S.lividans* MS7 Strain Shows a Substantial Reduction in its Ability to Hydrolyse Tripeptide bNA Substrates and GM-CSF in vitro

The *S.lividans* MS5 (*tap*⁺) and MS7 (*tap*⁻) strains were grown in liquid culture (TSB medium without thiostrepton) and samples of the cultures were collected at various time points during the fermentation. Cell-free supernatant fractions were isolated by centrifugation to remove the mycelial material. Aliquots (50 μ l) of the supernatants were added to each of the chromogenic tripeptide substrates APA-bNA or GPL-bNA (8nmol) in a final volume of 100 μ l. After incubation at 37°C for 45 minutes, 50 μ l of a solution of Fast Garnet GBC dye was added and the A_{540} measured using a microliter plate reader.

The results, summarized in Table IV, indicate that under these assay conditions, the supernatants derived from the MS7 culture were (within experimental error) devoid of any significant hydrolytic ability against these substrates, whereas the supernatant derived from *S.lividans* MS5 showed the ability to rapidly degrade substrates.

Table IV
Tripeptidyl Aminopeptidase Activity of MS5 and MS7
(A₅₄₀)

Substrate	APA-bNA		GPL-bNA	
	MS5	MS7	MS5	MS7
21 hours	1.459	0.337	0.952	0.338
25 hours	2.052	0.456	1.170	0.374
29 hours	1.808	0.390	1.151	0.399
45 hours	1.586	0.382	0.877	0.366

10 The same supernatant samples harvested at 25 hours were analyzed for the ability to degrade GM-CSF *in vitro* according to the teaching of Example 16. It was clear from native PAGE analysis that the rate of degradation of GM-CSF was significantly slower for MS7 than for MS5.

15 **Example 19. Production of Undegraded GM-CSF by the *S.lividans* MS7 Strain**

20 The GM-CSF expression plasmid vector pAPO.M-CSF GM-CSF was used to transform protoplasts of the *S.lividans* MS7 strain. Following the teaching of Example 11, liquid cultures were prepared from the transformed strain as well as transformants from the *S.lividans* MS5 strain. Cell free broth from the strains was harvested at various time points during fermentation and analyzed by native PAGE (FIG. 8).

25 The results indicate that while degradation of the secreted GM-CSF occurred in both strains, it was evident in MS7 only at later times of growth, as compared to the MS5 samples. This property of the new *S.lividans* MS7 strain allowed it to be used to produce a higher yield of undegraded GM-CSF than was possible using the wild-type *S.lividans* 66 strain.

30

Example 20. Production of Mutant Strains of *S.lividans* Defective in Protease Activities Using Chemical Mutagenesis

5 *S.lividans* 66 spores were treated with N-methyl-N-nitro-N-nitrosoguanidine (MNNG) (Hopwood, et al., 1985). Briefly, a suspension containing 2.5×10^{12} spores in 3 ml of Tris/maleic acid buffer was incubated at 30°C in a preweighed vial containing 10 mg of MNNG (which had been
10 solubilized in 0.5 ml DMSO immediately prior to the addition of the spore suspension). Aliquots of 1 ml were removed from the mixture at 30 minute intervals and washed twice by centrifugation to remove the MNNG. Serial dilutions of the treated spores were plated on
15 agar medium to determine the effectiveness of the mutagenic treatment in terms of the proportion of viable surviving colony forming units remaining compared to untreated spores. Survival rates of 2.8×10^{-3} %, 1.2×10^{-4} % and 9×10^{-6} % were observed after 30, 60 and 90 minutes, respectively.

20 Two hundred surviving colonies from each of the three treatment times were purified and examined for their ability to grow on minimal medium. Colonies which were unable to grow were classified as auxotrophic mutants of which 1, 4 and 2 were observed at the 30, 60 and 90
25 minute treatment times, respectively.

Spores from the 60 minute treatment were, therefore, examined for the presence of strains carrying mutations which inactivated specific proteolytic phenotypes. A direct agar plate screening technique was used in which
30 the colonies were overlayed with substrate mixture (containing 0.1 ml of GPL-bNA (Bachem Inc., 1 mg dissolved in DMSO), 0.1 ml Fast Garnet GBC (Sigma) dye (10 mg/ml in water), 6 ml of 50 mM phosphate buffer, pH 7.0 and 0.2 ml DMSO. The plates were incubated for
35 twenty minutes at room temperature and washed three

times with saline solution (Atlan, et al., 1989; Alvarez, et al., 1985).

Screening of 2,700 colonies using GPL-bNA revealed two colonies which did not turn red. Testing supernatants from liquid cultures of one of these colonies (12-5 or 12-8), with various chromogenic tripeptide substrates (Table V), confirmed that this specific hydrolytic ability had been either eliminated or at least very substantially reduced compared to the original untreated *S.lividans* strain.

Table V
Tripeptidyl Aminopeptidase Activity
(A_{540} above background)

Substrate	GPL-bNA	GPM-bNA	APF-bNA	D-FPR-bNA
Supernatants				
12-5/T2	0.01	0.01	0	0
12-5/T4	0.10	0.10	0.05	0.06
12-8/T2	0.02	0.02	0	0
12-8/T4	0.13	0.12	0.12	0.08
1-5/T2	0.01	0.01	0.01	0.02
1-5/T4	2.55	Max	Max	0.09

("Max" indicates a A_{540} reading of >3.0)

In a similar experiment to that described above, a L-bNA substrate was used, resulting in the isolation of one mutant (tap) strain (1-5) from 1500 colonies screened. By comparison, the Tap activity of this mutant strain was unchanged from that of wild type *S.lividans* 66.

Aliquots of each culture supernatant were added to reactions containing 2.5 mg M-CSF GM-CSF and incubated

at 32°C for 2 minutes. The proteins were separated by SDS-PAGE and visualized by Western blotting, using an antiserum raised against the amino terminal 35 amino acids of GM-CSF. At 40 h (T3), the cultures from the tap mutants, #11 and #12 contained less activity for converting M-CSF GM-CSF to M-CSF GM-CSF(-3) than those from the *S.lividans*, MS2 and the tap mutant, #1.

Protoplasts were prepared from the various *S.lividans* 66 mutants, and were transformed using the M-CSF GM-CSF expression vector pAPO.M-CSF GM-CSF (as described in Canadian Patent Number 1,295,567 and United States Patent Number 5,200,327). The transformed cells were grown in liquid culture and the supernatant fractions were collected following the teaching of Example 11. Aliquots of each culture supernatant were analyzed by SDS-PAGE. The transformants with the tap mutants, 12-5 and 12-8 generally showed more intact M-CSF GM-CSF at later time points in the culture than the *S.lividans*, MS2. However, the formation of M-CSF GM-CSF(-3) was not completely eliminated with the tap mutants.

* * * * *

The following examples relate to proteases, other than Tap, derived from *Streptomyces*, their DNA sequences and amino acid sequences. These proteases degrade certain substrates under certain conditions. Example 22 describes one such protease, which displayed a significant amino acid sequence homology with the *Bacillus subtilis* protease BPN' [using the BLAST program (Altschul, et al., 1990) to screen the protein sequence databases) and was therefore designated Ssp (Subtilisin-like-protein)]. An improved strain of *Streptomyces* in which this protease is impaired, was created. Southern blot hybridization indicated that Ssp is present in many *Streptomyces* species. Three other proteases, the DNA sequences and deduced amino acid sequences for two of them, are described in Examples 23, 25 and the N-terminal

amino acid sequence of the third protease is indicated in Example 24. A fourth protease, a unique metalloendoproteinase cleaving substrates with X-Pro sequences, requiring Pro residue in P2' sites is described in Example 26.

Example 21. Screening of the *S.lividans* Genomic Library Using APA-bNA

Following the teaching of Example 10, the *S.lividans* 66 genomic library was used to transform protoplasts of the MS7 mutant strain. Transformant colonies were screened with the substrate APA-bNA. Among the thirteen thousand colonies screened, sixteen clones were isolated by virtue of the plasmid-encoded phenotype (colonies appeared red against a background of pale colonies). Plasmid DNA was isolated from these colonies and used to transform *E.coli* competent cells from which larger quantities of plasmid DNA were isolated. Restriction mapping and Southern hybridization analysis enabled the division of the sixteen clones into nine distinct groups. *S.lividans* transformants from each group were grown in liquid medium (TSB-MOPS-Glucose) or modified R2YE (-KH₂PO₄, 1/2 YE) and the cell free broth was assayed for the hydrolysis of chromogenic tripeptide substrates and the degradation of M-CSF GM-CSF. The results are summarized in Table VI.

Table VI
***S.lividans* Clones with APA-bNA**
Hydrolyzing Activity by Plate Assay

APA-bNA Activity M-CSF GM-CSF Activity

Group	Examples	APA-bNA Activity			M-CSF GM-CSF Activity	
		Plate	TMP	R2YE*	TMG	RZYE*
1	P5-1 -2 -3 -12	++++	+++++	n.d.	+	n.d.
2	P5-4 -15	++	+++	+++	+	+
3	P5-5	++++	n.d.	n.d.	-	n.d.
4	P5-6 -7 -17 -20	++++	+	+++++		+
5	P5-9	++	+	++		-
6	P5-10	++	++	++++	-	+
7	P5-13	+	++	+		n.d.
8	P5-19	+	+	+		n.d.
9	P5-22	++++	+	+++		-

The four plasmid clones from the first group (P5-1, P5-2, P5-3 and P5-12) are identical to P3-5 and P3-13 containing the *tap* gene which were previously isolated using GPL-bNA. Also the single clone P5-5 was previously identified using GPL-bNA as P3-1, P3-3 and P3-6.

The degradation of M-CSF GM-CSF was determined according to the teaching of Example 2. Analysis of *in vitro* degraded M-CSF GM-CSF on native PAGE (FIG. 9) shows no significant M-CSF GM-CSF degradation relative to that of the control strain containing pSS12 (lane 1) with MS7 transformants containing P5-9 (lane 4) from Group 5 and P5-22 (lane 8) from Group 9. However, degradation of M-CSF GM-CSF to its -3 form was observed in modified R2YE cultures of MS7 containing

P5-4 (lane 2) and P5-15 (lane 6) of Group 2, P5-6 (lane 3) and P5-17 (lane 7) of Group 4, and P5-10 (lane 5) of Group 6. Plasmid DNA from each of these groups will be characterized in turn in Examples 22, 23 and 24.

5 **Example 22. Characterization of P5-4 and P5-15**

Following the teaching of Example 21, two clones were identified and characterized by restriction mapping as distinct from tap and others that were isolated using the
10 APA-bNA substrate. Restriction enzyme site mapping established that two clones (designated P5-4 and P5-15) were shown to represent overlapping fragments of *S.lividans* chromosomal DNA containing the Ssp-encoding gene.

15 FIGURE 10 shows the restriction enzyme sites present in the P5-4 and P5-15 DNA. The hydrolytic capabilities of strains containing the cloned DNA (or deletions thereof) was measured visually using the agar plate assay method. Southern hybridization against chromosomal DNA showed
20 the expected pattern of hybridizing bands indicating that no major DNA rearrangements had occurred during the isolation of these clones.

Following the teaching of Example 16, the region of DNA encoding the proteolytic activity was defined within
25 the deletion clones P5-4-1 and P5-4-3 (FIG. 10). Specifically, the larger of the two *Nco*I fragments deleted in P5-4-2, P5-4-4 and P5-4-5 appeared to be correlated with the proteolytic activity.

An SDS-PAGE analysis of protein secreted by strains
30 carrying the P5-4 DNA displayed a major protein band that migrated at a position consistent with a molecular weight of approximately 45,000 daltons. Preparative SDS-PAGE followed by electrotransfer to PVDF membrane (as described in Example 14) allowed direct automated Edman
35 degradation to be carried out to yield the amino acid

sequence NH₂-Asp-Thr-Gly-Ala-Pro⁵-Gln-Val-Leu-Gly-Gly¹⁰-
Glu-Asp-Leu-Ala-Ala¹⁵-Ala-Lys-Ala-Ala-Ser²⁰-Ala-Lys-Ala-
Glu-Gly²⁵-Gln-Asp-Pro-Leu-Glu³⁰.

DNA sequence analysis (shown in FIG. 11) of the P5-4
5 DNA revealed a potential protein coding region located
within the region of DNA defined by the two NcoI
fragments in FIG. 10. This was consistent with the
respective activities of the plasmid deletion clones P5-
4-1, P5-4-2, P5-4-3, P5-4-4 and P5-4-5. Inspection of
10 the predicted protein sequence revealed the exactly
matching, experimentally determined amino terminal amino
acid sequence noted above. Furthermore, the predicted
amino acid sequence also showed a putative signal
peptide at the amino terminus, followed by a putative
15 propeptide defined by the experimentally determined
amino terminal sequence of the secreted protease. The
amino acid sequences of the proteins predicted from the
P5-4 DNA sequence were compared with that of the *Bacillus*
protein subtilisin BPN' (FIG. 12), where 1 designates the
20 *S.lividans* sequence while 2 designates the *Bacillus*
sequence.

Fermentation yields of Ssp from the MS7 strain
carrying the P5-4 plasmid were greater when the medium
was supplemented with 5mM Ca²⁺. The enzyme has been
25 partially purified from a Ca²⁺ supplemented fermentation.
After removing the cells by centrifugation, the enzyme
precipitated in the 30-70% saturation range with ammonium
sulfate producing a fragile, floating pellet. The nature
of the pellet made it necessary to decant the supernatant
30 through gauze to get a good yield during collection. Ssp
was then subjected to ion exchange chromatography. The
enzyme bound to Q-Sepharose at pH 6.0, but the rate of
binding was slow. After binding the pH was lowered to 4.0
and the NaCl concentration was between 250 and 500mM for
35 elution. Further purification was obtained by size
exclusion chromatography on Superdex 200 at pH 8.0 in

the presence of CaCl_2 . This step indicated a solution molecular weight of 40-45kd and a band at 43kd was visible in the active fractions after silver staining a reducing Laemmli gel (FIG.2B). This process yielded
5 enzyme which was 80-90% pure. This preparation was used for the characterization below.

The enzyme cleaved APA-pNA, APM-pNA, APA-AMC, and APS-bNA at $800\mu\text{M}$ substrate. Unlike Tap, Ssp showed no preference for APA-pNA relative to APM-pNA. The
10 proteinase exhibited no activity towards Boc-APS-bNA, N-Ac-APA-pNA, Boc-FSR-AMC, D-PFR-pNA, T-bNA, S-bNA, R-pNA, L-pNA, P-pNA, N-Bz-R-pNA, Boc-AAPA-pNA, N-Ac-AAPA-bNA, N-Suc-AAPF-pNA, Boc-LSTR-pNA, or MAAPV-pNA.

Ssp converted M-CSF GM-CSF to M-CSF GM-CSF(-3). Ssp
15 sequentially removed tripeptide units from the N-terminal of IL-3 generating IL-3(-3), IL-3(-6), IL-3(-9), and IL-3(-12) from intact IL-3. The presence of a disulfide bond at Cys16 may block further processing.

Given the vulnerability of both M-CSF GM-CSF and IL-3
20 to cleavage by Ssp, the inhibition or elimination of the activity can have a significant impact on product yield and homogeneity from *Streptomyces* fermentations. Ssp is more resistant to APACMK than Tap requiring $81\mu\text{M}$ APACMK for complete inhibition while Tap was fully blocked by
25 $2\mu\text{M}$ APACMK. Ssp was also inhibited by PMSF (5mM, complete) and D-FFR-CMK (1mM, partial). The chloromethyl ketones L-CK, F-CK, and TLCK had no effect at 1mM. Unlike Tap, the chelators EGTA and EDTA were effective giving >95% inhibition against enriched Ssp and Ssp in
30 fermentation broth when the concentration of chelator was 0.25mM above the calcium ion concentration. The chelator, Iminodiacetic Acid, was not inhibitory. The following compounds were not inhibitory: captopril (1mM), thiorphan (1mM), iodoacetic acid (1mM), DTT (2.5mM), phosphoramidon
35 (1mM), elastatinal (0.5mM), and pepstatin (0.5mM).

Several conclusions were drawn from the accumulated data. First, Ssp appeared to be a tripeptidyl aminopeptidase which, like Tap, selectively removed tripeptides from substrates possessing a free alpha-amino group. The inhibitor profile was that of a subtilisin type enzyme as suggested by the DNA homology. This enzyme type was characterized by sensitivity to serine proteinase inhibitors and chelating agents. Unlike Tap, Ssp required the divalent cation, Ca^{2+} , for activity. While the use of simple chelating agents during fermentation may seem attractive, we found that many chelators (including EDTA and EGTA) were lethal to *Streptomyces*; therefore, the development of specific inhibitors or deletion mutants would be of critical importance in the control of this activity during the fermentation.

Deletion of the Ssp-encoding DNA from the *S.lividans* chromosome was accomplished following the teaching of Example 17. Specifically, the DNA from plasmid deletion clone P5-4-4 (FIG. 10) was subcloned into pT7T3 using the *EcoRI* site immediately adjacent to the leftward side of the DNA insert (shown in FIG. 10). Since there was no convenient restriction enzyme site to the rightward side of the DNA insert this was excised using the *XhoI* site (in the replication origin of the plasmid vector, pSS12) which was subsequently ligated to the *SalI*-digested pT7T3. Hence, overall the *EcoRI*-*XhoI* fragment was inserted in *EcoRI* and *SalI* digested T7T3 DNA. The fragment was subsequently excised by digestion with *EcoRI* and *HindIII* and inserted into the integration vector, pINT using the same restriction enzyme sites. The pT7T3 intermediate step was required because the *SalI* site in the multiple cloning site of pINT was not unique and, therefore, not convenient for subcloning purposes.

This integration clone was used to create strains containing the specific deletion at the *ssp* locus in two

S.lividans host strains. Firstly, the MS7 host strain was used to create a new strain designated MS11 (*pepP1*-, *pepP2*-, *slpA*-, *slpC*-, *tap*-, *ssp*-). Secondly, another *tap*-deleted strain (MS9) was used to create MS12 (*tap*-, *ssp*-). The deletion strains MS7, 9, 11 and 12 were cultured in TSB/PPG liquid medium for 22 hours and examined for the ability of cell-free broth to hydrolyse APA-pNA.

10

Table VII

APA-pNA Hydrolytic Activity of Various *S.lividans* Strains

Strain	$\Delta A_{405} \text{ ml}^{-1} \text{ min}^{-1}$
wild type	30.4
MS7	4.5
MS9	2.4
MS11	1.7
MS12	1.3

20

The results (Table VII) show a reduction in hydrolytic capability, with the MS12 strain showing the lowest activity. All the strains displayed a significantly reduced hydrolytic capability compared to *S.lividans* 66 but the MS9 strain showed a lower level than the MS7 strain. (This was shown in a separate experiment not to be due to the different integration clones used, since MS8 used the same integration clone as MS7 but was derived from *S.lividans* 66 protoplasts and showed indistinguishable properties to MS9.)

Southern hybridization experiments detected DNA sequences homologous to the *ssp* DNA in many *Streptomyces* species. According to the teaching of Example 15, Southern blot hybridization was performed using the 2.25

kb BamHI - KpnI DNA fragment which had been subcloned into pT7T3.18u as a probe. chromosomal DNA was isolated from *S.alboniger*, *S.ambofaciens*, *S.coelicolor*, *S.fradiae*, *S.griseus*, *S.lividans* 66, *S.parvulus*, *S.rimosus* and was
5 digested with either NcoI or SphI.

It should be noted that the same library of clones was screened as in Example 10. Presumably, the lower background level of APA-bNA-hydrolysing activity in MS7 (compared to *S.lividans*) allowed the P5-4 and P5-15
10 clones to be identified. This has been noticed by other workers particularly relating to neutral protease activities in *B.subtilis* (Sloma, et al., 1990).

Example 23. Characterization of P5-6 and P5-17

15 Following the teaching of Example 21, four clones were identified and characterized by restriction enzyme mapping as distinct from *tap*, *ssp* or others that were isolated using the APA-bNA substrate. Clone numbers P5-6 and P5-17 were shown to represent overlapping fragments
20 of chromosomal DNA (FIG. 13), wherein P5-7 and P5-20 were identical sibling clones of P5-6.

The common restriction enzyme site map of the P5-6 and P5-17 DNA and deletion clones derived from P5-17 were determined (FIG. 13). Activity against APA-bNA was shown
25 by the number of pluses adjacent to each plasmid and was estimated using the agar plate assay method described in Example 10.

Although these clones encoded significant hydrolytic capability against the APA-bNA substrate in
30 the agar plate assay, no activity above background was observed in cell free broth derived from cultures containing these plasmids grown in TSB media. Neither was it possible to experimentally identify the protein product of this locus. When cultured in liquid medium
35 resembling the agar medium composition (i.e. R2 without added phosphate or agar and containing 0.25% yeast

extract - instead of the usual 0.5%), degrading activity was observed in the cell free broth. However, in contrast to the Tap and Ssp proteins, there was no hydrolysis of GPL-bNA in R2, although there was
5 degradation of full-length M-CSF GM-CSF according to the methods described in Example 2.

DNA sequence analysis of the P5-6 DNA (FIG. 14) revealed a potential coding region. The predicted protein once again displayed a putative secretion signal
10 peptide, followed by a predicted protein of 492 amino acid residues (FIG. 14). Furthermore, when the amino acid sequence was compared to that of the Tap (FIG. 15) a strong homology was obvious around the region encoding the putative active site serine residue. The amino acid
15 sequence for Tap is in the upper row and the amino acid sequence for P5-6 is in the lower row.

Example 24. Characterization of P5-10.

Another cloned DNA fragment was isolated from the same
20 APA-bNA screening experiment described in Example 21. This DNA species was designated P5-10 and showed a different pattern of characteristic restriction enzyme sites (FIG. 16) than those observed for the other clones described above. The protease gene was localized to a
25 2.25-kb BamHI fragment by deletion subcloning followed by agar plate activity assay against APA-bNA (FIG. 16).

A significant protein band was observed by SDS-PAGE analysis of supernatants of strains carrying this plasmid. Its molecular weight was approximately 50,000
30 daltons. Amino terminal amino acid sequence analysis was carried out according to the teaching of Example 13 yielding the following sequence : Ala-Glu-Pro-Lys-Ala⁵-Val-Asp-Ile-Xaa-Asp¹⁰-Arg-Leu-Leu-Ser. The activity of supernatant material containing this protein from MS7
35 host cultures, grown in TSB medium, was very low against APA-bNA and GPL-bNA. However, when cultured in R2YE

liquid medium, a high level of activity was observed against APA-bNA but not GPL-bNA. Furthermore, degradation of full-length M-CSF GM-CSF, according to the methods described in Example 2, was also detectable in samples grown in R2YE but not TSB.

DNA sequence analysis of the 1.9-kb BamHI-SphI fragment of the P5-10 (FIG. 17) revealed a potential protein coding region of 474 amino acids which is consistent with a predicted protein of 53.2 kd. At the amino terminus of the predicted protein sequence there is a 26 amino acid sequence having the properties expected of a conventional signal peptide (van Heijne 1986). The predicted residues 27-40 matched exactly the experimentally determined sequence of the secreted protein. No strong homologies were observed when the predicted protein sequence was compared to protein database sequences, however, weak similarities were noticed to members of the serine carboxypeptidases and prolylendopeptidase families.

Example 25. Characterization of P8-1 and P8-2.

A chromogenic substrate was designed to model the amino terminal region of M-CSF GM-CSF except that the amino terminal residue was modified by the addition of a Boc-group (or other similar moieties such as Fmoc), such that proteases whose activity required a free NH₂-group would be unable to act directly on this substrate. However, any endoprotease present in the *S.lividans* host having a recognition sequence compatible with that of the substrate (specifically Boc-APARSPA-bNA) would be able to cleave and remove the Boc-group in addition to some portion of the peptide. Such cleavage would generate a smaller peptide-linked bNA moiety which would contain a free NH₂-group at the N-terminus and could be acted upon to release the chromogenic bNA moiety which could

subsequently be visualized by reaction with Fast Garnet GBC dye.

This strategy was used to screen the *S.lividans* 66 genomic DNA library after transformation into the MS5
5 host strain (tap+). After screening of eight thousand colonies, six clones were confirmed to encode the ability to degrade the substrate significantly faster than the host strain alone. Two clones proved on restriction enzyme site analysis to be identical to P5-6 described in
10 Example 23. Another clone was similarly shown to be the same as P5-17. Three other clones (P8-1, 2 and 3) were isolated and shown to represent the same region of chromosomal DNA (by Southern hybridization experiments). P8-3 contained a larger DNA fragment which was probably
15 derived from the co-cloning of non-contiguous *Sau3AI* fragments in the construction of the library. P8-1 contained an inserted DNA fragment of approximately 8 Kb, while P8-2 had a smaller insert (3.6 Kb). Deletion mapping followed by agar plate activity assay against
20 Boc-APARSPA-bNA localized the protease gene to a 2.2-kb *KpnI*-*BamHI* fragment of P8-1 (FIG. 18). DNA sequence analysis revealed a potential protein coding region of 515 amino acids in the central part of the P8-2 clone (FIG. 19). Comparison of the predicted protein sequence
25 derived from the DNA sequence (FIG. 19) with those encoded by the tap and P5-6 clones showed a significant homology between the proteins encoded by P8-2 and P5-6. A smaller but still significant homology was detectable with the Tap protein. Specifically of interest was the
30 conservation of amino acid sequences around the putative active site serine residues of these proteins as follows:

	Tap	-	G V S Y G T Y L G A V Y G T L F P D H V R R
	P5-6	-	G A S Y G T F L G A T Y A G L F P D R T G R
5	P8-2	-	G I S Y G T E L G G V Y A H L F P E H V G R

Deletion of P8-1 DNA sequences from the *S.lividans* chromosome was performed according to the teaching of Example 16. Specifically, the DNA from clone P8-1 was digested with *StuI* and ligated together to form the deletion subclone P8-1-1 which was missing an internal 1.55-kb *StuI* fragment that encoded the carboxy-terminal half of the protease. The 2.45-kb *MluI*-*BglII* fragment of P8-1-1 was then ligated into the *MluI* and *BamHI* sites of pINT. The resulting integration vector pINT.P8-1-2 contained the *StuI* deletion flanked by P8-1 DNA sequence of 1.1 and 1.35 kb. Alternatively, the 0.95-kb *BamHI*-*KpnI* fragment of P8-2 and the 1.25-kb *KpnI*-*PstI* fragment of P8-1 was ligated into the *BamHI* and *PstI* sites of pINT. The resulting integration vector pINT.P8-1-3 has a 3.5-kb *KpnI* deletion fragment that encoded the entire protease.

These integration vectors were used to create strains containing the specific deletions at the *slpE* locus in various *S.lividans* host strains, by transformation, resolution and hybridization screening following the teaching of Example 16. The strain MS12 was transformed with pINT.P8-1-3 and pINT.P8-1-2 to create the new strains designated MS16 and MS18, respectively (tap⁻, ssp⁻, slpE⁻). The strain MS15 (tap⁻, ssp⁻, pepN⁻), which was created from MS12 and an integration vector that was constructed from a DNA clone encoding the *S.lividans* aminopeptidase N gene (pepN) (Butler, et al., 1994), was transformed with pINT.P8-1-3 and pINT.P8-1-2 to create

the new strains designated MS17 and MS19 (*tap*⁻, *ssp*⁻, *pepN*⁻, *slpE*). Wild type *S.lividans* 66 was also transformed with pINT.P8-1-2 to create the new strain designated MS20 (*slpE*).

5 **Example 26. X-Pro Metalloendoproteinase Isolation and Characterization**

During the production of M-CSF GM-CSF using CANGENUS™, degraded forms of M-CSF GM-CSF, namely M-CSF
10 GM-CSF(-4) and GM-CSF(-6) were identified (FIG. 1A, Lane 4). Significant degradation of IL-3 was also observed (FIG. 1B).

FIGURE 1(B) shows an SDS urea gel electrophoresis (6M urea in the polyacrylamide gel) of IL-3 degradation. A
15 20-fold concentrated fermentation broth was prepared by subjecting a cell-free fermentation broth to ultrafiltration employing a membrane with a 10 kd cutoff. Lane 2 shows IL-3 before incubation. Lane 1 shows IL-3 after incubation at 32° C.

20 Initial studies employed wild-type *S.lividans*. The new protease was followed by assaying for the production of M-CSF GM-CSF(-4). A mutant strain (MS12, Example 20) (in which both the *Tap* and *Ssp* enzymes were deleted) was the mutant of choice since the absence of GM-CSF(-3)
25 generating activity simplified and improved the sensitivity of the assay for M-CSF GM-CSF(-4) production. The pH optimum, inhibitor profile, substrate specificity, and chromatographic behaviour of the MS12 and wild-type enzymes were essentially identical.

30 XP-Mep was purified by a combination of chromatography and electrophoresis. The bacteria were removed from the broth containing the enzyme by centrifugation followed by microfiltration through a 0.45μm membrane (Millipore). To reduce aggregation, the
35 broth was not concentrated. The broth was made 1.8M in ammonium sulfate and loaded onto a column of MacroPrep

Methyl, resin (BIORAD) a hydrophobic interaction column. The enzyme was eluted with 100mM Tris-HCl, pH 8.0.

5 The active fractions were dialysed against 2mM Tris-HCl, pH 8.0 to reduce the ionic strength. The dialysed protein was further purified by preparative isoelectric focusing (ROTOFOR™, BIORAD) employing a gradient from pH 3-10 and a 4% ampholyte loading. The active fractions were pooled and subjected to a second round of preparative IEF to improve the purity and to concentrate the enzyme. Upon cooling, the protease underwent a quantitative isoelectric precipitation. The precipitated enzyme was collected by centrifugation and redissolved in a 20mM buffer with a pH between 7 and 8. While not as precise as analytical IEF, the preparative runs indicated the enzyme has a pI in the 4.2-4.5 range.

20 The cleavage specificity of XP-Mep was examined using proteins, peptides, and synthetic substrates. The enzyme was capable of cleaving M-CSF GM-CSF, IL-3, IL-6, and gelatin. The cleavage of M-CSF GM-CSF by XP-Mep was followed by native gel electrophoresis and amino acid sequence determination of the products. The enzyme converted intact M-CSF GM-CSF to the M-CSF GM-CSF(-4) and M-CSF GM-CSF(-6) degradation forms. The protease cleaved the Arg'-Ser' (Arg'-Ser'-Pro' sequence) and Pro'-Ser' (Pro'-Ser'-Pro') bonds. Interestingly, when purified M-CSF GM-CSF(-3) was incubated with XP-Mep only GM-CSF(-6) was formed. If the concentration of XP-Mep was great enough, M-CSF GM-CSF was degraded to products of less than 10kd in size.

30 XP-Mep added to the degradation taking place during fermentation. XP-Mep converted M-CSF GM-CSF(-3) to GM-CSF(-6) during fermentation. Tap converted M-CSF GM-CSF to M-CSF GM-CSF(-3) and then was unable to generate further cleavage. After XP-Mep converted the M-CSF GM-CSF(-3) to M-CSF GM-CSF(-6), Tap was then able to further degrade the M-CSF GM-CSF. This enhanced

degradation proceeded to at least the M-CSF GM-CSF(-12) and, possibly, the M-CSF GM-CSF(-15) level. Tap was also capable of converting GM-CSF(-4) to the M-CSF GM-CSF(-7), M-CSF GM-CSF(-10), and, possibly, M-CSF GM-CSF(-13) degradation products. This synergistic effect means that production losses during fermentation may greatly exceed those estimated by measuring the production of M-CSF GM-CSF(-3) and M-CSF GM-CSF(-4).

XP-Mep degraded IL-3. When monitored by isoelectric focusing, the enzyme caused the gradual disappearance of the IL-3 band. When examined by SDS-PAGE, a set of multiple degradation products was clearly visible. The ability of the protease to cleave the IL-3(1-10) peptide was examined. The enzyme cleaved the peptide at the Thr⁶-Thr⁷ (Thr⁶-Thr⁷-Pro⁸) bond.

Two cleavage sites were identified when IL-6 was the substrate. The protease cut the Ala¹³-Ala¹⁴ (Ala¹³-Ala¹⁴-Pro¹⁵) and Arg¹⁷-Gln¹⁸ (Arg¹⁷-Gln¹⁸-Pro¹⁹) bonds.

The data obtained with protein substrates suggested that the enzyme cleaved at the N-terminal side of X-Pro sequences.

Several casein derived synthetic peptides were digested with XP-Mep. Beta-casomorphin (YPFPGPI, beta-casein 60-66) was cleaved to yield YFPF and GPI. With VAPFPQV (alpha-casein 25-31) as substrate, FPQV was formed. The peptide PFLQPE (beta-casomorphin 86-91) was cleaved to PFL and QPE. VVPPFLQPE (beta-casomorphin 83-91) was cleaved to VVPPFL and QPE.

A number of potential substrates based on the GM-CSF(-3) structure were synthesized. RAP-pNA, N-Ac-RAP-pNA, and RAPAPA-pNA were not cleaved by XP-Mep. N-Ac-RAPAPA-pNA was cleaved readily by the enzyme liberating N-Ac-RAP and APA-pNA which can be followed by adding Tap.

XP-Mep was tested against a variety of commercial and in-house substrates with no success. The protease failed

to cleave R-pNA, L-pNA, P-pNA, S-bNA, D-PFR-pNA, N-Bz-R-pNA, GR-pNA, pEGR-pNA, N-Bz-VLK-pNA, APA-pNA, SPA-bNA, Boc-APS-bNA, N-(3-carboxypropionyl)-APS-bNA, APPS-bNA, N-Ac-APPT-bNA, Boc-LSTR-pNA, N-Bz-GSHLV-4MbNA, and Boc-FSR-AMC.

The enzyme exhibited the inhibitor profile of a metalloproteinase. The enzyme was strongly inhibited by EDTA. Serine, aspartyl, and cysteinyl protease inhibitors had no measurable effect on activity in the M-CSF GM-CSF assay. The enzyme exhibited some sensitivity to divalent cations. Several more specialized metalloproteinase inhibitors, such as captopril and phosphoramidon, were tested but had no measurable effect on the enzyme activity.

Several other chelating agents were tested for inhibitory effects. Only EDTA and 1.10-phenanthroline were found to be strongly inhibitory at 1 mM. They were also the most potent inhibitors at pH values at or below neutrality. Partial inhibition was obtained with 10mM 2,3-dimercapto-1-propanesulfonate, 2,3-dimercapto-propanol, meso-2,3-dimercaptosuccinate, triethyl-enetetramine, or EGTA at pH 8.0. No effect was seen with 2',2-Dipyridylamine, 2',2-dipyridyl, salicylic acid, di-2-pyridyl ketone oxime, and iminodiacetic acid.

Divalent cations were tested for inhibitory/stimulatory effects. The protease was stimulated by 0.1-1.0mM Co^{2+} . Higher concentrations of Co^{2+} were inhibitory. Ca^{2+} , Mg^{2+} , and Mn^{2+} had no effect at all. Zn^{2+} was inhibitory above 1mM. Cu^{2+} and Ni^{2+} exhibited inhibitory effects above 5 μM .

XP-Mep was completely inactivated by heating at 55°C for 3 hours. The enzyme appears to be stable for 4 days at 37°C. The effect of pH on -4 activity towards M-CSF GM-CSF has been examined. The enzyme was active against M-CSF GM-CSF from pH 5.5 - 8.0 with maximal activity

from 6.0 - 7.0 based upon the recovery of intact M-CSF GM-CSF at the end of the assay. This profile was similar to that obtained with N-Ac-RAPAPA-pNA which exhibited a maximum at 6.0-6.5 and sharp drop in activity below pH 6.0.

The enzyme had a very strong tendency to aggregate. The aggregates were very high in molecular weight and could be readily separated from non-aggregated proteins by size exclusion chromatography. Numerous attempts to break down the aggregate were unsuccessful. While proteolytic activity was stable for at least 2 hours in 4M urea, 0.25M guanidine-HCl, 0.1% SDS, 1% NP40, 1% Tween80, 10mM CHAPS, 2% TritonX100, 1% sodium deoxycholate, 1% sodium taurodeoxycholate, 1.0M NaCl, 25mM beta-mercaptoethanol, or 1mM dithiothoureitol, so was the aggregate. The aggregate and activity were also stable to chloroform extraction, methanol precipitation, lysozyme, trypsin, elastase, DNase, RNase, and lipase treatments designed to eliminate bits of cellular debris that may act as nucleation sites for aggregation.

The non-aggregated protease had an apparent molecular weight of 55-60kd when examined by size exclusion chromatography. The protease gives an apparent molecular weight of 57-60kd when examined by reducing and non-reducing SDS-PAGE.

N-terminal sequencing by Edman degradation after non-reducing SDS-PAGE was conducted. Zymogram studies employing immobilized M-CSF GM-CSF and gelatin were conducted to try to confirm identity of the protease. The proteolytic activity of the band was completely abolished by treatment with EDTA before or after electrophoresis. The N-terminal sequence obtained was X-Ala-Gly-Ala-Pro-Ala-Thr-Glu-Ala-Lys-Leu-Asp-Phe-Ala-Val (in position X, it was not possible to make an unambiguous assignment). The amino acid composition was also determined (Cys and

Trp were not determined) after hydrolysis with 6N HCl (Table VIII).

Table VIII. Amino Acid Composition

	<u>Amino Acid</u>	<u>Mol Percentage</u>
5	Asp + Asn	14.7
	Glu + Gln	7.8
	Ser	5.3
	Gly	14.7
10	His	1.0
	Arg	4.6
	Thr	8.5
	Ala	12.6
	Pro	4.9
15	Tyr	2.6
	Val	8.3
	Met	1.1
	Ile	2.0
	Leu	7.1
20	Phe	2.2
	Lys	2.7

Example 27. Use of Peptide Leaders to Improve Secretion of Exogenous Proteins.

25 The *Streptomyces* expression vector (APO.H) containing the *aph* promoter followed by the protease B signal peptide (Garvin and Malek, U.S. Patent No. 5,200,327) was used for the construction of expression vectors with the propeptides. It contained

30 unique *Nsi*I and *Hind* III cloning sites for insertion of genes encoding exogenous proteins. The *Nsi*I site contains a GCA codon for alanine at the -1 position of the protease B signal peptide. Two tripeptide leaders that were used were Ala-Pro-Ala (designated AP3) and Ala-

35 Pro-Ala-Ala-Pro-Ala which was designated AP6. Oligonucleotides were designed to encode these amino acids and to create a *Pst* I site which was then used to introduce DNA fragments encoding proteins to be secreted. The pairs of oligonucleotides when annealed formed sticky

40 ends complementary to those of *Nsi*I and *Hind* III. The oligonucleotides APA.1 (GCGCCTGCAGCCTA) and APA.2 (AGCTTAGGCTGCAGGCGCTGCA) were used to make the pAP3.H vector by direct ligation to the *Nsi*I-*Hind*III vector

fragment of pAP0.H, containing the *aph* promoter and encoding the protease B signal peptide. Similarly, APA2.1 (GCGCCGGCGGCGCCTGCAGCCTA) and APA2.2 (AGCTTAGGCTGCAGGCGCCGCGGCGCTGCA) were used to make the
5 pAP6.H vector. Similar to pAP0.H, the two expression vectors pAP3.H and pAP6.H each have a unique *Pst*I site that contains a GCA codon for the carboxy-terminal alanine of each propeptide.

Synthetic DNA sequences were designed by reverse
10 translation of amino acid sequence for stem cell factor (SCF) (Martin, et al., 1990), interleukin-7 (IL-7) (Goodwin, et al., 1989) and erythropoietin (EPO) (Jacobs, et al., 1985) using a codon selection optimized for *Streptomyces*. These DNA sequences and their reverse
15 complements were used for the synthesis of 15 or 16 oligonucleotides which were annealed and ligated together as described in U.S. Patent No. 5,200,327. The completed synthetic genes were then ligated into the *Pst*I and *Hind*III sites of pT7T319U and used to transform *E.coli*.
20 After screening the transformants by restriction analysis of the plasmid DNA, the synthetic genes were determined to be authentic by DNA sequence analysis. The synthetic DNA sequences encoding SCF, IL-7 and EPO are presented in FIGS. 20, 21 and 22 and respectively. The amino acid
25 sequence translated from nucleotides 5 to 496, 5 to 460 or 5 to 502 in the respective DNA sequences are disclosed. The *Pst*I site contained a GCA codon for the alanine at the -1 position, which was compatible with the pAP0.H, pAP3.H and pAP6.H expression vectors.

30 *Pst*I-*Hind*III DNA fragments encoding SCF, IL-7 and EPO were each ligated to the *Pst*I-*Hind*III vector fragments of pAP0.H, pAP3.H and pAP6.H. DNA from each of the resulting plasmids was used to transform protoplasts of *S.lividans* 66. Single transformant colonies were grown
35 in 15 ml LB (containing 5 μ g/ml thiostrepton) seed medium for 3 days. After homogenization the cultures were

inoculated into 1 liter flasks containing 200 ml TSB. Aliquots were removed after 18, 24 and 30 hours of growth at 30°C. The proteins secreted into the culture supernatant fractions (15 µl aliquots) were analyzed by SDS PAGE and visualized by silver staining. The results for the SCF experiments show (FIG. 24) significantly greater protein secretion of SCF by pAP3.SCF and pAP6.SCF than by pAP0.SCF and pAP2.SCF. (The latter encodes a protease B with two amino acid alterations.) The inclusion of the propeptide increased the secretion of SCF approximately 20 fold, IL-7 approximately 10 fold and EPO approximately 5 fold relative to control vectors lacking the propeptides. Each protein was initially secreted with an amino terminal tripeptide or hexapeptide leader. At a later time in the same culture this initial form of each protein was processed to the mature form with the correct amino terminus by the action of the Tap which was secreted into the medium. The amino terminal structure of each of the proteins prevented the Tap from removing any tripeptides from the amino terminus of each mature protein. This invention is applicable to proteins having an amino terminal structure which would prevent Tap digestion of the mature protein. This invention is also applicable to proteins having inefficient signal peptide processing.

Example 28 Use of Proteases to Improve Secretion of Exogenous Proteins

The most common mechanism for the secretion of proteins across biological membranes involves the proteolytic removal of an amino terminal signal peptide with a signal peptidase. Certain amino acids at or near the amino terminus of the mature protein may block or greatly reduce the efficiency of the signal peptidase, leading to lower secretion of the protein. Some proteins are secreted at low levels using CANGENUS™ expression vector APO.H (see Canadian Patent No. 1,295,563,

1,295,566, and 1,295,567, and United States Patent Number 5,200,327.) Some of these proteins contain structural constraints located very close to the amino terminus of the mature protein, such as cysteine residues which are involved in a disulfide bond. This may cause steric hindrance to the signal peptidase, thereby preventing cleavage and subsequent release of the mature protein. In such a case, the efficiency of signal peptide removal is enhanced by insertion at the signal peptidase processing site of amino acids which provide a more flexible structure between the signal peptide and the amino terminus of the mature protein. The additional amino acids could be removed from the amino terminus of the secreted protein by an aminopeptidase. The action of the aminopeptidase is stopped by the amino acid or protein structure at the amino terminus of mature protein. The aminopeptidase may be present in the culture medium into which the protein is being secreted, or may be subsequently added to the secreted protein during the downstream processing.

The present invention teaches a process for increasing the amount of secreted proteins. Such proteins may have a primary amino terminal sequence which imposes certain physicochemical properties and/or conformational properties. These properties may cause steric hindrance and thereby interfere with the processing of the signal peptide. Structural constraints could also include disulphide bonds.

In illustrative embodiments, suitable proteins are interleukin-7 (IL-7), stem cell factor (SCF) and erythropoietin (EPO), which have disulfide bonds involving the amino terminal, second, fourth and seventh amino acids, respectively. A signal peptide which is suitable for use for the secretion of IL-7, SCF and EPO is the 37 amino acid signal peptide from the *Streptomyces*

griseus protease B precursor (Canadian Patent Nos. 1,295,563; 1,295,566 and 1,295,567).

5 The present invention further describes the use of short propeptides that are multiples of three amino acids in length which, when placed between the signal peptide and the exogenous protein, can increase the level of secreted protein. A peptide leader of either three (APA) or six (APAAPA) amino acids is placed between the protease B signal peptide and the mature protein.

10 A signal peptidase and a tripeptidyl aminopeptidase (Tap or Ssp) successively remove the protease B signal peptide and the amino terminal peptide leader respectively from proteins secreted from *Streptomyces lividans*. The action of Tap removes peptides from the propeptide, but does not cleave the exogenous protein, due to an
15 amino-terminal primary sequence or structure, such as a disulfide bond, that prevents further degradation activity.

20 Tap or Ssp are used to remove a propeptide from the amino terminus of a fusion protein comprising an exogenous protein. In a process for the production of an exogenous protein by the secretion of said fusion protein into the growth medium, Tap or Ssp may be initially present in the growth medium, secreted into the medium during growth, or added after growth to a preparation of
25 said fusion protein.

A further feature of this invention is a *Streptomyces* expression system which has a recombinant DNA sequence encoding a natural *Streptomyces* protease, in addition to
30 linked regulatory sequences which can include a promoter sequence, a transcriptional start sequence, untranslated messenger RNA leader sequence, including a ribosome-binding site sequence, a signal sequence, and a transcription termination sequence. A vector of such an expression system, when transformed into a suitable
35 *Streptomyces* host, has the capacity to direct significant

production of a protease due to the multicopy nature of the vector utilized.

Those skilled in the art can use standard methodology to construct recombinant DNA sequences containing various combinations of the aforementioned components of different protease genes, in combination with transcriptional or translational information from non-protease genes: (1) to increase or decrease the production capacity of a *Streptomyces* host for any of the proteases listed; (2) to express exogenous proteins in a *Streptomyces* host or another suitable eukaryotic or prokaryotic host; or (3) to express endogenous proteins in a *Streptomyces* host or another suitable host.

Example 29. Secretion of Soluble Forms of the Enzymes Encoded by P5-6 and P8-2.

No extracellular hydrolytic activity could be observed in liquid cultures of strains carrying the cloned P8-2 DNA sequence of FIG. 19 even when modified R2 liquid medium was used. Moreover, SDS PAGE analysis with silver staining did not detect extracellular proteins of the anticipated sizes in modified R2 liquid cultures of *S.lividans* MS7 carrying the cloned DNA sequences of FIG. 14 (eg. P5-6) or FIG. 19 (eg. P8-2). Although the strains carrying these cloned DNA sequences clearly exhibited hydrolytic activities against their respective substrates on modified R2 agar plates, significant levels of these activities could not be localized to either the intracellular or extracellular fractions.

Consistent with these observations, the amino termini of the potential coding regions of P5-6 and P8-2, unlike conventional signal peptides, contained sequences which matched well with the signal peptidase II consensus sequence characteristic of lipoproteins. As predicted by von Heijne (1989), the signal peptidase II processing would precede the cysteines in the sequence LATACSAGGAS of P5-6 (FIG. 14) and LTAGCSGGSS of P8-2 (FIG. 19). Each

sequence showed a striking clustering of turn-producing amino acids following the cysteine, consistent with the amino termini of lipoproteins. The highly positively charged amino terminus of the potential coding region of P5-6, with 7 arginines and a single aspartate, has been commonly found on other Gram positive signal peptides. Overall, the amino-terminal sequences for the potential coding regions of P5-6 and P8-2 were consistent with membrane bound forms of each enzyme, designated *SlpD* and *SlpE*, respectively.

In order to allow biochemical purification of the predicted proteins from culture supernates, to examine their hydrolytic capabilities and to confirm that the predicted proteins were directly responsible for these activities, the nucleotides encoding both the putative promoter region and the lipoprotein signal peptide including the +1 cysteine were replaced by sequences for the aminoglycoside phosphotransferase (*aph*) promoter and encoding the protease B signal peptide and the six amino acid propeptide, as described in Example 27. This was accomplished by the use of oligonucleotides to adapt the *SlpD* and *SlpE* proteins at their amino-termini with appropriate cloning sites, for ligation into the expression vector pAP6.H.

To adapt the N-terminus of the *SlpD* protein, oligonucleotides encoding the 11 amino acids of *SlpD* immediately downstream of the SPase II +1 cysteine were synthesized. An *EcoRI* cloning site at the 5' end allowed for ligation of the oligonucleotides into the *EcoRI* site contained within the polylinker of a T7T318U based subclone (#4) of *SlpD* clone p5-6. This subclone also contained a *HindIII* site from the polylinker located 380 nucleotides downstream of the *SlpD* stop codon. The oligonucleotides also contained at their C-terminus a BamH I site, which joined to a natural BamHI site within

the *SlpD* encoding sequence, located 30 nucleotides downstream from the SPase II +1 cysteine.

A subclone containing these oligonucleotides was subjected to DNA sequence analysis, a routine procedure employed to confirm the fidelity of the cloned oligonucleotide sequence, and the sequence was found to be correct. An *NsiI* cloning site contained within the N-terminus of the oligonucleotides allowed for ligation to the *Pst I* site of AP6.H and subsequent joining of the protease B signal plus leader directly to the *SlpD* at the serine residue immediately adjacent to the SPase II cysteine. The 1920 *NsiI* to *HindIII* fragment encoding *SlpD* was subsequently cloned into AP6.H to produce AP6.*SlpD*.

An analogous strategy was used to adapt the N-terminus of the *SlpE* protein with oligonucleotides encoding the 35 amino acids of *SlpE* immediately downstream of the SPase II +1 cysteine. A *PstI* compatible site located at the 5' end allowed for ligation of the oligonucleotides into the *PstI* site located within the polylinker of a T7T318U based subclone (#5) of *SlpE* clone p8-2. The oligonucleotides also contained at their 3' end a *PflMI* site which joins to a natural *PflMI* site within the *SlpE* encoding sequence, located 100 nucleotides downstream from the SPase II +1 cysteine. At the 3' end of one of the oligonucleotides creating the *PflMI* site, there was a potential secondary structure which could potentially have caused difficulties in cloning by forming a relatively stable hairpin, thus providing the *PflMI* sticky end from participating in the ligation. The sequence of this oligonucleotide and its complement were modified to abolish the hairpin structure, while still encoding the correct amino acid sequence for *SlpE*.

DNA sequence analysis of two of the three pT7T3.18U subclones containing these oligonucleotides showed that their 5' ends did indeed contain the nucleotide sequences

from the oligonucleotides (i.e., they contained an *NsiI* site). Surprisingly, however, the sequences at their 3' ends upstream of the *PflMI* cloning site, where the nucleotides should have been substituted to abolish the potential hairpin structure, contained wild type nucleotides. The *SlpE* encoding sequence remained completely intact and in the correct reading frame, and sequences past the *PflMI* site also were intact and in the correct frame.

10 An *NsiI* cloning site contained within the N-terminus allowed for the subsequent ligation in the correct reading frame into the *PstI* site of AP6.H and the joining of the protease B signal plus leader directly to the *SlpE* at the serine residue immediately adjacent to the SPase II +1 cysteine. A *SacI* site located 238 nucleotides downstream of the *SlpE* stop codon was used in conjunction with a *HindIII* - *SacI* 8mer adapter (AGCTAGCT) to join the 3' end of the *SlpE* clone to the *HindIII* site in the AP6.H expression plasmid. The 1820 bp *NsiI* to *SacI* fragment encoding *SlpE* was then used along with the *HindIII* - *SacI* adapter in a three-way ligation into AP6.H to produce AP6.*SlpE*.

25 When these plasmids were used to transform protoplasts of MS11, secreted proteins for both AP6.*SlpD* and AP6.*SlpE* were observed at approximate molecular weights of 55kd and 56kd, respectively. Direct automated N-terminal Edman degradation analysis of the secreted proteins produced the following amino acid sequences: SAGGASTXAG for *SlpD* and APAAPASGGSSDEDK for *SlpE*. For *SlpD*, culture supernatants showed a dramatic increase in the ability to hydrolyse APA-bNA.

Table IX
Soluble Protease Substrate Assays

5	Transformant	Timepoint	A_{405}	A_{540}
	SS12	18	0.144	0.100
		23	0.132	0.038
		41	0.126	0.018
	p5-6	17.5	1.147	0.246
		23	0.990	0.278
		41	0.105	0.000
	p8-2	17.5	0.115	0.084
		23	0.111	0.015
		41	0.108	0.036

10 The A_{405} values reflected the APA-bNA assay on 20 μ l cell free broth from Tap-deleted *S. lividans* 66 cultures. The A_{540} values reflected the Boc-APARSPA-bNA assay on 20 μ l cell free broth from *S. lividans* 66 cultures. There was no adjustment for dry weights.

15 This correlated with the N-terminal sequence data on SlpD which showed that it was lacking the leader peptide APAAPA, which may have been cleaved due to autocatalytic activity of the SlpD itself. In contrast, SlpE culture supernatants showed no ability to hydrolyse APA-bNA, correlating with the presence of an intact P6 leader at the N-terminus of the secreted protein.

Example 30. Use of Tap for the Processing of the Propeptide from Secreted SCF

25 The Tap protein was purified from a liquid culture of *S. lividans* according to the teaching of Example 1. Alternatively, Tap can be expressed by transformants of *S. lividans* 66 harbouring the plasmid pCAN94 (P3-5) which contains the entire tap gene, including promoter/regulatory sequences, a protein coding sequence, and a putative transcription termination sequence. Tap expression can be further enhanced by the use of a plasmid, pCAN155, in which the tap gene, excluding natural sequence upstream of its transcription start

30

point, was placed downstream of the strong, constitutively expressed *ermE** promoter. pCAN155 was constructed via 3-way ligation of the large *Bam*HI - *Hind*III fragment of pCAN149, and the 0.875 kb *Bam*HI - *Kpn*I and 1.8 kb *Kpn*I - *Hind*III fragments of pPepT, as described. pCAN149 is a derivative of the pAPO.M-CSF GM-CSF expression plasmid in which the small *Bam*HI - *Mlu*I fragment was replaced by a *Bgl*II - *Mlu*I fragment containing the *ermE** promoter and a sequence encoding the amino terminus of the protease signal peptide. pPepT is a derivative of pT7T318U (Pharmacia) into which a 3.0 kb fragment *Pst*I - *Bam*HI from pCAN94 was subcloned. A partial *Bam*HI digest was required to generate this fragment due to the presence of other internal *Bam*HI sites.

pCAN155 and pCAN94 were transformed into *S.lividans* 66 strain MS11 (*tap*,*ssp*) and grown in liquid TSB medium. Secreted proteins were TCA-precipitated from the extra-cellular broth at 17.5, 23.5 and 41.5 hours after inoculation, and analyzed by SDS PAGE. The level of secreted 55 kd Tap protein was substantially higher from pCAN155 than from pCAN94 (P3-5), indicating the relative promoter strengths of *ermE** and *tap*, respectively. The secreted Tap protein continued accumulate until 41.5 hours of culture to a level of approximately 2 g/l.

Appropriate dilutions of cell-free broth samples collected at various time points from independent cultures harbouring pCAN94, and pCAN155 were tested for ala-pro-ala pNA hydrolysis as described previously. The results are shown in Table X.

Table X
Ala-Pro-Ala-pNa Hydrolysis Activity

5	Time Point (h)	pCAN155 (ΔA_{405} /min/ml)	pCAN94 (ΔA_{405} /min/ml)
	17.5	257	12
	23.5	2922	286
	41.5	56500	10500
10	71.5	50000	10000

Table IX illustrates that at all 3 time points the pCAN155 transformants expressed the highest amount of secreted product, followed by the pCAN94 transformants. The pCAN138 transformants represented a control culture of *S.lividans* MSII essentially negative for Tap activity.

Secreted SCF from culture supernatants of the MS12 strain harboring the pAP6.SCF vector were digested with a preparation of Tap to remove the amino-terminal hexapeptide. Aliquots (10 μ l) of the culture supernatants, containing approximately 100 ng of APAAPA-SCF, were mixed with 0, 1 and 2 μ l of Tap (200 ΔA_{405} /min/ml) and incubated at 37°C for 1 to 3 hours. The proteins were then analyzed by SDS PAGE with silver staining. The results indicated that Tap digestion converted the APAAPA-SCF to APA-SCF and SCF with increasing incubation time and enzyme concentration.

Example 31. An Immunoassay Using Tap.

Tap as a unique protease with a well established assay using a synthetic substrate for determination of its activity (described in this patent application) may be applied as a useful tool for making an immunoassay. In microwell ELISA, antigens were immobilized in a microwell and probed by labelled antibody (conjugate). The enzyme-labelled reagents were detected with the appropriate substrate, which was converted to a visible colored product at the reaction site. The intensity of color produced was proportional to the amount of measured antigen.

To date, the most common enzymes used for generating color have been alkaline phosphatase or horseradish peroxidase. In this example, those enzymes were replaced with Tap and using synthetic substrates, developed and described in this patent application, such as APA-pNA for visible color and APA-AMC for fluorescence technology detection.

To demonstrate this invention, IL-3 was used as an example for antigen quantitation. Rabbit anti-IL-3 antisera (Cangene Corporation) was used as the first antibody. The second antibody, goat anti-rabbit IgG linked to biotin (Sigma), and streptavidin (Boehringer Mannheim GmbH) were used as the amplification system. Tap linked to biotin was used as the enzyme. The Tap was purified as described in Example 1 and 9.0 ml of the Tap (approximately 0.3 mg/mL) were biotinylated with D-Biotinyl-E-aminocaproic acid N-hydroxysuccinimide ester as described in Biochemia Bulletin of Boehringer Mannheim (1989, Antibodies and Reagents for Immunochemistry, at page 115). Serial dilutions of recombinant hIL-3 (Cangene Corporation) were applied to the microplate wells (100 μ L/well), and then incubated at 4°C for over 16 hours. The wells then were washed and 5% BSA (bovine serum albumin) was added as a blocker. After

1 hour incubation, the wells were washed and rabbit anti hIL-3 sera (Cangene Corporation) was added at a dilution of 1/2000. Incubation was performed at 37° C for 1 hour. The wells were then washed and the second antibody, goat anti-rabbit IgG-Biotin (Sigma), was added at a dilution of 1/2000 for 1 hour at 37° C. After washing, a mixture of Streptavidin and Biotin-Tap was added. This mixture was prepared previously as follows: 40 μ L of Streptavidin (Boehringer Mannheim, 1 mg/mL) and 35 μ L of Biotin-Tap were added to 5 mL Tris buffer pH 8.0 containing 1% BSA. The mixture was pre-incubated for 45 minutes before being added to the microplate assay. The mixture was washed from the microplate after incubation for 45 minutes at room temperature. Then 100 μ L of the enzyme substrate (0.8 mM) were added. For color development, APA-pNA was used as a substrate and the absorbance was read after 2 and 16 hours incubation at 405nm. For faster analysis, APA-AMC (Cangene Corporation) was used as a fluorescent substrate, where the incubation was performed for 30 minutes and the assay was analyzed at excitation/emission of 400/450nm by the multiwell plate scanning fluorescent system using a Fluorescence Concentration Analyzer (Pandex).

A hIL-3 calibration curve was generated (FIG. 23) using ELISA technology with Tap as the enzyme and APA-pNA as the substrate for color forming (Panel A) incubated for either 2 hours (o---o) or 16 hours (Δ --- Δ), and APA-AMC as a fluorescent substrate (Panel B) incubated for 30 minutes.

* * * * *

The present invention has been described in terms of particular embodiments found or proposed by the present inventors to comprise preferred modes for the practice of the invention. It will be appreciated by those of skill in the art that, in light of the present disclosure, numerous modifications and changes can be made in the particular embodiments exemplified without departing from the intended scope of the invention. For example, due to codon redundancy, changes can be made in the underlying DNA sequence without affecting the protein sequence. Moreover, due to biological functional equivalency considerations, changes can be made in protein structure without affecting the biological action in kind or amount. All such modifications are intended to be included within the scope of the appended claims.

CITED DOCUMENTS

- The documents listed below are incorporated herein by reference to the extent that they supplement, explain, provide a background for, or teach methodology, techniques and/or compositions employed herein.
- Altschul, S.F., W. Gish, W. Miller, E.W. Myers and D. Lipman. 1990. Basic Local Alignment Search Tool, *J. Mol. Biol.* 215: 403-410.
- 10 Ashe, B.M. and Zimmennan (1977) *Biochem. Biophys. Res. Commun.* 75:194-199.
- Atlan, D., P. Laloi and R. Portalier. 1989. Isolation and characterization of aminopeptidase-deficient *Lactobacillus bulgaricus* mutants. *Appl. Env. Microbiol.* 55:1717-1723.
- 15 Alvarez, N.G., C. Bordallo, S. Gascon and P.S. Rendueles. 1985. Purification and characterization of a thermosensitive X-prolyl dipeptidyl aminopeptidase from *S. cerevisiae*. *BBA* 832:119-125.
- 20 Aretz, W., K-P. Koller and G. Riess. 1989. Proteolytic enzymes from recombinant *Streptomyces lividans* TK24. *FEMS Microbiol. Lett.* 65:31-36.
- 25 Balow, R-M., Tomkinson, B., Ragnorsson, U. and Zetterqvist, O. 1986. *J. Biol. Chem.* Purification, Substrate Specificity and Classification of Tripeptidyl Peptidase II. 261 (5) 2409-2417.
- 30 Bender, E., K-P. Koller and J.W. Engels. 1990a. Secretory synthesis of human interleukin-2 by *Streptomyces lividans*. *Gene* 86:227-232.
- 35 Bender, E., Vogel, R., Koller, K.P. and J.W. Engels. 1990b. Synthesis and Secretion of Hirudin by *Streptomyces lividans*. *Appl. Microbiol. Biotechnol.* 34:203-207.
- 40 Bibb, M.J., M.J. Bibb, J. M. Ward and S.N. Cohen. 1985. Nucleotide sequences encoding and promoting expression of three antibiotic resistance genes indigenous to *Streptomyces*. *Mol. Gen. Genet.* 199:26-36.
- 45 Bibb, M.J., P.R. Findlay and M.W. Johnson. 1984. The relationship between base composition and codon usage in bacterial genes and its use for the
- 50

simple and reliable identification of protein-coding sequences. *Gene* 30:157-166.

- 5 Brawner, M., D. Taylor and J. Fornwald. 1990. Expression of the soluble CD-4 receptor in *Streptomyces*. *J. Cell. Biochem., supplement* 14A p103.
- 10 Butler, M.J., C.C. Davey, P. Krygsman, E. Walczyk, and L.T. Malek. 1992. Cloning of genetic loci involved in endoprotease activity in *S.lividans* 66: a novel neutral protease gene with an adjacent divergent putative regulatory gene. *Can. J. Microbiol.*, in the press.
- 15 Butler, M.J., J.S. Aphale, M.A. DiZonno, P. Krygsman, E. Walczyk, L.T. Malek. 1994. Intracellular Aminopeptidases in *Streptomyces lividans* 66. *J. Indust. Microbiol.* 13:24-29.
- 20 Davies, B.J. 1964. *Ann. N.Y. Acad. Sci.* 121, 404
- Diedrichs, K., Boone, T., and Karplus, P.A. (1991) *Science* 254:1779-82.
- 25 Doebber, T. W., Divor, A. R. , and Ellis, S. (1978) *Endocrinology* 103:1794-1804.
- Doggette, P.E., and F.R. Blattner. 1986. Personal access of sequence databases on personal computers. *Nucleic Acids Res.* 14:611-619.
- 30 Fink, A.L and Meehan, P. (1979) *Proc. Nat'l Acad. Sci. USA* 76:1566-69.
- 35 Fornwald, J.A., Donovan, J.J., Gerber, R., Keller, J., Taylor, D.P., Arcuri, E.J. and Brawner, M.E. 1993. Soluble forms of the human T cell receptor CD4 are efficiently expressed by *Streptomyces lividans*. *Bio/Technology* 11:1031-1036.
- 40 Fukusawa, K.M. and M. Harada. 1981. Purification and properties of dipeptidyl peptidase IV from *Streptococcus mitis* ATCC 9811. *Arch. Biochem. Biophys.* 210:230-237.
- 45 Hanson, H. and M. Frohne. 1976. Crystalline leucine aminopeptidase from lens in proteolytic enzymes (Ed., L. Lorand) *Methods Enzymol.* 45:504-521.
- 50 Henderson, G., P. Krygsman, C.J. Lui, C.C. Davey and L.T. Malek. 1987. Characterization and structure of genes for proteases A and B from *Streptomyces griseus*. *J. Bacterial.* 169:3778-3784.

- 5 Hopwood, D.A., M.J. Bibb, K.F. Chater, T. Kieser, C.J. Bruton, H.M. Kieser, D.J. Lydiate, C.J. Thompson, C.P. Smith, J.M. Ward and H. Schourempe. 1985. Genetic manipulation of *Streptomyces*, a laboratory manual. The John Innes Foundation, Norwich, U.K.
- 10 Hunkapiller, M. W., Forgac, M.D., and Richards, J.H. (1976) *Biochem.* 15: 5581-85.
- 15 Illingworth, C., Larson, G. and Hellekant, G.. 1989. Secretion of the sweet-tasting plant protein thaumatin by *Streptomyces lividans*. *J. of Industrial Microbiology* 4:37-42.
- 20 Ingram, C., M. Brawner, P. Youngman and J. Westphaling. 1989. *xylE* functions as an efficient reporter gene in *Streptomyces* spp.: Use for the study of gal P1, a catabolite-controlled promoter. *J. Bacteriol.* 177:6617-6624.
- 25 Koller, K.P., Riess, G., Sauber, K., Uhlmann, E. and Wallmeier, H.. 1989. Recombinant *Streptomyces lividans* secretes a fusion protein of tendamistat and proinsulin. *Biotechnology* 7:1055-1059.
- 30 Kreiger, T.J., Bartfeld, D., Jenish, D.L., Hadary, D. 1994. Purification and characterization of a novel tripeptidyl aminopeptidase from *Streptomyces lividans* 66. *FEBS Letters* 352: 385-388.
- 35 Kreil, G. 1990. Processing of precursors by dipeptidyl aminopeptidases: a case of molecular ticketing. *TIBS.* 15:23-26.
- 40 Lichenstein, H., Brawner, M.F., Miles, L.M., Meyers, C.A., Young, P.R., Simon, P.L. and Eckhardt, T. 1988. Secretion of interleukin-1 β and *Escherichia coli* galactokinase by *Streptomyces lividans*. *Gene.* 129:129-134.
- 45 Lloyd, R.J. and G.G. Pritchard. 1991. Characterization of X-prolyl dipeptidyl aminopeptidase from *Lactococcus lactis* subsp. *lactis*. *J. Gen. Microbiol.* 137:49-55.
- 50 Malek, L.T., G. Soostmeyer, C.C. Davey, P. Krygsman, J. Compton, J. Gray, T. Zimny and D. Stewart. 1990. Secretion of Granulocyte Macrophage Colony Stimulating Factor (M-CSF GM-CSF) in *Streptomyces lividans*. *J. Cell. Biochem., supplement* 14A, p127.

- Maniatis, T., E.F. Fritsch and J. Sambrook. 1982. Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
- 5 McDonald J.K., Hoisington, A.R. and Eisenhauer, D.A. 1985. Partial Purification and Characterization of an Ovarian Tripeptidyl Peptidase: A lysosomal exopeptidase that sequentially releases Collagen-related (Gly-Pro-x) Triplets. 126:63-71.
- 10 Menn, F-M., Zylstra, G.J. & Gibson, D.T. 1991. Location and sequence of the tool F gene encoding 2-hydroxy -6-oxohepta-2, 4-dienoate hydrolase in Pseudom... putide F1. Gene 104:91-94.
- 15 Pearson, W.R. and D.J. Lipman. 1988. Improved tools for biological sequence comparison. Proc. Natl. Acad. Sci. USA. 85:2444-2448.
- 20 Proudfoot, A.E.I, Brown, S. C., Bernard, A.R., Bonnefoy, J. -Y., and Kawashima, E.H. (1993) J. Protein Chem. 12: 489-97.
- 25 Schoellmann, G. and Shaw, E. 1963. Direct evidence for the presence of histidine in the active center of chymotrypsin. Biochemistry 2:252.
- 30 Shaw, E., Mares-Guia, M., and Cohen, W. 1975. Evidence for an active center histidine in trypsin through the use of a specific reagent, TLCK, the chloromethyl ketone derived from N-tosyl-lysine. Biochemistry 4:2219.
- 35 Tagakuchi, S., I. Kumagai, J. Nakayama, A. Suzuki and K. Miura. 1989. Efficient extracellular expression of a foreign protein in *Streptomyces* using secretory protease inhibitor (SSI) gene fusions. Biotechnology 7:1063-66.
- 40 Tinoco, I., Jr., P.N. Borer, B. Dengler, M.D. Levine, O.C. Uhlenbech D.M. Crothers and J. Gralla. 1973. Improved estimation of secondary structure in ribonucleic acid. Nature New Biol. 246:40-41.
- 45 Tomkinson, B. and Jonsson, A-K. 1991. Characterization of cDNA for Human Tripeptidyl Peptidase II: The N-Terminal Part of the Enzyme is Similar to Subtilisin. Biochemistry 30:168-174.
- 50 Ueda, Y, Tsumoto, K., Watanabe, K. and Kumagai, I. 1993. Synthesis and expression of a DNA encoding the Fv domain of an anti-lysozyme monoclonal

antibody, HyHEL10, in *Streptomyces lividans*. *Gene*. 120:129-134.

- 5 von Heijne, G. 1989. The structure of signal peptides from bacterial lipoproteins. *Protein Engineering* 2:531-534.
- 10 Wilbur, W.J. and D.J. Lipman. 1983. Rapid Similarity searches of nucleic acid and protein data banks. *Proc. Natl. Acad. Sci. USA*. 80:726-730.
- 15 Yoshimoto, T., N. Murayama, T. Honda, H. Tone, and D. Tsuru. 1988. Cloning and expression of aminopeptidase P gene from *E. coli* HB101 and characterization of expressed enzyme. *J. Biochem*. 104:93-97.
- 20 Yoshimoto, T., H. Tone, T. Honda, K. Osatomi, R. Kobayashi, and D. Tsuru. 1989. Sequencing and high expression of aminopeptidase P gene from *E. coli* HB101. *J. Biochem*. 105:412-416.
- 25 Canadian Patents No. 1,295,563, No. 1,295,566 and No. 1,295,567.
- United States Patent No. 5,200,327.
- 30 PCT/US92/01598 (Sloma, et al.)

35

We Claim:

1. An isolated and purified, endogenous protease of *Streptomyces*.
2. The protease of claim 1, wherein the protease is
5 a tripeptidyl aminopeptidase.
3. The protease of claim 1, wherein the protease is a metalloendoproteinase.
4. The protease of claim 1, having an amino acid sequence as set out in FIG. 5, 11, 14, 17 or 19.
- 10 5. The protease of claim 3, wherein the protease cleaves substrates with X-Pro sequences, where the Pro residue is in the P2' site.
6. An isolated DNA molecule encoding an endogenous protease of *Streptomyces*.
- 15 7. The isolated DNA molecule of claim 6 having a nucleic acid sequence according to FIG. 5, 11, 14, 17 or 19.
8. An isolated DNA molecule encoding an impaired, endogenous protease of *Streptomyces*.
- 20 9. The isolated DNA molecule of claim 8, wherein said molecule lacks all or part of the sequence between site 2 and site 8 of the nucleotide sequence having the restriction map of FIG. 6.
10. The isolated DNA molecule of claim 8, wherein
25 said molecule lacks all or part of the sequence between site 5 and site 7 of a nucleotide sequence having the restriction map of FIG. 6.
11. A genetic expression system comprising an impaired endogenous protease of *Streptomyces*.
- 30 12. The genetic expression system of claim 11, further comprising a recombinant molecule encoding an exogenous gene product and wherein the system is capable of producing the product.
13. A genetic expression system comprising a
35 recombinant DNA molecule which includes

(a) a DNA molecule of claim 6 and 7 and (b) a regulatory sequence operatively linked to the DNA molecule, said system capable of producing the protease encoded by said DNA molecule.

- 5 14. A genetic expression system comprising a recombinant DNA molecule which includes all or part of a nucleotide sequence capable of regulating a DNA molecule encoding the protease of claim 1 and wherein said system is capable of
10 producing the protease.
- 15 15. A vector including the DNA molecule of claim 6 or 7.
- 15 16. A prokaryotic or eukaryotic host cell transformed or transfected with the recombinant DNA molecule of claim 6, 7, 8, 9 or 10.
- 20 17. A method for producing an exogenous gene product by a suitable host cell, said method comprising culturing the genetic expression system of claim 12 under suitable conditions and recovering the exogenous gene product.
- 25 18. A method for producing a protease by a suitable host cell, said method comprising transforming the host cell with the vector of claim 15 and placing the transformed cell in conditions that allow production of the protease.
19. The method of claim 17 or 18, wherein the host cell is a *Streptomyces* host cell.
20. A protease inhibitor comprising L-alanyl-L-prolyl-L-alanine chloromethylketone.
- 30 21. A method of making the inhibitor of claim 20, comprising the steps of:
- 35 (a) extending a chain of Boc-AP to obtain Boc-APA-OBz;
- (b) de-blocking the C-terminal end of Boc-APA-OBz to obtain Boc-APA; and

(c) simultaneously extending C-terminal end, and de-blocking the N-terminal end, of Boc-APA to obtain APA-CMK.

- 5 22. A strain of *Streptomyces* displaying impaired expression of at least one endogenous protease and comprising a DNA molecule capable of encoding the protease.
- 10 23. The strain of *Streptomyces* of claim 22, wherein the endogenous protease is tripeptidyl aminopeptidase.
24. The strain of claim 22, selected from the group comprising *S. lividans*, *S. ambofaciens*, *S. coelicolor*, *S. alboniger*, *S. parvulus* and *S. rimosus*.
- 15 25. The strain of claim 22, which expresses an exogenous gene product.
26. The strain of claim 22, wherein a DNA molecule encoding for the protease lacks all or part of the molecule between site 2 and site 8 of the molecule having the restriction map of FIG. 6.
- 20 27. The strain of claim 22, wherein the DNA molecule encoding for the protease lacks all or part of the molecule between site 5 and site 7 of the molecule having the restriction map of FIG. 6.
- 25 28. The strain of claim 22, wherein the impaired expression decreases the quantity or activity of the endogenous protease.
29. The strain of claim 22, wherein the impaired expression increases the quantity, quality or stability of the exogenous gene product.
- 30 30. The strain of claim 22, wherein the protease is impaired by one of the following: deleting nucleotides in the nucleic acid molecule encoding for the protease, deleting and substituting nucleotides in a nucleic acid molecule encoding
- 35

for the protease mutating nucleotides in the nucleic acid molecule encoding the protein.

- 5 31. A kit for an enzyme-linked immunosorbent assay, said kit comprising in separate containers, the protease of claim 1 covalently linked to a carrier, and a substrate which when cleaved by the protease generates a detectable and measurable signal.
- 10 32. A method for improving the expression and secretion of a mature protein from a genetic expression system, said method comprising the steps of:
- 15 (a) in the system, expressing a construct that comprises a nucleotide molecule encoding a polypeptide comprised of (i) a first sequence encoding a precursor of the mature protein and (ii) a second sequence encoding a substrate for a protease, wherein said second sequence is added to the N-terminus of said first sequence, such that said polypeptide is obtained; and then
- 20 (b) exposing said polypeptide to the protease such that the second sequence is cleaved from the first sequence to form the mature protein, wherein steps (a) and (b) are carried out under conditions for secretion of the mature protein.
- 25 33. The method of claim 32, wherein the second sequence is a tripeptide.
- 30 34. The method of claim 33, wherein the tripeptide is Ala-Pro-Ala.
- 35 35. The method of claim 32, wherein the second sequence is Ala-Pro-Ala-Ala-Pro-Ala.
36. A polypeptide comprising (a) a leader which is a substrate for a signal peptidase, (b) a

propeptide which is a substrate for a protease, and (c) an exogenous protein.

- 5 37. The polypeptide of claim 36, wherein the structure of the exogenous protein constrains degradation of the exogenous protein by the protease.
- 10 38. The polypeptide of claim 36, wherein, absent the propeptide, the structure of the exogenous protein constrains cleavage of the leader sequence by the signal peptidase.
39. The polypeptide of claim 36, wherein the protease cleaves the propeptide from the polypeptide, thereby yielding an isolated exogenous protein.
- 15 40. A use of the protease of claim 1 to remove an amino acid, peptide or polypeptide from a substrate.
41. A use of the protease of claim 3 to digest a protein of connective tissue.
- 20 42. A use of the protease of claim 40, wherein the peptide is a peptide leader.
43. A use of the protease of claim 40, wherein the polypeptide is a fusion protein.
- 25




FIG. 1

FIG. 2




3/50

FIG. 3



4/50

FIG. 4

5/50

FIG. 5(A)

```

GGCGGGGACC GGCCGACGGC CCCGCCGAAC GAACGCCCTT CTCCGTTTAT CGGATTGGCA    60
AAGAAGTAGC ACTGGCCCTG TTCTCAGGAA ACCCAGAGCG GCGAGGATCC CCGTACTTGT    120
CGCGAACACG TACGGGGAGG GCCAC TTG AGG AAG AGC AGC ATA CGG CGG AGG    172
fMet Arg Lys Ser Ile Arg Arg Arg
-35

GCG ACC GCC TTC GGC ACG GCC GGA GCA CTG GTC ACC GCC ACG CTG ATC    220
Ala Thr Ala Phe Gly Thr Ala Gly Ala Leu Val Thr Ala Thr Leu Ile
-30 -25 -20 -15

GCC GGC GCC GTC TCG GCA CCC GCC GCG AGC GCC GCC CCG GCC GAC GGC    268
Ala Gly Ala Val Ser Ala Pro Ala Ala Ser Ala Ala Pro Ala Asp Gly
-10 -5 1

CAC GGG CAC GGG CGG AGC TGG GAC CGG GAG GCG CGC GGT GCC GCC ATC    316
His Gly His Gly Arg Ser Trp Asp Arg Glu Glu Ala Arg Gly Ala Ala Ile
5 10 15

GCC GCC GCC CGC GCC GCC CGG GGC ATC GAC TGG GAG GAC TGC GCA    364
Ala Ala Ala Arg Ala Ala Arg Ala Gly Ile Asp Trp Glu Asp Cys Ala
20 25 30

GCC GAC TGG AAC CTG CCC AAG CCC ATC CAG TGC GGC TAC GTC ACG GTG    412
Ala Asp Trp Asn Leu Pro Lys Pro Ile Gln Cys Gly Tyr Val Thr Val
35 40 45 50

CCG ATG GAC TAC GCC AAG CCG TAC GGC AAG CAG ATC AGG CTC GCC GTC    460
Pro Met Asp Tyr Ala Lys Pro Tyr Gly Lys Gln Ile Arg Leu Ala Val
55 60 65

```

FIG. 5(B)

6/50									
GAC CGC ATC GGC AAC ACC GGA ACC AGG AGC GAG CGC CAG GGC GCC CTG Asp Arg Ile Gly Asn Thr Gly Thr Arg Ser Glu Arg Gln Gly Ala Leu 70 75 80	508								
ATC TAC AAC CCC GGC GGT CCC GGC GGC TCC GGC CTG CGT TTC CCG GCC Ile Tyr Asn Pro Gly Gly Pro Gly Gly Ser Gly Leu Arg Phe Pro Ala 85 90 95	556								
CGC GTC ACG AAC AAG AGC GCG GTC TGG GCC AAC ACG GCC AAG GCC TAC Arg Val Thr Asn Lys Ser Ala Val Trp Ala Asn Thr Ala Lys Ala Tyr 100 105 110	604								
GAC TTC GTC GGC TTC GAC CCG CGC GGC GTC GGC CAC TCC GCG CCC ATC Asp Phe Val Gly Phe Asp Pro Arg Gly Val Gly His Ser Ala Pro Ile 115 120 125 130	652								
TCC TGC GTC GAC CCG CAG GAG TTC GTC AAG GCA CCC AAG GCC GAC CCC Ser Cys Val Asp Pro Gln Glu Phe Val Lys Ala Pro Lys Ala Asp Pro 135 140 145	700								
GTG CCC GGC TCC GAG GCC GAC AAG CGC GCC CAG CGC AAG CTC GCC CGC Val Pro Gly Ser Glu Ala Asp Lys Arg Ala Gln Arg Lys Leu Ala Arg 150 155 160	748								
GAG TAC GCC GAG GGC TGC TTC GAG CGC AGC GGC GAG ATG CTC CCG CAC Glu Tyr Ala Glu Gly Cys Phe Glu Arg Ser Gly Glu Met Leu Pro His 165 170 175	796								

6/50

7/50

FIG. 5(C)

ATG ACC	ACG CCG	AAC ACC	GCG CGC	GAC CTC	GAC GTC	ATC ATC	CGC GCC	GCC GCC	844
Met Thr	Thr Pro	Asn Thr	Ala Thr	Arg Asp	Leu Asp	Val Ile	Arg Ala	Ala Ala	
180			185		190				
CTC GGC	GAG AAG	CTC AAC	TAC CTC	GGC GTC	TCC TAC	GGC ACC	TAC TAC		892
Leu Gly	Glu Lys	Leu Asn	Tyr Tyr	Leu Gly	Val Ser	Tyr Gly	Thr Tyr	210	
195		200		205					
CTC GGC	GCC GTC	TAC GGC	ACC CTC	TTC CCG	GAC CAC	GTC CGC	CGC ATG		940
Leu Gly	Ala Val	Tyr Thr	Leu Phe	Pro Asp	His Val	Arg Arg	Met Met		
		215		220		225			
GTC GTC	GAC AGC	GTC AAC	CCG TCC	CGC GAC	AAG ATC	TGG TAC	CAG CAG		988
Val Val	Asp Ser	Val Val	Asn Pro	Ser Arg	Lys Ile	Trp Tyr	Gln Gln		
		230		235		240			
GCC AAC	CTG GAC	CAG GAC	GTC GCC	TTC GAG	GGC CGC	TGG AAG	GAC TGG		1036
Ala Asn	Leu Asp	Gln Asp	Val Ala	Phe Phe	Gly Arg	Trp Lys	Asp Trp		
245			250			255			
CAG GAC	TGG GTC	GCC GCG	AAC GAC	GCC GCC	TAC CAC	CTC GGC	GAC ACC		1084
Gln Asp	Trp Val	Ala Ala	Asn Asp	Ala Tyr	His Leu	Gly Asp	Thr Thr		
260			265		270				
CGC GCC	GAG GTC	CAG GAC	CAG TGG	CTG AAG	CTG CGC	GCC GCC	GCC GCG		1132
Arg Ala	Glu Val	Gln Asp	Gln Trp	Leu Lys	Leu Arg	Ala Ala	Ala Ala		
275		280		285			290		
AAG AAG	CCG CTG	GGC GGC	GTC GTC	GGA CCG	GCC GAG	CTG ATC	TCC TTC		1180
Lys Lys	Pro Leu	Gly Gly	Val Val	Gly Pro	Ala Glu	Leu Ile	Ser Phe		
		295		300			305		

8/50

FIG. 5(D)


TTC CAG AGC GCC CCG TAC TAC GAC TCC GCC TGG GCG CCG ACC GCG GAG	1228
Phe Gln Ser Ala Pro Tyr Asp Ser Ala Trp Ala Pro Thr Ala Glu	
310 315 320	
ATC TTC AGC AAG TAC GTC GCC GGC GAC ACC CAG GCG CTC GTC GAC GCC	1276
Ile Phe Ser Lys Tyr Val Ala Gly Asp Thr Gln Ala Leu Val Asp Ala	
325 330 335	
GCC GCA CCC GAC CTG TCC GAC ACC GCG GGC AAC GCC TCC GCG GAG AAC	1324
Ala Ala Pro Asp Leu Ser Asp Thr Ala Gly Asn Ala Ser Ala Glu Asn	
340 345 350	
GGC AAC GCC GTC TAC ACG GCC GTC GAG TGC ACC GAC GCC AAG TGG CCC	1372
Gly Asn Ala Val Tyr Thr Ala Val Glu Cys Thr Asp Ala Lys Trp Pro	
355 360 365 370	
GCC AAC TGG CGC ACC TGG GAC CGG GAC AAC ACC CGG CTC CAC CGC GAC	1420
Ala Asn Trp Arg Thr Trp Asp Arg Asp Asn Thr Arg Leu His Arg Asp	
375 380 385	
CAC CCG TTC ATG ACC TGG GCC AAC GCC TGG ATG AAC CTG CCC TGT GCC	1468
His Pro Phe Met Thr Trp Trp Ala Asn Ala Trp Met Asn Leu Pro Cys Ala	
390 395 400	
ACC TGG CCG GTC AAG CAG CAG ACC CCG CTG AAC GTG AAG ACC GGC AAG	1516
Thr Trp Pro Val Lys Gln Thr Thr Pro Leu Asn Val Lys Thr Gly Lys	
405 410 415	

9/50

FIG. 5(E)


GGA CTT CCG CCG GTG CTG ATC GTC CAG TCC GAG CGT GAC GCC GCC ACC	1564
Gly Leu Pro Pro Val Leu Ile Val Gln Ser Glu Arg Asp Ala Ala Thr	
420 425 430	
CCG TAC GAG GGC GCC GTC GAA CTG CAC CAG CCG TTC CGG GGA TCC CGC	1612
Pro Tyr Glu Gly Ala Val Glu Leu His Gln Arg Phe Arg Gly Ser Arg	
435 440 445 450	
CTG ATC ACC GAG CCG GAC GCC GGC TCC CAC GGC GTC ACC GGC CTG GTC	1660
Leu Ile Thr Glu Arg Asp Ala Gly Ser His Gly Val Thr Gly Leu Val	
455 460 465	
AAC CCG TGC ATC AAC GAC CCG GTC GAC ACC TAC CTG CTC ACC GGC AGG	1708
Asn Pro Cys Ile Asn Asp Arg Val Asp Thr Tyr Leu Leu Thr Gly Arg	
470 475 480	
ACG GAC GCC CCG GAC GTG ACC TGC GCG CCG CAC GCC ACG CCC AGG CCG	1756
Thr Asp Ala Arg Asp Val Thr Cys Ala Pro His Ala Thr Pro Arg Pro	
485 490 500	
TAA CCCGGGCTCA GGCCAAGCGG GGGAGGGGG CGACCGGTCC GACCGGCCCGC	1809
End	
CCCCCCCCC CACCTGTGCG TACCGTCCCT CGGCCCAGGC GTCCTCCGCC GCGTAGTCGA	1869
AGAGGTCGCC GTACGCCCTG AACATCTTCG GGTAGGCCT	1908

10/50



11/50

FIG. 7



12/50

FIG. 8






FIG. 9

1 2 3 4 5 6 7 8



14/50



15/50

FIG. 11(A)

GGTACCAGGC GACGAAGGCG ACGGTCAGCG GGAACGCCGAA GGAACGGAAG GAGCGGCGCA 60
 GTTCGGCGAA CTCGGCGCTC TGCTGCACTT CGGAGAACTC CTCGGCGGAG GGGAGGCGGT 120
 GCTCCTCTTG CGAGGGGGCG TCCTCTTTGG AGGGGGGCGG TGCCTCGGT GGCACGAGAG 180
 TCTCCTCGTA CGACGGACAT GACGGCTTGG ACCTCGGTGT TCTCGCAGGG GGCTGATCGT 240
 GCTCGGGCTC CCGTCCCAAC GACACGGCGC CCCGCGGGGC CCGGTTCAAC ACCCGTGGCA 300
 CTTTCCGAAG TCGTCCCTCG CGGTCATTG CTGGCCAGGG ACTTCGGGG ATAGCTTCAC 360
 CCTGCACCAC TACGTCATGT ACCTGCCCCG CCCGTTTCAC CCGTGCCCCG GCAGGTGCTG 420
 TTTGCCGGAT GATGTGGAGA CCCCATGGAT CATCTGCGCT TCCCGCGCGA CCCGCGCTCC 480
 AGACGGGGGC TCGTTTCCCG AGCTTTCCCG ACGGACTGGA GACATCACGC ATG ACC 536
 fMet Thr

GCT CCC CTC TCG CGT CAC CGC CGT GCC CTC GCG ATT CCG GCG GGC CTG 584
 Ala Pro Leu Ser Arg His Arg Arg Ala Leu Ala Ile Pro Ala Gly Leu
 -120 -115 -110

GCC GTG GCC GCG TCG CTC GCG TTC CTG CCG GGC ACC CCG GCC GCG GCG 632
 Ala Val Ala Ala Ser Leu Ala Phe Leu Pro Gly Thr Pro Ala Ala Ala
 -105 -100 -95

ACC CCC GCG GCC GAG GCC GCG CCC TCG ACG GCG GCG GAC GCG ACC TCG 680
 Thr Pro Ala Ala Glu Ala Ala Pro Ser Thr Ala Ala Asp Ala Thr Ser
 -90 -85 -80 -75

CTC AGC TAC GTC AAC GTC GCC TCC GGG CAC CGT CCT TCG GCC ACC 728
 Leu Ser Tyr Val Val Asn Val Ala Ser Gly His Arg Pro Ser Ala Thr
 -70 -65 -60

FIG. 11(B)

GTG CGG CGG GCG ATA GCC AAG GCG GGC GGC ACG ATC GTC ACG TCG TAC	776
Val Arg Arg Ala Ile Ala Lys Ala Gly Gly Thr Ile Val Thr Ser Tyr	
-55	-45
GAC CGG ATC GGC GTG ATC GTC GTC CAC TCC GCC AAC CCC GAC TTC GCC	824
Asp Arg Ile Gly Val Ile Val His Ser Ala Asn Pro Asp Phe Ala	
-40	-30
AAG ACC GTG CGC AAG GTG CGC GTG CAG TCG GCC GGT GCC ACC CGC	872
Lys Thr Val Arg Lys Val Arg Gly Val Gln Ser Ala Gly Ala Thr Arg	
-25	-15
ACC GCG CCA CTG CCC TCG GCC GCC ACC ACC GAC ACG GGC GCG CCG CAG	920
Thr Ala Pro Leu Pro Ser Ala Ala Thr Thr Asp Thr Gly Ala Pro Gln	
-10	5
GTG CTC GGC GGC GAG GAC CTG GCC GCC GCC AAG GCC TCC GCG AAG	968
Val Leu Gly Gly Glu Asp Leu Ala Ala Lys Ala Ala Ser Ala Lys	
10	20
GCC GAG GGC CAG GAC CCG CTG GAG TCG CTC CAG TGG GAC CTG CCC GCC	1016
Ala Glu Gly Gln Asp Pro Leu Glu Ser Leu Gln Trp Asp Leu Pro Ala	
25	35

16/50

17/50

FIG. 11(C)

ATC AAG GCG GAC AAG GAC CAC GAG AAG TCG CTG GGC AGC AGG AAG GTG	1064
Ile Lys Ala Asp Lys Ala His Glu Lys Ser Leu	50
40	
45	
ACC GTC GCC GTC ATC GAC ACC GGC GTC GAC ACC CAC CCG GAC ATC	1112
Thr Val Ala Val Ile Asp Thr Gly Val Asp	65
55	
60	
GCC CCG AAC TTC GAC CCG CAG GCG TCC GTC AAC TGT GTG GCG GGC AAG	1160
Ala Pro Asn Phe Asp Arg Gln Ala Ser Val Asn Cys Val Ala Gly Lys	85
75	
80	
CCG GAC ACC GCC GAC GCG GCC TGG CCG AGC GCG GAG AGC CCG	1208
Pro Asp Thr Ala Asp Gly Ala Trp Arg Pro Ser Ala Ala Glu Ser Pro	100
90	
95	
CAC GCG ACC CAC GTG GCC GCG GAG ATA GCC GCC GCC AAC GGC GTC	1256
His Gly Thr His Val Ala Gly Glu Ile Ala Ala Lys Asn Gly Val	115
105	
110	
GGC ATG ACC GGC GTG GCA CCC GGG GTG AAG GTG GCC GGC ATC AAG GTC	1304
Gly Met Thr Gly Val Ala Pro Gly Val Lys Val Ala Gly Ile Lys Val	130
120	
125	

18/50

FIG. 11(D)

TCC AAC CCC GAC GGC TTC TTC TAC ACC GAG GCC GTG GTC TGC GGC TTC	1352
Ser Asn Pro Asp Gly Phe Phe Tyr Thr Glu Ala Val Cys Gly Phe	150
135	
ATG TGG GCG GCC GAG CAC GGC GTC GAC GTG ACC AAC AGC TAT TAC	1400
Met Trp Ala Ala Glu His Gly Val Thr Asn Ser Tyr Tyr	165
155	
ACC GAC CCG TGG TAC TTC AAC TGC AAG GAC CCC GAC CAG AAG GCG	1448
Thr Asp Pro Trp Tyr Phe Asn Cys Lys Asp Asp Pro Asp Gln Lys Ala	180
170	
CTC GTC GAG GCC GTC TCG CGG GCC TCC CGG TAC GCG GAG AAG AAG GGC	1496
Leu Val Glu Ala Val Ser Arg Ala Ser Arg Tyr Ala Glu Lys Lys Gly	195
185	
GCG GTC AAC GTC GCC GCG GCC GGC AAC GAG AAC TAC GAC CTC ACC TCC	1544
Ala Val Asn Val Ala Ala Ala Gly Asn Glu Asn Tyr Asp Leu Thr Ser	210
200	
GAC GAG ATC ACC GAC CCG TCC TCG CCC AAC GAC ACC ACG CCC GGC GAC	1592
Asp Glu Ile Thr Asp Pro Ser Ser Pro Asn Asp Thr Thr Pro Gly Asp	230
215	

19/50

FIG. 11(E)

CGG ACC GTC GAC CCG TCG AAG TGC CTG GAC ATC CCG ACC CAG CTG CCG	1640
Arg Thr Val Asp Pro Ser Lys Cys Leu Asp Ile Pro Thr Gln Leu Pro	235 240 245
GGT GTC GTG ACG GTC GCG GCG ACC GGT GCG AAG GGC CTC AAG TCG TCC	1688
Gly Val Val Thr Val Ala Ala Thr Gly Ala Lys Gly Leu Lys Ser Ser	250 255 260
TTC TCC AAC CAC GGG CTG GGC GTC ATC GAC ATC GCC GCG CCC GGC GGC	1736
Phe Ser Asn His Gly Leu Gly Val Ile Asp Ile Ala Ala Pro Gly Gly	265 270 275
GAC TCG ACG GCC TAC CAG ACC CCG GAG CCG CCC GCC ACG AGC GGC CTG	1784
Asp Ser Thr Ala Tyr Gln Thr Pro Glu Pro Pro Ala Thr Ser Gly Leu	280 285 290
ATC CTG GGC ACG CTG CCC GGC GGC AAG TGG GGC TAC ATG GCC GGT ACG	1832
Ile Leu Gly Thr Leu Pro Gly Gly Lys Trp Gly Tyr Met Ala Gly Thr	295 300 305 310
TCC ATG GCC TCC CCG CAC GTC GCG GGC GTC GCC GCC CTC ATC AAG TCG	1880
Ser Met Ala Ser Pro His Val Ala Gly Val Ala Ala Leu Ile Lys Ser	315 320 325

FIG. 11(F)


20/50

ACG CAC CCG CAC GGC TCC CCC GCC ATG GTG AAG GCG CTG CTG TAC GCC	1928
Thr His Pro His Ala Ser Pro Ala Met Val Lys Ala Leu Tyr Ala	340
330	
GAG GCC GAC GCC ACG GCG TGC ACC AAG CCG TAC GAC ATC GAC GGC GAC	1976
Glu Ala Asp Ala Thr Ala Cys Thr Lys Pro Tyr Asp Ile Asp Gly Asp	355
345	
GGC AAG GTC GAC GCG GTG TGC GAG GGC CCG AAG AAC CGC AAC GGC TTC	2024
Gly Lys Val Asp Ala Val Cys Glu Gly Pro Lys Asn Arg Asn Gly Phe	370
360	
TAC GGC TGG GGC ATG GCC GAC GCG CTG GAC GCG GTG ACC TGG TAG CCGGT	
Tyr Gly Trp Gly Met Ala Asp Ala Leu Asp Ala Val Thr Trp ter	385
375	
ACGCGTACCC GGTGCGTGAG GCGGGGGCGG CCGTCCGGTT CCCGTCCGGT CCGCCGCCCCC	2074
CGTCGTCGTC GTCGTACGAC AGTATCTTCG CCATGGACAC TTACGAGGAT CC	2185

22/50

FIG. 12(B)

G P::: :::KV :.DG . :. G: WA :. :.DV.N S . :
 2 LGV-APSASLYAVKVLGADSGQYWIINGIEWAIANNMVDVINMSLGGPSGS-----
 190^ 200^ 210^ 220^ 230^ 360v
 1 KALVEAVSPRASRYAEKKGAVNVAAAGNENYDLTSDEITDPSSPNDTPGDRTVD-----PS
 AL AV A G V VAAAGNE T SS PG
 2 AALKAADVKA---V-ASGVVVVAAAGNEG-----TSGSSSTVGYPG-KYPSVIAVGAV
 240^ 250^ 260^ 270^ 280^
 1 KCLDIPTQLPGVVVAAATGAKGLKSSFSNHGLGVIDIAAPGGDSTAYQTPEPPATSGL-IL
 370v 380v 390v 400v 410v 420v
 2 DSSN-----RASFSSVG-PELD-----VMAPGVSIQ
 290^ 300^ 310^
 1 GTLPGGKMGYMGATSMASPHVAGVAAALIKSTHPHASPAMVKALLYAEADATACTKPYDIDG
 430v 440v 450v 460v 470v 480v
 2 :TLPG.K.G .GTSMASPHVAG.AALI S.HP: : : V:: L .::: : Y:::
 STLPGNKYGAYNGTSMASPHVAGAAALILSKHPNWTNTQVRSSLENTTTLGDSFYYGKGL
 320^ 330^ 340^ 350^ 360^ 370^
 1 DGKVDVAVCEGPKNRNGFYGWMGADALDAVTW
 490v 500v 510v
 2 . .A.
 INVQAAAQ
 380^



24/50

FIG. 14(A)

CCCCGGCCCCG	CGTCGGAGTC	ATGACCGGTT	GACGCCGTAA	CACGTACGGG	GCACGCGCAC	60
CAGCACCCGC	AACTGCTTCG	TCGCGGAGAG	TTACGCTCGC	TGA ATG	GAC ACA AGG	115
				Met	Asp Thr Arg	
					-45	
CGC ACT CAC	CGC AGG ACC	CGC ACC GGC	GGC ACC CGT	TTC CGG	GCC ACG	163
Arg Thr His	Arg Arg Thr	Arg Thr Gly	Gly Thr Arg	Phe Arg	Ala Thr	
					-30	
					-35	
CTG CTC ACC	GCC GCG CTC	GCC ACC GGC	TGC TCG	GCC GGG	GCG GCG	211
Leu Leu Thr	Ala Ala Leu	Ala Thr Ala	Cys Ser	Ala Gly	Gly Ala	
					-15	
					-20	
TCG ACG TCC	GCC GGA TCC	CCC GCG GGC	AAG GCG	GCC GCG	ACG GAG	259
Ser Thr Ser	Ala Gly Ser	Pro Ala Ala	Lys Ala	Gly Ala	Thr Glu	
					5	
					1	
					-5	
GCG GCC ACG	GCG ACC CTG	ACC CCC CTG	CCG AAG	GCC ACG	CCC GCG	307
Ala Ala Thr	Ala Thr Leu	Thr Pro Leu	Pro Lys	Ala Thr	Pro Ala Glu	
					20	
					15	
					10	
CTG TCC CCG	TAC TAC GAG	CAG AAG CTC	GGC TGG	CGC GAC	TGC GGC	355
Leu Ser Pro	Tyr Tyr Glu	Gln Lys Leu	Gly Trp	Arg Asp	Cys Gly Val	
					35	
					30	
					25	

FIG. 14(B)

CCG GGC TTC CAG TGC GCC ACC ATG AAG GCC CCG CTC GAC TAC GCC AAG
 Pro Gly Phe Gln Cys Ala Thr Met Lys Ala Pro Leu Asp Tyr Ala Lys
 40 45 50 403

CCC GGC GAC GGC GAC GTC CGG CTC GCG GTG GCC CCG AAG AAG GCC ACG
 Pro Ala Asp Gly Asp Val Arg Leu Ala Val Ala Arg Lys Lys Ala Thr
 55 60 65 451

GGG CCG GGC AAG CGC CTC GGC TCG CTG CTG GTC AAC CCG GGC GGA CCG
 Gly Pro Gly Lys Arg Leu Gly Ser Leu Leu Val Asn Pro Gly Gly Pro
 70 75 80 85 499

GGC GGC TCG GCG ATC GGC TAC CTC CAG CAG TAC GCG GGC ATC GGC TAC
 Gly Gly Ser Ala Ile Gly Tyr Leu Gln Gln Tyr Ala Gly Ile Gly Tyr
 90 95 100 547

CCG GCG AAG GTC CGC GGC CAG TAC GAC ATG GTG GCG GTC GAC CCC CGG
 Pro Ala Lys Val Arg Ala Gln Tyr Asp Met Val Ala Val Asp Pro Arg
 105 110 115 595

GGC GTG GCC CGC AGT GAA CCC GTC GAG TGC CTG GAC GGG CGC GAG ATG
 Gly Val Ala Arg Ser Glu Pro Val Glu Cys Leu Asp Gly Arg Glu Met
 120 125 130 643

GAC GCG TAC ACG CGC ACC GAC GTC ACC CCG GAC GAC GCG GGC GAG ACG
 Asp Ala Tyr Thr Arg Thr Asp Val Thr Pro Asp Ala Gly Glu Thr
 135 140 145 691

FIG. 14(C)

GAC GAG CTG GTC GAC GCC TAC AAG GAG TTC GCC GAG GGC TGC GGG GCG Asp Glu Leu Val Asp Ala Tyr Lys Glu Phe Ala Glu Gly Cys Gly Ala 150 155 160 739
GAC GCG CCG AAG CTG CTG CGC CAC GTC TCC ACG GTC GAG GCG GCA CGC Asp Ala Pro Lys Leu Lys Leu Arg His Val Ser Thr Val Glu Ala Ala Arg 170 175 789
GAC ATG GAC GTC CTG CGC GCG GTG CTG GGC GAC GAG AAG CTG ACC TAC Asp Met Asp Val Leu Arg Ala Val Leu Gly Asp Glu Lys Leu Thr Tyr 185 190 835
GTG GGA GCG TCG TAC GGC ACC TTC CTG GGC GCG ACC TAC GCC GGT CTG Val Gly Ala Ser Tyr Gly Thr Phe Leu Gly Ala Thr Tyr Ala Gly Leu 200 205 210 883
TTC CCC GAC CGG ACG GGC CGC CTG GTC CTG GAC GGC GCG ATG GAC CCC Phe Pro Asp Arg Thr Gly Arg Leu Val Leu Asp Gly Ala Met Asp Pro 215 220 931
TCG CTG CCC GCC CGC CTG AAC CTG GAG CAG ACG GAG GGC TTC GAG Ser Leu Pro Ala Arg Arg Leu Asn Leu Glu Gln Thr Glu Gly Phe Glu 230 235 240 979
ACG GCG TTC CAG TCC TTC GCG AAG GAC TGC GTG AAG CAG CCG GAC TGC Thr Ala Phe Gln Ser Phe Ala Lys Asp Cys Val Lys Gln Pro Asp Cys 250 255 260 1027

26/50

27/50

FIG. 14(D)

CCC CTC GGC GAC AAG GAC ACC CCC GAC CAG GTC GGC AAG AAC CTC	1075
Pro Leu Gly Asp Lys Asp Thr Thr Pro Asp Gln Val Gly Lys Asn Leu	
265 270 275	
AAG TCC TTC TTC GAC GAC CTG GAC GCG AAG CCC CTG CCC GGC GAC	1123
Lys Ser Phe Phe Asp Asp Leu Asp Ala Lys Pro Leu Pro Ala Gly Asp	
280 285 290	
GCC GAC GGC CGC AAG CTC ACC GAA TCC CTC GCC ACC ACC GGC GTG ATC	1171
Ala Asp Gly Arg Lys Leu Thr Glu Ser Leu Ala Thr Thr Gly Val Ile	
295 300 305	
GCC GCG ATG TAC GAC GAG GGC GCC TGG CAG CAG CTG CGC GAG TCC CTC	1219
Ala Ala Met Tyr Asp Glu Gly Ala Trp Gln Gln Leu Arg Glu Ser Leu	
310 315 320 325	
ACC TCG GCG ATC AAG GAG GAG AAG GAC GGT GCG GGC CTG CTG ATC CTC TCC	1267
Thr Ser Ala Ile Lys Glu Lys Asp Gly Ala Gly Leu Leu Ile Leu Ser	
330 335 340	
GAC AGC TAC TAC GAG CGC GAG GCC GAC GGC GGC TAC AGC AAC CTG ATG	1315
Asp Ser Tyr Tyr Glu Arg Glu Ala Asp Gly Gly Tyr Ser Asn Leu Met	
345 350 355	

FIG. 14(E)

TTC GCC AAC GCC GTG AAC TGC CTC GAC CTC CCC GCC GCG TTC TCC Phe Ala Asn Ala Ala Val Asn Cys Leu Asp Leu Pro Ala Ala Phe Ser 360 365 370	1363
TCC CCG GAC GAG GTG CGC GAC GCC CTC CCC GAC TTC GAG AAG GCG TCC Ser Pro Asp Glu Val Arg Asp Ala Leu Pro Asp Phe Glu Lys Ala Ser 375 380 385	1411
CCG GTC TTC GGC GAG GGC CTC GGC TGG TCC TCC CTG AAC TGC GCG TAC Pro Val Phe Gly Glu Gly Leu Ala Trp Ser Ser Leu Asn Cys Ala Tyr 390 395 400 405	1459
TGG CCG GTG AAG CCC ACG GGG GAG CCG CAC CGC ATC GAG GCG GCC GGC Trp Pro Val Lys Pro Thr Gly Glu Pro His Arg Ile Glu Ala Ala Gly 410 415 420	1507
GCC ACC CCG ATC GTC GTG GTC GGC ACC ACC CGC GAC CCG GCC ACC CCC Ala Thr Pro Ile Val Val Val Gly Thr Thr Arg Asp Pro Ala Thr Pro 425 430 435	1555

28/50

FIG. 14(F)

29/50

TAC CGC TGG GCC GAG GCC CTC TCC GAC CAG CTC ACC TCC GGC CAC CTC	1603
Tyr Arg Trp Ala Glu Ala Leu Ser Asp Gln Leu Thr	440 445 450
CTC ACC TAC GAG GGA GAC GGC CAC ACC GCG TAC GGC CGC GGC AGC TCC	1651
Leu Thr Tyr Glu Gly Asp	455 460 465
TGC ATC GAC TCC GCG ATC AAC ACG TAC CTG CTG ACC GGC ACC GCC CCG	1699
Cys Ile Asp Ser Ala Ile Asn Thr Tyr Leu Leu Thr Gly Thr Ala Pro	470 475 480 485
GAG GAC GGC AAG CGC TGC TCG TAA CCCC GCCTGCCCGC CCGGGACCC AGCCTCCGG	1758
Glu Asp Gly Lys Arg Cys Ser ter	490
GGGCGGGTTC GGAGCACCCC GGGAAACTGT GTAGACTTGC CGACGTTGCT GATCGCACCA TGG	1821

FIG. 15(A)

FIG. 15(B)

P5-6 MDTRRTHRRTRTGGTRFRATLLTAALLATACSAGGASTSAGSPAACAAG
 Tap R:: R R:: ::L:TA:L:A.A SA :AS:::. :. :
 MRKSSIRRRATAFGTAGALVTATLIAGAVSAPAAAPADGHHGRS

P5-6 ADGDVRLAVARKKATG-PGKRLGSLLVNPGPGGSAIGYLQQYAGIGYP
 Tap : ::RLAV.R .TG ::.R G:L: NPGPGGS:: :. :. :
 YGKQIRLAVDRIGNTGTRSERQCALIYNPGPGGSLRFPARVTNKSAY

P5-6 DAYKEFAEGCGADAPKLLRHVSTVEAARDMDVLRVAVLGDEKLTYYGASY
 Tap . :E:AEGC . : :L.H::T ::ARD:DV:RA.LG::KL.Y:G.SY
 KLAREYAEGCFERSGEMLPHMTTPNTARDLDVIRAAALGEKKLNYLGVSY

P5-6 K-DCVKQPDCLGDKDTPDQVGKNLKSFFDDLDKPLPAGDADGRKLT
 Tap . :::::..LGD. ::. :L:: . . KPL G:: G.
 DWVAANDAAYHLGDTRAEVQDQWLKLRA---AAKKPL--GGVVGP---

P5-6 YSNLMFANAAVNCLDLPAAFSSPDEVDRDALPDFFEKASPVFGEGLAWSSL
 Tap .N . :AV:C D : :. : RD. . :::: P . : : AW :L
 AENGNAVYTAVECTDAKWPAWRTWDRDN-TRLHRDHPFMTWANAWMNL

P5-6 LT-YEGDGHHTAYGRSSCIDSAINTYLLTGTAPEDEGKRCS
 Tap :T ::::H.. G :CI:: :TYLLTG :. : C:
 ITERDAGSHGVTGLVNPCINDRVDTYLLTGRTDARDVTCAPHATPRP

FIG. 15(B)

31/50

FIG. 15(B)

FIG. 15(A) →	ATEAATATLPLPKATPAELSPYEQKLGWRDCGVPGFQCATMKAPLDYAKP	101
	. . A : : : : A : . A : . : : : W. P : QC : : . . P : DYAKP	96
	WDREARGAAIAAARAAGID-WEDCAADWNL-PKP-IQCGYVTVPMMDYAKP	
	-AKVRAQYDMVAVDPRGVARSEPVECLDGREMDAYTRTDVTPDDAGETDELV	200
	A : . . YD.V : DPGV : : S.P : . C:D : E. . : : D . P : : : : . .	
	WANTAKAYDFVGFDPRGVGHSAPISCVDPQEFVKAPKADPVPGSEADKRAQR	197
	GTFLGATYAGLFPDRTGRLVLDGAMPDPSLPARRL--NLEQTEGFEFATAFSFA	299
	GT:LGA.Y : .LFPD : . R:V:D : . : : PS : NL:Q. : FE. : :	
	GYLGAVYGTLPFDHVRMVVDSVVNPSRDKIWKYQANLDDQDVAFEGRWKDWQ	298
	ESLATGTGVIAMYDEGAWQQLRRESLTSAIKEKDGAGLLILSDSYEREADGG	399
	. . L : A : YD : AW. . E : : : : A : : : : . : : : .	
	AELISFFQSAPYYD-SAWAPTAEIFSKYVAGDTQALVDAAAPDLSDTAGNAS	300
	NCAYWPVKPTGEPHRIEAGATPIVVVGTTTRDPATPYRWAEALSDQLTSGHL	500
	CA WPK. . : : G . P : : : V : . RD:ATPY A . L : : : : L	
	PCATWPVKQQTPLNVKTGKGLPPVLIVQSERDAATPYEGAVELHQFRGRSRL	490
		540
		537
FIG. 15(A) →		

32/50

FIG. 16




FIG. 17(A)

GGATCCTCTG CTGACTCTGG TGTCGCGGGA GTTGCTCCGA TAGCTTCCXG CGGACATCAG	60
TTTACACAGG AGGGTGC ATG CGC AAG GCG CTC AGA TGG CTG CTG GCG CTC	110
fMet Arg Lys Ala Leu Arg Trp Leu Leu Ala Leu	10
GTG GTG CTC ATA GGC ACC GTC AGC ACG GCG GGG GCG GCC ACC GCC GCC	158
Val Val Leu Ile Gly Thr Val Ser Thr Ala Gly Ala Thr Ala Ala	25
GAG CCG AAG GCC GTC GAC ATC AAG GAC CCG CTG TCC ATA CCG GGC	206
Glu Pro Lys Ala Val Asp Ile Lys Asp Arg Leu Leu Ser Ile Pro Gly	40
ATG AGC CTG ATC GAG GAG AAG CCG TAC ACC GGC TAC CCG TTC TTC GTC	254
Met Ser Leu Ile Glu Glu Lys Pro Tyr Thr Gly Tyr Arg Phe Val	55
CTC AAC TAC ACC CAG CCG GTG GAC CAC CCG CAC CCG TCC AAG GGC ACG	302
Leu Asn Tyr Thr Gln Pro Val Asp His Arg His Pro Ser Lys Gly Thr	75
TTC CAG CAG CCG ATC ACC GTG CTG CAC AAG GAC GTG AAC CCG CCG ACG	350
Phe Gln Gln Arg Ile Thr Val Leu His Lys Asp Val Asn Arg Pro Thr	90
GTC TTC TAC ACC GGC GGC TAC AAC GTC TCC ACG AAC CCC AGC CGG CGC	398
Val Phe Tyr Thr Gly Gly Tyr Asn Val Ser Thr Asn Pro Ser Arg Arg	105

FIG. 17(B)

GAG CCG ACC CAG ATC GTG GAC GGC AAC CAG GTC TCC ATG GAG TAC CGC Glu Pro Thr Gln Ile Val Asp Gly Asn Gln Val Ser Met Glu Tyr Arg	110 115 120	446
TAC TTC ACG CCG TCC CGG CCC GCG GCC GCG GAC TGG TCC AAG CTG GAC Tyr Phe Thr Pro Ser Arg Pro Ala Pro Ala Asp Trp Ser Lys Leu Asp	125 130 135	494
ATC TGG CAG GCC GCC AGC GAC CAG CAC CGC ATC TTC AAG GCC CTC AAG Ile Trp Gln Ala Ala Ser Asp Gln His Arg Ile Phe Lys Ala Leu Lys	140 145 150 155	542
CCG CTC TAC TCC AGG AAC TGG ATC TCC ACC GCG GGC TCC AAG GGC GGC Pro Leu Tyr Ser Arg Asn Trp Ile Ser Thr Gly Gly Ser Lys Gly Gly	160 165 170	590
ATG ACC GCC ACC TAC TAC TAC GAG CGC TTC TAT CCG CGT GAC ATG GAC GGC Met Thr Ala Thr Tyr Tyr Glu Arg Phe Tyr Pro Arg Asp Met Asp Gly	175 180 185	638
GTC GTC GCC TAC GTC GCC CCC AAC GAC GTG GTG AAC AAG GAG GAC TCG Val Val Ala Tyr Val Ala Pro Asn Asp Val Val Asn Lys Glu Asp Ser	190 195 200	686
GCC TAC GAC CGC TTC TTC GCC GTC GGC ACC GAC GAG TGC CGC GAC Ala Tyr Asp Arg Phe Phe Ala Arg Val Gly Thr Asp Glu Cys Arg Asp	205 210 215	734

35/50

FIG. 17(C)

AAG CTC AAC GGC GTG CAG CGC GAG GCG CTG GTG CGC CGG CCG CTG Lys Leu Asn Gly Val Gln Arg Glu Ala Leu Val Arg Arg Ala Pro Leu 220 225 230 235	782
GAG AAG AAG TAC GCG GCG TAC GCG GCC GAG AAC GGC TAC ACC TTC GAC Glu Lys Lys Tyr Ala Ala Tyr Ala Ala Glu Asn Gly Tyr Thr Phe Asp 240 245 250	830
ACC ATC GGC AGC CTC GAC CGC GCC TAC GAG GCC GTC GTC CTC GAC TAC Thr Ile Gly Ser Leu Asp Arg Ala Tyr Glu Ala Val Val Leu Asp Tyr 255 260 265	878
GTG TGG GGC TTC TGG CAG TAC AGC ACC CTC GCC GAC TGC GCC GAC ATC Val Trp Gly Phe Trp Gln Tyr Ser Thr Leu Ala Asp Cys Ala Asp Ile 270 275 280	926
CCG GCC GAC GCC AAG AAC GGC ACC GAC GAC GCG ATC TGG GGC TCC GTC Pro Ala Asp Ala Lys Asn Ala Thr Asp Asp Ala Ile Trp Gly Ser Val 285 290 295	974
GAC GCG ATC TCC GGC TTC TCC GCC TAC ACG GAC CAG GGC CTG GAG ACG Asp Ala Ile Ser Gly Phe Ser Ala Tyr Thr Asp Gln Gly Leu Glu Thr 300 305 310 315	1022
TAC ACG CCG TAC TAC TAC CAG GCG GGC ACC CAG CTG GGC CCG ACG Tyr Thr Pro Tyr Tyr Gln Ala Gly Thr Gln Leu Gly Ala Pro Thr 320 325 330	1070

36/50

FIG. 17(D)

ATC CAC TTC CCG CAC ATC GAG AAG AAG TAC ATC CGC TAC GGC TAC CAG Ile His Phe Pro His Ile Glu Lys Lys Tyr Ile Arg Tyr Gly Tyr Gln 335 340 345	1118
CCG CCG CCG AAC TTC GTG CCC CGC TCG ATC CCG ATG AAG TTC GAG CCG Pro Pro Arg Asn Phe Val Pro Arg Ser Ile Pro Met Lys Phe Glu Pro 350 355 360	1166
TGG CCG ATG CCG GAC GTC GAC ACC TGG GTG CGG CAC AAC GCC CGG CAC Trp Ala Met Arg Asp Val Asp Thr Trp Val Arg His Asn Ala Arg His 365 370 380	1214
ATG CTG TTC GTG TAC GGC GAG AAC GAC CCG TGG GGC GCC GAG CGC TTC Met Leu Phe Val Tyr Gly Glu Asn Asp Pro Trp Gly Ala Glu Arg Phe 385 390 395 400	1262
CGC CTC GGC CAC GGC GCG CGT GAC TCC TAC GTG CTC ACC GCG CCC GGC Arg Leu Gly His Gly Ala Arg Asp Ser Tyr Val Leu Thr Ala Pro Gly 405 410 415	1310
ATG AAC CAC GGT GCG AAC GTG GCC GGT CTG GTG CCC GAC CAG AAG GCG Met Asn His Gly Ala Asn Val Ala Gly Leu Val Pro Asp Gln Lys Ala 420 425 430	1358
CGG GCC ACG GGG CCG ATC CTG GAC TGG GCG GGC GTC GCC CCG GCC AAG Arg Ala Thr Gly Arg Ile Leu Asp Trp Ala Gly Val Ala Pro Ala Lys 435 440 445	1406
GTC CAG GAG AAC CCG TCG GCG GCC AGG CCG CTG GCG ACG TTC GAC GCC Val Gln Glu Asn Pro Ser Ala Ala Arg Pro Leu Ala Thr Phe Asp Ala 450 455 460	1454

FIG. 17(E)

AGG CTG GAC CAG CAG CCG GAC GAC GTC GAG CGC GAG CCG GCG CTG CGC CCG TAG 1502
 Arg Leu Asp Gln Arg Arg Asp Val Glu Arg Glu Pro Ala Leu Arg Pro Stop
 465 470 475

37/50

GGCCTGCTCC TCCGGCACGG TGA CTGTGTC CGGCCGCTCA CAGCGGCCGG GCACATCCCA 1562
 CCGGGCGCTC GCCGCCGAGC CCGACGTACA GACCGGTCGA GGTCCGGCAC TGAGCCCGGG 1622
 TGGCGACCGC CTCGACCACC TTGA ACTGCG GTGCGTACCC GCCCCCGCCG GCGCAGGCCG 1682
 CCTCGCGGAC CTTGCCGCCG CCGATGTCTG GGACGCAGTC GCCGACGACG GTGCGCGGAC 1742
 CTCCTCCGCC GCCCGGATCA CCGGGATGCG GCGGCTGCAG CTTGCCCATG C 1793

FIG. 18




FIG. 19(A)

GGTACCGCG GCCAAGACCG TGTGCTCCTG ACCGCGGACG CCACCACAGG TCGGCAGAAG 60
 CAGCAGATCG ACAGAAGTAG CAGGTCAGAG CGTTATCCAC AGGCGTCGGC GGTGCTGCC 120
 CCGGCCACCT ACCATGGCAG GAACGCCATC CGCCGCACGG CGCGGACGGC TTGCCAGGGG 180
 GGAGAGGAC ATG GCG CGT CTC GTC CGG TGG ACG GCT CTG ACG GCC GCC GCC GCA 234
 fMet Ala Arg Leu Val Arg Trp Thr Ala Leu Thr Ala Ala Ala Ala
 5 10 15
 CTG CTG ACG GCG GGC TGC AGC GGC GGC TCG TCC GAC GAG GAC AAG GAC 282
 Leu Leu Thr Ala Gly Cys Ser Gly Gly Ser Ser Asp Glu Asp Lys Asp
 20 25 30
 GAC GGG GGC AGG AGC AGC GCG GGA CCT TCG GCG GCG GCA CCC TCC GGG 330
 Asp Gly Gly Arg Ser Ser Ala Gly Pro Ser Ala Ala Ala Pro Ser Gly
 35 40 45
 GTG CCG GAG GCA CTG GCG TCC CAG ACG CTG GAC TGG GCC CGA TGC GAG 378
 Val Pro Glu Ala Leu Ala Ser Gln Thr Thr Trp Ala Arg Cys Glu
 50 55 60
 GGC AGC GAC GAT GCC CCG GCG CCG GAC GGC GAC TGG CGG TGC GCC ACG 426
 Gly Ser Asp Asp Ala Pro Ala Pro Asp Gly Asp Trp Arg Cys Ala Thr
 65 70 75

39/50

40/50

FIG. 19(B)

CTG AAG GCA CCG CTG GAC TGG TCC GAC CCC GAC GGC GAG ACG ATC GAT	474
Leu Lys Ala Pro Leu Asp 85	
80	
CTC GCG CTG ATC CCG TCC CCG GCG AGC GGG GAC GAC CGC ATC GGC TCC	522
Leu Ala Leu Ile Arg Ser Arg Ala Ser Gly Asp Asp Arg Ile Gly Ser	
100	
CTG CTG TTC AAC TTC GGC GCG CCG GGC GCC TCC GGC GTC TCC ACG ATG	570
Leu Leu Phe Asn Phe Gly Gly Pro Gly Ala Ser Gly Val Ser Thr Met	
115	
CCG TCC TAC GCC GAC ACC GTC TCC TCC CTG CAC GAG CGG TAC GAC CTG	618
Pro Ser Tyr Ala Asp Thr Val Ser Ser Leu His Glu Arg Tyr Asp Leu	
130	
GTG AGC TGG GAC CCG CGC GGG GTG GCC GCC AGC AGC GAG GGC GTC CGC TGC	666
Val Ser Trp Asp Pro Arg Gly Val Ala Ala Ser Glu Gly Val Arg Cys	
145	
CGC ACC GAC GAG GCG ATC GAG GCC GCC GAG TCG GTG GAC TCC ACG CCG	714
Arg Thr Asp Glu Ala Ile Glu Ala Ala Glu Ser Val Asp Ser Thr Pro	
160	
GAC TCC CCG GCC GAG GAG CAG GCC TAC CTG AAG GAC GCC GCC GAC TTC	762
Asp Ser Pro Ala Glu Glu Gln Ala Tyr Leu Lys Asp Ala Ala Asp Phe	
180	

41/50

FIG. 19(C)

GGC AGG GGC TGC GAG AAG GCC GGC AAG CTC ATG GAA CAC GTC TCG Gly Arg Gly Cys Glu Lys Ala Ala Gly Lys Leu Met Glu His Val Ser	810
ACC ACG GAC ACG GCC CGC GAC ATG GAC CTG ATG CGG CAC GTC CTG GGC Thr Thr Asp Thr Ala Arg Arg Met Asp Leu Met Arg His Val Leu Gly	858
GAC GAG AGG ATG CAC TAC TTC GGC ATC TCC TAC TAC GGC ACC GAA CTC GGC Asp Glu Arg Met His Tyr Tyr Phe Gly Ile Ser Tyr Gly Thr Glu Leu Gly	906
GGC GTC TAC GCC CAT CTG TTC CCC GAG CAC GTG GGC CGC GTG ATC CTC Gly Val Tyr Ala His Leu Phe Pro Glu His Val Gly Arg Val Ile Leu	954
GAC GCG GTG GTG GAC CCG GGC GCC GAC ACG ATG GGC CAC GCC GAG AAC Asp Ala Val Val Asp Pro Gly Ala Asp Thr Met Gly His Ala Glu Asn	1002
CAG GCC AGG GGT TTC CAG CGC GCG GCG CTG GAC GAC TAC CTG GAG TCG ACC Gln Ala Arg Gly Phe Gln Arg Ala Leu Asp Asp Thr Tyr Leu Glu Ser Thr	1050
GGC CAG GAA CCC GAG GGG TCG CGG AAG ATC GCC GGC CTG CTG GAG Gly Gln Glu Pro Glu Gln Gln Ser Arg Lys Ile Ala Gly Leu Leu Glu	1098

FIG. 19(D)

CGG CTG GAC GCC GAG CCA CTG CCC ACG TCC TCG CCG GGG CCG GAG CTG	1146
Arg Leu Asp Ala Glu Pro Leu Pro Thr Ser Ser Pro Gly Arg Glu Leu	
305 310 315	
ACG CAG ACC CTC GCG TTC ACC GGC ATC GTG CTG CCG CTG TAC AGC GAG	1194
Thr Gln Thr Leu Ala Phe Thr Gly Ile Val Leu Pro Leu Tyr Ser Glu	
320 325 330 335	
AGC GGC TGG CCG GCC CTG ACC AGT GCG CTG AAG GCG GCC GAG GAG GGC	1242
Ser Gly Trp Pro Ala Leu Thr Ser Ala Leu Lys Ala Ala Glu Glu Gly	42/50
340 345 350	
GAC GGC TCG GAG TTG CTG GCC CTC GCC GAC GGC TAC AAC GAG CGT GAT	1290
Asp Gly Ser Glu Leu Leu Ala Leu Ala Asp Gly Tyr Asn Glu Arg Asp	
355 360 365	
CCC TCG GGG CGC TAC GGC ACG ACC CAC CAC TCG CAA AGG GTC ATA TCG	1338
Pro Ser Gly Arg Tyr Gly Thr Thr Thr His Ser Ser Gln Arg Val Ile Ser	
370 375 380	
TCG CTG GAC AAG CAG AGG CCG ACC GTG GAG GAG ACG AAG AAG CTG	1386
Cys Leu Asp Asp Lys Gln Arg Pro Thr Val Glu Glu Thr Lys Lys Leu	
385 390 395	

43/50

FIG. 19(E)

CTG CCG AGG TTC GAG AAG GTC TCT CCC GTC TTC GGC GCC TTC CTC GGC	1434
Leu Pro Arg Phe Glu Lys Val Ser Pro Val Phe 410	
400	
TGG GAC ACG GCC GGG TGG TGC CAC GAC TGG CCG GTG GCC GGT CAG CAC	1482
Trp Asp Thr Ala Glu Val Ser Cys His Asp Trp Pro Val Ala Gly 430	
420	
GAG ACC GCG GAG GTG AGC GCG CCC GAC GCG GCC CCG GTC CTG GTG GTC	1530
Glu Thr Ala Glu Val Ser Ala Pro Asp Ala Ala Pro Val Leu Val Val	
435	
GGC AAC ACG GCG GAC CCG GCC ACN GCG CCC TAC GAG GGC GCC CGC AGG ATG	1578
Gly Asn Thr Gly Asp Pro Ala Thr Pro Tyr Glu Gly Ala Arg Arg Met	
450	
GCG GAC GAG CTG GGC AAG GAC GTC GGC GTG GTG CTG ACC TGG CAG GGC	1626
Ala Asp Glu Leu Gly Lys Asp Val Gly Val Val Leu Thr Trp Gln Gly	
465	
GAG GGA CAC GGT GCC TAC GCG AAC GGA AGC GAC GAC TGT GTC GAC TCC GCG	1674
Glu Gly His Gly Ala Tyr Gly Asn Gly Ser Asp Cys Val Asp Ser Ala	
480	
GTG GAC GCC TAC CTG TTG AAG GCG ACG GTG CCG AAG GAC GGC AAG GTC	1722
Val Asp Ala Tyr Leu Leu Lys Gly Thr Val Pro Lys Asp Gly Lys Val	
500	
TGC TCA TGA CGGCGGCGGG GGCTTCGGGC ACCTGCGGTG CGCGAAACCC CCGCCG	1771
Cys Ser End	

FIG. 20(B)

GGTCAACATCGTGGACGACCTGGTGGAGTGCCTCAAGGAGAACTCGAGCAAGGACCTCAA
-----+-----+-----+-----+-----+-----+-----+
CCAGTTGTAGCACCTGCTGGACCACTCACGCAGTTCCTCTTGAGCTCGTTCCTGGAGTT
300

GAAGAGCTTCAAGTCCCCGAGCCCCGCCCTGTTCACGCCCGAGGAGTTCTTCCGGATCTT
-----+-----+-----+-----+-----+-----+-----+
CTTCTCGAAGTTCAGGGGGCTCGGGGGGACAAGTGGGGCTCCTCAAGAAGGCCCTAGAA
360

44/50

CAACCGCTCGATCGACGCCCTTCAAGGACTTCGTGCGTCCGAGACCTCCGACTGCGT
-----+-----+-----+-----+-----+-----+-----+
GTGGCGAGCTAGCTGCGGAAGTTCTTGAAGCAGCACCGCAGGCTCTGGAGGCTGACGCA
420

GGTCAGCTCGACCCCTCAGCCCCGGAGAGGACTCGCGGGTGTGCGTCAACAAGCCGTTTAT
-----+-----+-----+-----+-----+-----+-----+
CCAGTCGAGCTGGAGTGGGGCTCTTCTGAGCGCCCCACAGCCAGTGGTTCGGCAAGTA
480

Hind III

GCTGCCCCCGTCGCCCTA
-----+-----+-----+-----+-----+-----+-----+
CGACGGGGGGCAGCGGATTCGA
502

45/50

FIG. 21(A)

PstI
GACTGCGACATCGAGGGGAAGGACGGCAAGCAGTACGAGTCGGTGCTGATGGTGTC
-----+-----+-----+-----+-----+-----+-----+
ACGTCGACGCTGTAGCTCCCTTCCTGCGGTTGCTCATGCTCAGCCACGACTACCCACAG
60
CATCGACCAGTTGCTGGA CTGATGAAGGAGATCGGGCTCCA ACTGCCCTCAACAACGAGTT
-----+-----+-----+-----+-----+-----+-----+
GTAGCTGGTCAACGACCTGAGCTACTTCCTCTAGCCGAGGTTGACGGAGTTGTTGCTCAA
120
CAACTTCTTCAAGCGCCACATCTGGGACGCCCAACAAGGAGGGAATGTTCTCTGTTCCGGGC
-----+-----+-----+-----+-----+-----+-----+
GTTGAAGAAGTTCGCGGTGTAGACGCTGCGGTTGTTCTCCCTTACAAGGACAAGGCCCG
180
CGCGCGCAAGCTGCGCCAGTTCTCAAGATGAATTCCACCGGGGACTTCGACCTCCACCT
-----+-----+-----+-----+-----+-----+-----+
GCGCGCGTTGACGCGGTCAAGGAGTTCTACTTAAGGTGGCCCTGAAGCTGGAGGTGGA
240

FIG. 21(B)

GCTCAAGGTCTCGGAGGGCACGACCATCCTGCTGAACCTGCACGGGCCAGGTCAAGGGACG
-----+-----+-----+-----+-----+-----+-----+
CGAGTCCAGAGCCTCCCGTGTGCTAGGACGACTTGACGTGCCCCGGTCCAGTTCCTCCCTGC 300

GAAGCCCCGCCCTCGGGAGGCCACGACCGACGAAGAGCTTGAGGAAACAAGTCCCT
-----+-----+-----+-----+-----+-----+-----+
CTTCGGGCGGGAGCCCTCCGGGTGCGCTGCTTCTCGAACCTCCTTTGTTCAGGGA 360

GAAGGAGCAGAAAGCTCAACGACCTGTGCTTCCTGAAGCGGTGCTCCAGGAGATCAA
-----+-----+-----+-----+-----+-----+-----+
CTTCCTCGTCTTCTTCGAGTTGCTGGACACGAAAGGACTTCGCCAACGAGGTCTCTAGTT 420

HindIII

GACGTGCTGGAACAAGATCCTCATGGGCACCAAGGAACACTGA
-----+-----+-----+-----+-----+-----+-----+
CTGCACGACCTTGTTCCTAGGAGTACCCGTGGTTCCTTGTGACTTCGA 467

SUBSTITUTE SHEET (RULE 26)

48/50

FIG. 22(B)

```

CCTCCTGGTGAAC TCGTCCAGCCGTGGAGCCGCTCCAGCTGCACGTGCA CAAGGCCGT
-----+-----+-----+-----+-----+-----+-----+
GGAGGACCACTTGAGCAGGGTCGGCACCCCTCGGCGAGGTCGACGTGTTCCGGCA
300



CTCCGGGCTCCGGTCCCTGACCACGCTGCTGCGCGCCCTCGGTGCCAGAGAGGCCAT
-----+-----+-----+-----+-----+-----+-----+
GAGGCCGAGGCCAGGACTGGTGCAGACGACGCGCGGAGCCACGGGTCTTCCTCCGGTA
360

CTCGCCCCCGGACGCCCGCAGCGCCCGCCCGCTGCGGACGATCAGGCGGACACCTTCCG
-----+-----+-----+-----+-----+-----+-----+
GAGCGGGGCTCGGCGGTGCGCGGGCGGACGCCCTGCTAGTGCCTGCGGCTGTGGAAGGC
420

CAAGCTGTTCCGGTCTACTCGAACTTCTCGGGGGAAGCTGAAGCTCTACACCGGCGA
-----+-----+-----+-----+-----+-----+-----+
GTTGACAAGGCCCAAGATGAGCTTGAAGGACGCCCCCTTCGACTTCGAGATGTGGCCGCT
480


StuI                               Hind III
GGCCTGCCGACGGCGACCGGTA
-----+-----+-----+-----+-----+-----+-----+
CCGGACGGCGTGCCCGCTGGCCATTCTGA
508

```

49/50
FIG. 23(A)**FIG. 23(B)**

50/50

FIG. 24





INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : C12N 15/57, 9/52, 9/48, 15/76, 1/21, 1/15, C07K 5/06, C12N 15/67, 15/62, C07K 14/47, C12P 21/06, G01N 33/535 // (C12N 1/21, C12R 1:465)</p>	A3	<p>(11) International Publication Number: WO 95/17512</p> <p>(43) International Publication Date: 29 June 1995 (29.06.95)</p>
<p>(21) International Application Number: PCT/US94/14772</p> <p>(22) International Filing Date: 22 December 1994 (22.12.94)</p> <p>(30) Priority Data: 08/173,508 23 December 1993 (23.12.93) US</p> <p>(60) Parent Application or Grant (63) Related by Continuation US 08/173,508 (CIP) Filed on 23 December 1993 (23.12.93)</p> <p>(71) Applicant (for all designated States except US): CANGENE CORPORATION [CA/CA]; 6280 Northwest Drive, Mississauga, Ontario L4V 1J7 (CA).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): BARTFELD, Daniel [IL/CA]; 89 Overlook Place, North York, Ontario M3H 4P5 (CA). BUTLER, Michael, J. [GB/GB]; Worts Causeway, Cambridge CB1 4RN (GB). HADARY, Dany [IL/CA]; 40 Maryvale Crescent, Richmond Hill, Ontario L4C 6P8</p>	<p>(CA). JENISH, David, L. [CA/CA]; 4104 Fieldgate Drive, Mississauga, Ontario L4W 2C4 (CA). KRIEGER, Timothy, J. [US/CA]; 24 Jameson Crescent, Brampton, Ontario L6S 3W3 (CA). MALEK, Lawrence, T. [US/CA]; 3 Viewmount Crescent, Brampton, Ontario L6Z 4P4 (CA). WALCYZK, Eva [CA/CA]; 6037 Childham Crescent, Mississauga, Ontario L5N 2R8 (CA). SOOSTMEYER, Gisela [CA/CA]; 166 Hedgerow Lane, Kleinburg, Ontario L0G 1C0 (CA).</p> <p>(74) Agents: BENT, Stephen, A. et al.; Foley & Lardner, Suite 500, 3000 K Street, N.W., Washington, DC 20007-5109 (US).</p> <p>(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ).</p> <p>Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p> <p>(88) Date of publication of the international search report: 28 December 1995 (28.12.95)</p>	
<p>(54) Title: PROTEASES FROM STREPTOMYCES AND USE THEREOF IN PROTEIN EXPRESSION SYSTEMS</p>		
<p>(57) Abstract</p> <p>A family of proteases endogenous to <i>Streptomyces</i> cells degrades exogenous proteins secreted from <i>Streptomyces</i> host cells. The previously unidentified proteases include (1) tripeptidyl aminopeptidase designated "Tap", (2) tripeptidyl aminopeptidase designated "Ssp", (3) X-Pro-Metalloendoproteinase designated "XP-Mep", and (4) other proteases derived from <i>Streptomyces</i> which degrade certain substrates under certain conditions. Degradation was alleviated by selective inhibition of secreted proteases or by using improved strains which lack or have impaired degradation proteases. An irreversible inhibitor was designed based upon the mechanism and substrate specificity of the target protease. Hosts expressing proteases were also produced. Uses of the proteases include immunoassays and proteolytic removal of peptides and polypeptides to improve secretion of exogenous proteins.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 94/14772

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/57 C12N9/52 C12N9/48 C12N15/76 C12N1/21
 C12N1/15 C07K5/06 C12N15/67 C12N15/62 C07K14/47
 C12P21/06 G01N33/53 //(C12N1/21,C12R1:465)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE CHEMABS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US LOSEVA, A. L. ET AL 'Properties of immobilized complexes of Streptomyces griseus proteinases on different carriers' see abstract & UKR. BIOKHIM. ZH. (1979), 51(4), 345-9 CODEN: UBZHD4, ---	1,2
X	WO,A,93 00925 (AMGEN INC.) 21 January 1993 see the whole document --- -/--	1,6,8, 11-19, 22,24, 25,28-30



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
 "E" earlier document but published on or after the international filing date
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 "O" document referring to an oral disclosure, use, exhibition or other means
 "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
 "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

24 July 1995

Date of mailing of the international search report

28. 11. 95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax (+31-70) 340-3016

Authorized officer

VAN DER SCHAAL C.A.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 94/14772

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>GENE, vol.111, pages 125 - 130 H. LICHENSTEIN ET AL 'Cloning and characterization of a gene encoding extracellular metalloprotease from Streptomyces lividans' see the whole document ---</p>	<p>1,6, 13-16, 18,19</p>
X	<p>CHEMICAL ABSTRACTS, vol. 119, no. 3, 19 July 1993, Columbus, Ohio, US; abstract no. 23336, J. APHALE AND W. STROHL 'Purification and properties of an extracellular aminopeptidase from Streptomyces lividans 1326' page 385 ; see abstract & J. GEN. MICROBIOL., vol.139, no.3, pages 417 - 424 ---</p>	<p>1,6, 13-16, 18,19</p>
A	<p>EP,A,0 219 237 (1CETUS CORPORATION) 22 April 1987 see the whole document ---</p>	<p>32</p>
P,X	<p>FEBS LETTERS, vol.352, 3 October 1994 pages 385 - 388 T. KRIEGER ET AL 'Purification and characterization of a novel tripeptidyl aminopeptidase from Streptomyces lividans 66' see the whole document -----</p>	<p>1,2,4, 6-19, 22-30,40</p>

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 94/ 14772

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

- 6 subjects See additional sheet PCT/ISA/210

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

- see additional sheet PCT/ISA/210, pt. 1

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US94/ 14772

FURTHER INFORMATION CONTINUED FROM PCT/ISA/210

1. claims 2,4,7,9,10,20,21,23,26,27 completely and
1,6,8,11-19,22,24,25,28-40,42,43 partially

Tripeptidyl aminopeptidases from Streptomyces, impaired forms thereof, uses thereof (e.g. in expression systems or enzyme linked immunosorbent assays), DNA encoding and methods to produce them, and an inhibitor therefor.

2. claims 3,5,41 completely and
1,6,8,11-19,22,24,25,28-40,42,43 partially

Metalloendoproteinase from Streptomyces, impaired forms thereof, uses thereof (e.g. in expression systems or enzyme linked immunosorbent assays, DNA encoding and methods to produce it.

3. claims 8,11,12,17,22-30 partially

DNA encoding impaired proteases from Streptomyces other than mentioned in subject 1 or 2, expression systems containing it.

4. claim 31 partially

Kit for enzyme-linked immunosorbent assays comprising a protease from Streptomyces other than mentioned in subject 1 or 2, covalently linked to a carrier.

5. claims 32-39 partially

Methods to improve expression and secretion of mature protein from a genetic expression system using other proteases than mentioned in subject 1-3.

6. claims 40,42,43 partially

Use of proteases from Streptomyces other than mentioned in subject 1-3 to remove an amino acid, peptide or polypeptide from a substrate.

The International Searching Authority also draws attention to the fact that any further search for claims as grouped above may rise to further objections concerning the unity of said claimed inventions within the sense of Rule 13.1 PCT.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. .onal Application No

PCT/US 94/14772

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9300925	21-01-93	AU-B- 655312	15-12-94
		AU-A- 2307592	11-02-93
		CA-A- 2090463	02-01-93
		EP-A- 0546156	16-06-93
		JP-T- 6501396	17-02-94
		NZ-A- 243356	27-04-94

EP-A-0219237	22-04-87	US-A- 4870017	26-09-89
		US-A- 4865974	12-09-89
		AU-B- 596810	17-05-90
		AU-B- 6294486	26-03-87
		JP-C- 1761398	20-05-93
		JP-B- 4048431	06-08-92
		JP-A- 62115281	26-05-87
		JP-A- 3277287	09-12-91
		US-A- 5013662	07-05-91

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.